Express Mail No.: <u>ED 608 969 344 US</u>

Sheet 2 of 3 of List of References

LIST OF REFERENCES	CITED BY	APPLICANT
--------------------	----------	-----------

(Use several sheets if necessary)

ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
APPLICANT	09/0/3,403
Srivastava et al.	
FILING DATE	ART UNIT
June 4, 2001	1643

*EXAMINER		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
INITIAL	A31	5,947.646	07/19/99	Srivastava et al.	TROUBS ATTEM
	A32	5,968.526	10/19/99	Garman et al.	
	A33	5,997,873	12/7/99	Srivastava et al.	
	A34	6,007,821	12/28/99	Srivastava et al.	
	A35	6,027,731	2/22/2000	Pauza	
	A36	6,030,618	02/29/00	Srivastava	
	A37	6,033,561	3/7/2000	Schoendorfer	
	A38	6,048,530	4/11/00	Srivastava	
	A39	6,136,315	10/24/00	Srivastava	
	A40	6,156,311	12/05/00	Strickland et al.	
	A41	6,162,436	12/19/00	Srivastava	
	A42	6,168,793	1/2/01	Srivastava et al.	
	A43	6,312,711	11/6/01	Duchateau et al.	
	A44	6,333,311	12/25/2001	Nuijens et al.	
· · · · · · · · · · · · · · · · · · ·	A45	6,338,945	01/15/02	Nicolette	
	A46	6,403,092	6/11/02	Pizzo et al.	
	A47	6,433,141	8/13/02	Wallen et al.	
	A48	6,689,363	02/10/04	Sette et al.	,
	A49	6,709,672	3/23/04	Henot et al.	
	A50	6,713,608	3/30/04	Wallen et al.	
	A51	6,730,302	5/4/04	Fujihara et al.	
-	A52	6,797,480	9/28/04	Srivastava	
	A53	6,986,389	01/06	Li	
	A54	7.176,515	03/06/07	Srivastava et al.	
	A55	7,179,462	02/20/07	Srivastava et al.	-
<u></u>	A56	7.132.109	11/07/06	Srivastava	

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 344 US</u> Sheet 3 of 3 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	filing date June 4, 2001	ARTUNIT 1643	

BOI	DE 196 02 985 A1	1/27/96	Germany	
B02	GB 2 251 186A	7/1/92	United Kingdom	
B03	WO 00/03003	1/20/00	University of Nottingham	
B04	WO 00/10597	03/02/00	Immunology Limited	
B05	WO 00/34494	6/15/00	The Government of the United States of America represented by the Secretary, Dept. of Health and Human Services	
B06	WO 00/38760	7/6/2000	Occulogix Corp	
B07	WO 00/46246	8/10/00	The General Hospital Corp.	
B08	WO 00/54801	9/21/2000	Entremed Inc	
B09	WO 01/91787	6/12/01	University of Conneticut Health Center	
B10	WO 01/92474	12/06/01	University of Conneticut Health Center	
BII	WO 02/07755	1/3/2002	The General Hospital Corporation	
B12	WO 02/11669	02/14/02	Antigenics, LLC	
B13	WO 02/15930	2/28/02	Duke University	
B14	WO 02/30434	4/18/02	University of Conneticut Health Center	
B15	WO 02/32923	4/25/02	University of Conneticut Health Center	
B16	WO 02/34205	5/2/02	University of Conneticut Health Center	
B17	WO 03/015712	02/27/03	University of Conneticut Health Center	
B18	WO 03/090686	11/06/03	University of Conneticut Health Center	
B19	WO 03/092624	11/13/03	University of Conneticut Health Center	
B20	WO 04/035602	04/29/04	University of Conneticut Health Center	
B21	WO 04/075636	09/10/04	University of Conneticut Health Center	
B22	WO 04/74454	09/02/04	University of Conneticut Health Center	
B23	WO 05/120558	12/22/05	University of Conneticut Health Center	
B 24	WO 89/12455	12/28/89	Whitehead Institute for Biomedical Research Medical Research Council	

EXAMINER	DATE CONSIDERED
THE CONTROL OF THE CO	ADED 600. Describes through citation if not in conformance and not

Express Mail No.: ED 608 969 358 US Sheet 1 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

	FOREIGN PATENT DOCUMENTS				
-	B25	WO 90/02564	3/22/90	Codon Dragon	
	B26	WO 91/15572	10/17/91	The Wellcome Foundation Limited	
	B27	WO 92/01717	2/6/92	Burnie, James et al.	
	B28	WO 92/08484	5/29/92	University College London	
	B29	WO 92/08488	5/29/92	University College London	
	B30	WO 93/14118	7/22/93	Medical Research Council	
	B31	WO 93/17712	9/16/93	Biocine Sclavo Spa Rappuoli	
•	B32	WO 93/18146	9/16/93	Institut National de la Sante et de la researche medicale	
	B33	WO 93/18147	9/16/93	Institute Nazionale per lo studio e la cura dei tumori fondazione giovanni pascale	
	B34	WO 93/18150	9/16/93	Biocine S.P.A.	
	B35	WO 93/21529	10/28/93	Duke University	
	B36	WO 93/24136	12/9/93	Terman, David S.	
	B37	WO 94/03208	2/17/94	Yeda Research and Development Company, Ltd	
	B38	WO 94/04676	3/3/94	The Victoria University of Manchester	
	B 39	WO 94/11513	5/26/94	Medical Research Council Colston	
	B40	WO 94/14471	7/7/1994	Washington University	
,	B41	WO 94/29459	12/22/94	Whitehead Institute for Biomedical Research	
	B42	WO 97/04794	2/13/97	The American National Red Cross – The General Hospital Corporation	
	B43	WO 97/06685	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B44	WO 97/06821	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B45	WO 97/06828	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B46	WO 97/10001	03/20/97	Fordham University	
	B47	WO 97/26910	7/31/97	Max-delbruck medizen milleck	
	B48	WO 98/42752	10/01/98	Brigham and Woman's Hospital Inc.	
	B49	WO 98/46739	7/23/97	Juridicial Foundation the Chemo-Sero- therapeutic Research Institute	
	B50	WO 99/29834	06/17/99	Fordham University	

EXAMINER	DATE CONSIDERED
TEVANDED 13: 1:0.6	THE PERSON DE LEGISLATION OF THE PERSON OF T

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 2 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

Examiner	T		T
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C08	ABBAS et al., 1991, Cellular and Molecular Immunology, W.B. Saunders Co., Philadelphia (Chapters 15-18)	
	C09	AGOSTONI et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.	
	CIO	ALDOVINI et al., 1992, "The New Vaccines", Technology Review pp. 24-31	
,	CH	AMATO et al., 1999, "Active Specific Immunotherapy in Patients with Renal Cell Carcinoma (RCC) Using Autologous Tumor Derived Heat Shock Protein-Peptide Complex-96 (HSPP-96) Vaccine" American Society Clinical Oncology Meeting, abstract 1278	
	C12	ANDERSEN, P. 1994, "Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins," Infect. Immun. 62(6):2536-44	
	C13	ANDUS et al., Synthesis of alpha 2-macroglobulin in rat hepatocytes and in a cell-free system. FEBS Lett. 1983 Jan 10;151(1):10-14	
	C14	ANTHONY et al., 1999, "Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule," Vaccine 17(4):373-83	
	C15	BANCHEREAU et al., 1998, "Dendritic cells and the control of immunity," Nature 392:245-252	
	C16	BARRIOS et al., 1992, "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and BacillusCalmette Guerin priming," Eur. J. Immunol. 22(6):1365-72	
	C17	BARRIOS et al., 1994, "Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and Dna K proteins requires cross-linking with antigen," Clin. Exp. Immunol. 98(2):229-233	
	C18	BARRIOS et al., 1994, "Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD." Clin Exp Immunol. 98(2):224-8	
	CI9	BARTLETT, 1972 "Effect Of Host Immunity On The Antigenic Strength Of Primary Tumors." J. Natl. Cancer Inst. 49:493-504	
	C20	BASOMBRÍO (1970) "Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene", <i>The Institute for Cancer Research</i> 30:2458-2462	
	C21	BASU and SRIVASTAVA, 1999, "Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity" J. Exp. Med. 189:797-802	
	C22	BASU et al., 2000, "Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway," Int. Immunol. 12(11):1539-46	
	C23	BASU et al., 2001, "CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin," Immunity 14:303-313	
	C24	BEDNAR et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.	
	C25	BELLONE et al., 1999, "Cancer Immunotherapy: synthetic and natural peptides in balance," Immunology Today 20(10): 457-462	
	C26	BEVERLY, 1988, "Tumour Immunology." In: <i>Immunology</i> , 3rd Edition, Roitt, Ed., Mosby, London, pp. 17.1-17.12	

EXAMINER		DATE CONSIDERED
1-27. 140.4 1.1.1.1.7	 	the American Cooperation of the

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 3 of 6 of List of References

	ATTY: DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C27	BINDER and Srivastava, 2004, "Essential role of CD91 in re-presentation of gp96-chaperoned peptides," Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133	
	C28	BINDER et al., 2000, "CD91: a receptor for heat shock protein gp96," Nature Immunol. 1(2):151-155	
•	C29	BINDER et al., 2001, "Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatability complex I molecules," J. Biol. Chem. 276(20): 17163-17171	
	C30	BIRKENMEIER G., 2001, "Targetting the Proteinase Inhibitor and Immune Modulatory Function of Human α2-Macroglobulin." Mod. Asp. Immunobiol. 2(1):32-36	
	C31	BLACHERE and SRIVASTAVA (1993) "Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells", J. Cellular Biochem. Keystone Symposia, 17D: pp. 124, Abstract NZ 502	
	C32	BLACHERE et al., 1993, "Heat Shock Protein Vaccines Against Cancer," Journal of Immunotherapy 14:352-356	
	C33	BLANDER et al., 1993, "Major cytoplasmic membrane protein of Legionella pnumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease," J. Clin. Invest. 91(2):717-23	
	C34	BODEY et al., 2000, Anticancer Res 20:2665-2676 Abs	
	C35	BOSCH et al., 1999, "State of the art of therapeutic apheresis in Europe", Ther. Apher. 3(3):197-8	
	C36	BRELOER et al., 1999, "in vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins," J. Immunol. 162:3141-3147	
	C37	BUMOL et al., 1988 "Characterization Of The Human Tumor And Normal Tissue Reactivity Of The KS1/4 Monoclonal Antibody." Hybridoma 7:407-415	
	C38	CARSWELL et al., 1970, "Immunogenic Properties Of Reticulum Cell Sarcomas Of SJL/J Mice." Natl. Cancer Inst. 44:1281-1288	
	C39	CASSEL et al., 1977, "Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses," Cancer 40:672-679	
	C40	CASSEL et al., 1983 "A Phase II Study On The Postsurgical Management Of Stage II Malignant Melanoma With A Newcastle Disease Virus Oncolysate." Cancer, 52:856-860	
	C41	CASTELLI et al., 2001, "Human Heat Shock Protein 70 Peptide Complexes Specifically Active Antimelanoma T cells." Cancer Res 61:222-227	
	C42	CHANDAWARKAR et al., 2004, "Immune modulation with high-dose heat shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis," Int'l. Immunol. 16:315-324	
	C43	CHU et al., 1994, α ₂ -Macroglobulin: A Sensor for Proteolysis," Ann. N.Y. Acad. Sci. 737:291-307	T
	C44	CLARKE et al. 1988, "Purification of Complexes of Nuclear Oncogene p53 with Rat and Escherichia coli Heat Shock Proteins: In Vitro Dissociation of hsc70 and dnaK from Murine p53 by ATP" Mol. and Cell. Biol. Vol. 8 (3) 1206-1215	
	C45	COLLEN et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.	
	C46	COSTANZO, 1996, "New monoclonal antibodies," Curr. Opin. Cardiol. 11(2):204-7	T

EXAMINER	DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 4 of 6 of List of References

	1	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		
	1	ART UNIT 1643

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
minus	C47	CRAIG, 1993, "Chaperones: Helpers Along the Pathways to Protein Folding," Science 260:1902-4	
	C48	D'ANDREA, 2005, "Add Alzheimer's disease to the list of autoimmune diseases," Med. Hypotheses 64(3):458-463	
	C49	DASH, et al., 2002 "Slow-Tight Binding Inhibition of Xylanase by an Aspartic Protease Inhibitor." J. Biol. Chem. 277:17978-17986	
	C50	DAVIDOFF et al., 1992, "Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers	
. 	C51	DEL GIUDICE et al., 1994, "Hsp70: a carrier molecule with built-in adjuvanticity", Experientia 30;50(11-12):1061-6	
	C52	DERMER, 1994, "Another Anniversary for the War on Cancer," Biotechnology 12:320	
	C53	DEUTSCHER et al., 1992 "Guide to protein purification." Meth. Enzymol., 182:610-611	
	C54	DUBOIS et al., 1980, "Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells," Cancer Res. 40:4204-4208	
	C55	DUBOIS, et al., 1982 "Purification and Biochemical Properties of Tumor-Associated Transplantation Antigens From Methylcholanthrene-Induced Murine Sarcomas." Proc. Natl. Acad. Sci USA, 79:7669-7673	
	C56	ELLGAARD ET AL., 1997,"Dissection of the domain architecture of the alpha2macrglobulin-receptor associated protein." Eur. J. Biochem 244:544-51	
	C57	EPPLEN et al., 1997, "Genetic predisposition to multiple sclerosis as revealed by immunoprinting," Ann. Neurol. 41(3):341-52.	
	C58	ESPANA et al., 1996, Clin. Chem 42(3):545-550	
	C59	ESTIN et al., 1989, "Transfected mouse melanoma lines that express various levels of human melanoma-associated antigen p97," J. Natl. Cancer Inst. 81:445-448	
	C60	EVANS et al., 1999, Q.J. Med 92:299-307	
	C61	FALK et al., 1990, "Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules", Nature 348:248-251	
	C62	FALK et al., 1991, "Identification of Naturally Processed Viral Nonapeptides Allows Their Quantification in Infected Cells and Suggests an Allele-specific T Cell Epitope Forecast". J Exp. Med 174:425-434	
	C63	FALK et al., 1991, "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC Molecules", <i>Nature</i> 351:290-296	
	C64	FALK et al., 1992, "Specificity of antigen processing for MHC class I restricted presentation is conserved between mouse and man", Eur. J. Immunol. 22:1323-1326	
	C65	FAY et al., 1979, "Leukopheresis Therapy of Leukemic Reticuloendotheliosis (Hairy Cell Leukemia)", Blood 54: 747-749	
	C66	FEDWEG and SRIVASTAVA "Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor rejection antigen", Mount Sinai School of Medicine NZ 206, p. 108	
	C67	FENG et al., 2002, "Exogenous heat shock proteins provide adjuvant effects on enhancing the immunogenicity of apoptotic tumor cells and inducing antitumor immunity," AACR 93 rd Annual Meeting, Vol. 43, April 6-10, Abstract #2214	
	C68	FERRERO et al., 1995, The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA 92(14):6499-503	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conform	nance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: ED 608 969 358 US Sheet 5 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
mitiais	C69	FLYNN et al., 1989, "Peptide binding and release by proteins implicated as catalysts of protein assembly",	+
		Science 245:385-390	
	C70	FLYNN et al., 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", Nature 353:726-730	
	C71	FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and chemotaxis", Immunology 50(2):251-9	
	C72	FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New York p4	
	C73	GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489	
	C74	GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55	
	C75	GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4	
	C76	GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5	T
	C77	GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64	
	C78	GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71	
	C79	GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95	
	C80	GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41	
	C81	GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416	T
	C82	GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909	
	C83	GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476	Ī
	C84	GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234	
	C85	GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846	
	C86	GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120	T
	C87	HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116	
	C88	HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.	
	C89	HARLOW et al., 1988, "Antibodies: A Laboratory Manual" ch 6:139-243	T

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conform	nance with MPEP 609; Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 6 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE	ART UNIT
	June 4, 2001	1643

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т	
	C90	HEEB et al., 1995, "Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera." Biochem, Mol. Biol. Int. 37(5):917-23		
	C91	HEISKALA et al., 1988 "Characteristics Of Soluble Tumour-Derived Proteins That Inhibit Natural Killer Activity." Scand. J. Immunol. 28:19-27		
	C92	HENTTU AND VIHKO, 1989 "cDNA Coding For The Entire Human Prostate Specific Antigen Shows High Homologies To The Human Tissue Kallikrein Genes." <i>Biochem. Biophys. Res. Comm.</i> 160:903-910		
- 11-1	C93	HERZ AND STRICKLAND, 2001, "LRP: a multifunctional scavenger and signaling receptor," J. Clin. Invest. 108:779-784		
	C94	HERZ et al., 1990, "Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver", J. of Biol. Chem. 265(34): 21355-21362.		
<u>-</u>	C95	HERZ et al., 1991, "39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor." J.Biol.Chem. 266(31):21232-21238.		
	C96	HEY et al., 1988, "Cloning of a novel member of the low-density lipoprotein receptor family", Gene 216: 103-111.		
	C97	HINDS et al., 1987, "Immunological Evidence for the Association of p53 with a Heat Shock Protein, hsc70, in p53-plus-ras-Transformed Cell Lines" Mol. and Cell. Biol. Vol.7 (8) 2863-2869		

EXAMINER	DATE CONSIDERED	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 1 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
	APPLICANT Srivastava et al.	
	FILING DATE	ARTUNIT
	June 4, 2001	1643

	NON PATENT LITERATURE DOCUMENTS
C98	HINDS et al., 1990, "Mutant p53 DNA Clones from Human Colon Carcinomas Cooperate with ras in Transforming Primary Rat Cells: A Comparison of the "Hot Spot" Mutant Phenotypes" Cell Growth and Differentiation Vol. 1 571-580
C99	HOLLINSHEAD, 1988, "Immunotherapy," in: Cancer: The Outlaw Cell, LaFond, ed., American Chemical Society, Washington, DC pp. 237-250 (Chapter 14)
C100	HORN et al., 1995, "Analysis of the binding of Pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library", J. of Biol. Chem. 270 (20): 11770-11775.
C101	HORWITZ et al., 1995, Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 92(5):1530-4
C102	
C103	HUBBARD et al., 1992, "Immunization of mice with mycobacterial culture filtrate proteins," Clin. Exp. Immunol. 87(1):94-8
C104	HUGHES et al., 1970, "A Study In Clinical Cancer Immunotherapy", Cancer, 26:269-278
	HUGHES et al., 1981, "Characterization of plasma membrane proteins identified by monoclonal antibodies", J. of Biol./ Chem. 256(2): 664-671.
C106	HUMPHREY et al., 1984, "Adjuvant immunotherapy for melanoma," J. Surg. Concol. 25:303-305
	HUNTER, N. et al., 1991, "Suppression of experimental allergic encephalomyelitis by alpha(2)-macroglobulin," Immunology 73:58-63
C108	
C109	ISHII et al., 1999, "Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96", J Immunol. 162(3):1303-9
C110	
CIII	JAIN et al., 1994, "Barriers to drug delivery in solid tumors." Sc Am 171(1):58-65
C112	JAKOB et al., 1993, "Small Heat Shock Proteins Are Molecular Chaperones", J. Biol. Chem. 268:1517-1520
C113	JAMES, K., 1980, "Alpha (2) macroglobulin and its possible importance in immune systems," Trends in Biol. Sci. p.43-47
C114	JANETZKI et al., 2000, "Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study" Int. J. of Cancer 88:232-238
C115	JANEWAY, Travers, Walport, and Shlomchick, 2001, Immunobiology, 5th ed., Garland Publishing, New York (Part V, Sections 13-1 to 13-15)
C116	JARDETZKY et al., 1991, "Identification of Self Peptides Bound to Purified HLA-B27", Nature 353:326-329
	JINDAL et al., 1989, "Primary structure of a human mitochondrial protein homologous to the bacterial and plant chaperonins and to the 65-kilodalton mycobacterial antigen. Mol Cell Biol. 9(5):2279-83
CII8	JOCHAM et al., 2004, "Adjuvant Autologous Renal Tumour Cell Vaccine and Risk of Tumour Progression in Patients with Renal-Cell Carcinoma After Radical Nephrectomy: Phase III, Randomised Controlled Trial." The Lancet, Vol 363:594-599

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 2 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

C119	KATSANIS et al., 2000, "Augmentation of Tumor Lysate Immunogencity by enrichment of Chaperone Proteins Using Free Solution Isoelectric Focusing (FS-IEF)" Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer, abstract 431
C120	KATSUTANI et al., 1992, "Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice." Fundam Appl Toxicol.19(4):555-62.
C121	KIM et al., 1998, "A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognized apolipoprotein E", J. Biochem. 124: 1072-1076.
C122	KIMBER et al., 2002, "Lactoferrin: influences on langerhans cells, epidermal cytokines, and cutaneous inflammation." Biochem Cell Biol. 2002;80(1):103-7.
C123	KOJIMA et al., 2002, "Combination therapy of tumor-derived gp96 and GM-CSF or IL-12-gene transduced tumor cells in the control of LLC tumor," AACR 93 rd Annual Meeting, Vol. 43, Abstract #5516
C124	is an essential receptor for HSP60 activation of monomuclear cells", J Immunol. 164(1):13-17
	KOO, 1982, "Characterization of growth-inhibitory activities associated with an alpha-macroglobulin of mice," Cancer Res. 42(5):1788-97
C126	KORNFELD et al., 1980, "Plasmapheresis in Myasthenia Gravis," Plasma Therapy, 2(3): 127-133
C127	53:1333-1336
C128	protein (LRP) is the alpha 2-macroglobulin receptor", FEBS Lett. 276(1-2):151-5
C129	KUHLMANN et al., 1997, "Drug Research: from the idea to the product," International Journal of Pharmacology and Therapeutics 35:541-552
	LAKEY et al., 1987, "Identification of a peptide binding protein that plays a role in antigen presentation", Proc. Natl. Acad. Sci. USA 84:1659-1663
C131	LANZAVECCHIA, 1993, "Identifying Strategies for Immune Intervention", Science 260:937-944
	LÉVY, 1991, "ATP is Required for In Vitro Assembly of MHC Class I Antigens but Not for Transfer of Peptides across the ER Membrane", Cell 67:265-274
C133	LI and SRIVASTAVA, 1993, "Tumor rejection antigen gp96/grp94 is an ATPase: Implications for protein folding and antigen presentation", EMBO J. 12(8):3143-3151
C134	Lysates of Autologous and Allogeneic Cultured Melanoma Cells." Cancer, 55:713-720
C135	Freeman and Company 2000
C136	LUESCHER et al., 1991, "Specific Binding of Antigenic Peptides to Cell-associated MHC Class I Molecules", Nature 351:72-77
C137	induce protection against tumors", J. Exp. Med. 178:343-348
C138	21(10):2297-302
C139	

|--|

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 3 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

C140	MAKI (1991) "The Human Homologue of the Mouse Tumor Rejection Antigen GP96", Ph.D. thesis,
	Cornell University
C141	MARTIN et al., 1986, "Role of Murine Tumor Models in Cancer Treatment Research", Cancer Research
	46:2189-2192
C142	MATSUTAKE et al., 2001, "The immunoprotective MHC II epitope of a chemically induced tumor
	harbors a unique mutation in a ribosomal protein," PNAS 98(7):3992-3997
C143	··
	induction of heat shock protein expression", Nat. Med. 5:581-7
C144	MELIEF et al., 1992, "Lessons from T Cell Responses to Virus Induced Tumours for Cancer Eradication
	in General", Career Surveys 13:81-99
C145	MELNICK, 1985, "Virus Vaccines: An Overview", Proceedings of the First Annual Southwest Foundation
	for Biomedical Research International Symposium, Houston, Texas, 8-10 November 1984, American
	Society for Microbiology pp. 1-13
C146	MÉNORET and CHANDAWARKAR, 1998, "Heat-shock protein-based anticancer immunotherapy: an
	idea whose time has come" Semin. in Oncology 25:654
C147	
	constitutive hsp70 in rat colon carcinomas," J. Immunol. 155:740-7
C148	, , , , , , , , , , , , , , , , , , , ,
	Clin. Apheresis 1: 25-32
C149	
C150	Biotherapy 10:173-185 MOESTRUP et al., 1990, "Immunocytochemical identification of the human aplpha 2-macroglobulin
10130	receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte
	differentiation antigen", Exper. Cell Res. 190: 195-203.
0151	
C151	1 1.10 20 11 to 1 to any 1991, 1 man job of an Banca and a Banca and a partie and a man a man and a man a
	receptor (low density lipoprotein receptor-related protein). J. Biol. Chem. 266(21):14011-14017.
C152	, , , , , , , , , , , , , , , , , , , ,
	Complexed to Heat Shock PRotein 70." Proc. Natl. Acad. Sci. 97(7):3485-3490
	MSNBC News Services, 2000, "Mixed Results on new cancer drug."
C154	· · · · · · · · · · · · · · · · · · ·
	Recombinant Interleukin-2", Science 225:1487-1489
C155	
0156	and immunoglobulin heavy chain binding protein", Cell 46(2):291-300
C156	1
0157	Studies." Cancer 40:680-686
C157	• · · · · · · · · · · · · · · · · · ·
C159	Potent Tumor Vaccines." Eur. J. Immunol. 27:589-597
C158	1
C150	against bound peptides" J. Immunol. 162:6426 NATALI et al., 1987 "Immunohistochemical Detection Of Antigen In Human Primary And Metastatic
C159	NATALI et al., 1987 Immunonistochemical Detection Of Antigen in Human Primary And Metastatic
	Melanomas By The Monoclonal Antibody 140.240 And Its Possible Prognostic Significance." Cancer, 59:55-63

EXAMINER	DATE CONSIDERED
MEN ANAINTED. Initial if a foregreen a social and subother or not situation is in conform	names with MDED 600; Denvy line through sitution if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 4 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403		
	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

	NON PATENT LITERATURE DOCUMENTS	
C160	NIELAND et al., 1996, "Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94", Proc. Natl. Acad. Sci. USA 93:6135-6139	
C161		
C162	OETTGEN AND OLD, 1991 "The History Of Cancer Immunotherapy." In: Introduction To The Biologic Therapy Of Cancer", Devitta et al., Eds., Lippincott, Philadelphia, PA, pp.87-119 (Chapter 6)	
C163		
C164	OFFICE ACTION mailed on 05/18/05 for U.S. Application No. 09/625,137 filed 07/25/00	
C165	OFFICE ACTION mailed on 10/05/04 for U.S. Application No. 09/625,137 filed 07/25/00	
C166	OFFICE ACTION mailed on 11/02/05 for U.S. Application No. 09/625,137 filed 07/25/00	
C167	OFFICE ACTION mailed on 12/31/02 for U.S. Application No. 09/625,137 filed 07/25/00	
C168	OFFICE ACTION mailed on 02/08/06 for U.S. Application No. 09/668,724 filed 09/22/00	
C169		
C170	OFFICE ACTION mailed on 05/07/02 for U.S. Application No. 09/668,724 filed 09/22/00	
C171	OFFICE ACTION mailed on 06/20/07 for U.S. Application No. 09/668,724 filed 09/22/00	
C172	OFFICE ACTION mailed on 07/07/04 for U.S. Application No. 09/668,724 filed 09/22/00	
C173		
C174	OFFICE ACTION mailed on 03/13/06 for U.S. Application No. 09/750,972 filed 12/28/00	
C175	OFFICE ACTION mailed on 06/05/02 for U.S. Application No. 09/750,972 filed 12/28/00	
C176		
C177	OFFICE ACTION mailed on 01/11/06 for U.S. Application No. 10/225,367 filed 08/20/02	
C178	•	
C179	OFFICE ACTION mailed on 04/18/07 for U.S. Application No. 10/225,367 filed 08/20/02	
C180	OFFICE ACTION mailed on 09/25/06 for U.S. Application No. 10/225,367 filed 08/20/02	
C181	OFFICE ACTION mailed on 10/19/07 for U.S. Application No. 10/225,367 filed 08/20/02	
C182	OFFICE ACTION mailed on 01/03/06 for U.S. Application No. 10/427,857 filed 05/01/03	
C183	OFFICE ACTION mailed on 10/15/07 for U.S. Application No. 10/546,106 filed 10/11/05	
C184	OFFICE ACTION mailed on 02/22/07 for U.S. Application No. 10/784,012 filed 02/20/04	
C185	OFFICE ACTION mailed on 08/07/06 for U.S. Application No. 10/784,012 filed 02/20/04	
C186	OFFICE ACTION mailed on 11/02/07 for U.S. Application No. 10/784,012 filed 02/20/04	
C187	OHASHI et al., 2000, Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J. Immunol. 164:558-561	
C188	OLD et al., 1962 "Part II. Antigens Of Tumor Cells. Antigenic Properties Of Chemically-Induced Tumors." Ann. N.Y. Acad. Sci. 101:80-106	
C189	OPEKUN et al., 1999, "Novel therapies for Helicobacter pylori infection." Aliment Pharmacol Ther. 13(1):35-42.	
C190	PAL P.G., et al., 1992, "Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis." Infect Immun. 60(11):4781-92	
L		

EXAMINER	DATE CONSIDERED
#EVALUED I Willie Commended which are not ditation in in conform	sange with MPEP 600: Deau line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 5 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C191	PALLADINO et al., 1987, "Expression of shared tumor-specific antigen by two chemically induced
	BALB/c sarcomas", Cancer Research 47:5074-5079
C192	PARDOLL, 2000, "Therapeutic vaccination for cancer", Clin. Immunol. 95(1 Pt 2): S44-62
C193	PATTILLO, 1974 "Combination Chemotherapy-Immunotherapy Indirect Chemotherapy Sensitivity
	Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and
	Application: Proceedings of a Chicago Sumposium, Crispen, Ed. ITR, Chicago, IL, pp. 189-204
C194	PAUL, Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189-
	220 Cited On pp.1173-1174
C195	PAUL. Fundamental Immunology. 1993 Third Edition, Raven PRess, NY
C196	PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No.
	PCT/US03/14390
C197	PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No.
	PCT/US01/23098
C198	PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No.
	PCT/US01/18041
C199	PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No.
	PCT/US02/26573
C200	PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No.
	PCT/US2004/005110
C201	PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110
C202	PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by
	ADP-affinity chromatography" J. Immunol. Meth. 204:13
C203	PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4
	Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667
C204	PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4
C205	PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major
	heat shock protiens", Nature Vol 320 (13) 182-184
C206	PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl
	oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787
C207	
	18:769-778
C208	PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82
C209	RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol.
	3(2):139-54
C210	
	in treated patients." Thromb Haemost. 64(2):276-80.
C211	REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-
	Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882
C212	
	and Related Techniques, December 1984
C212	
C213	transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-
	induced sarcomas, Meth A and CI-4," Int. J. Cancer 27:789-796
	Induced sarcomas, frem A and Cl-7, Inc. 3. Cancel 21.702-770

EXAMINER	DATE CONSIDERED
	ish MDED 400. Draw line through sitution if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 6 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
	ROTHMAN, 1989, "Polypeptide Chain Binding Proteins: Catalysts of Protein Folding and Related Processes in Cells", Cell 59:591-601
C215	RÖTZSCHKE et al., 1990, "Isolation and Analysis of Naturally Processed Viral Peptides as Recognized by Cytotoxic T cells", Nature 348:248-251
C216	ROTZSCHKE, 1990, "Characterization of Naturally Occurring Minor Histocompatibility Peptides including H-4 and H-Y" Science 249: 283-287
C217	SALK et al., 1993, "A Strategy for Prophylactic Vaccination Against HIV", Science 260:1270-1272
C218	SALLUSTO et al., 1994, "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha." J. Exp. Med. 179(4):1109-1118
C219	SANO et al., 1987, "The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity," Cancer Immunol. Immunother. 25(3):180-184
C220	SAUTER et al., 2000, "Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells", J. Exp. Med. 191:423-434
ļ	SCHREIBER, 1989 "Tumor Immunology." In: Fundamental Immunology, 2nd Edition, Paul, ed., pp; 923-955
C222	SCHUMACHER et al., 1991, "Peptide Selection by MHC Class I Molecules", Nature 350:703-706
C223	SENGUPTA et al., 2004, "Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HI A Class I and Class II." J. Immunol, 173:1987-1993
C224	SILVA et al., 1994, "A single mycobacterial protein (hsp 65) expressed by a transgenic antigen-presenting cell vaccinates mice against tuberculosis", Immunology 82(2):244-8
C225	SINGH, 1997, "Neuroautoimmunity: pathogenic implications for Alzheimer's disease," Gerontology 43:79-94
C226	SMORODIN et al., 1991, "The complex of α-2 Macroglobulin with CD2 in the Plasma of Gastric Carcinoma Patients." Scand J. Immunol 33:699-706
C227	SORGER and PELHAM, 1987, "The glucose-regulated protein grp94 is related to heat shock protein hsp90". I Mol. Biol. 194(2):341-4
C228	SOTGIU et al., 1998, "Genetic susceptibility to multiple sclerosis in Sardinians: an immunological study," Acta. Neurol. Scand. 98(5):314-7
C229	
C230	SPERO et al., 1980, "Plasma Exchange in Preparation of Mild Factor IX Deficient Hemophiliacs for Surgical Procedures," 19-22
C231	SRIVASTAVA and HEIKE, 1986, "Tumor-specific immunogenicity of stress-induced proteins: Convergence of two evolutionary pathways of antigen presentation?", Seminars in Immunology 3:57-64
C232	SRIVASTAVA and OLD (1989) "Gp96 Molecules: Recognition Elements in Tumor Immunity", Human Tumor Antigens and Specific Tumor Therapy, pages 63-71
C233	SRIVASTAVA and UDONO, 1994, "Heat shock protein-peptide complexes in cancer immunotherapy" Curr. Opin. Immunol. 6:728
C234	

EXAMINER	DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 7 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C235	is also its Tumor-Associated Transplantation Antigen", Int. J. Cancer 33:417-422
C236	SRIVASTAVA et al., 1987, "5'-structural analysis of genes encoding polymorphic antigens of chemically induced tumors." Proc. Natl. Acad. Sci USA 84(11):3807-3811
C237	SRIVASTAVA et al., 1988, "Individually distinct transplantation antigens of chemically induced mouse tumors," Immunol. Today 9:78-83
C238	
C239	
C240	
C241	
C242	SRIVASTAVA PK, 1994, "Heat shock proteins in immune response to cancer: the Fourth Paradigm", Experientia. (11-12):1054-60
C243	
C244	
C245	STACK et al., 1982, "Autologous x-irradiated tumour cells and percutaneous BCG in operable lung cancer," Thorax 37(8):588-593
C246	encephalitis and multiple sclerosis," J. Exp. Med. 194:F27-F30
C247	STENMAN et al., 1991, "A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer," Cancer Res. 51(1):222-6
C248	A
C249	SUBBARAO et al., 1992, "A General Overview of Viral Vaccine Development," Genetically Engineered Vaccines 327:51-57
C250	SUZUE et al., 1997, "Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway," Proc. Natl. Acad. Sci. USA 94(24):13146-51
C251	
C252	SUZUE K., Young R.A., 1996, "Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1" p24. J Immunol. 156(2):873-9
C253	
C254	TAIT, BD, 1990, "Genetic susceptibility to type I diabetes: a review," J. Autoimmun. 3 Suppl. 1:3-11
C255	THE MERCK MANUAL of Diagnosis and Therapy, 1999, Beers and Berkow eds., Merck Research Laboratories, Whitehouse Station N.J., pp. 1871 and 1872

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conform	nance with MPEP 609: Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 8 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C256	THOMAS et al., 1982, "Molecular and Cellular Effects of Heat Shock and Related Treatments of Mammalian Tissue-Culture Cells", Cold Springs Harbor Symp Quant Biol 46:985-996
C257	TODRYK et al., 1999, "Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake," J. Immunol. 163:1398-1408
C258	TWINING et al., 1977, "Large scale separation of protease inhibitors from malignant human breast tissue." Mol. Cell. Biochem. 18(2-3):101-7
C259	UDONO et al., 1994, "Comparison of Tumor-Specific Immunogenicities of Stress-Induced Proteins gp96, hsp90, and hsp70," J. Immunol., 152(11):5398-5403
C260	UDONO, 1993, "Heat shock proteins HSP70, HSP90 and GP96 elicit tumor specific immunity to the tumors from which they are isolated", J. Cell. Biochem. Suppl. 17D:113 (Abstract NZ225)
C261	ULLRICH et al., 1986, "A mouse tumor-specific transplantation antigen is a heat shock-related protein," Proc. Natl. Acad. Sci. USA 83(10):3121-3125
C262	0 1 martin
C263	
C264	
C265	
C266	
C267	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
C268	WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054.
C269	
C270	WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884
C271	WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem. 257:14949-14959
C272	Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237
C273	WELCH et al., 1995, "Morphological study of the mammalian stress response: characterization of changes in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211
C274	
C275	in vivo and in vitro." The Biochemical Journal. England 313:71-76
C276	
C277	

EXAMINER	DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 9 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C278	YAMAUCHI et al., 2000, "Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study." Mycoses.43(5):197-202.
C279	YANG et al., 1999, "Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8+ and CD4+ T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity," Int. J. Cancer 83:532-540
C280	YEDAVELLI et al., 1999, "Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model" <i>Int. J. Mol. Med.</i> 3:243
C281	YU et al., 1991, "Sequence Analysis of Peptides Bound to MHC Class II Molecules", Nature 353:622-627
C282	
C283	ZIMECKI et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." Arch Immunol Ther Exp (Warsz). 47(2):113-8.

EXAMINER	DATE CONSIDERED
----------	-----------------



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Express Mail No.: <u>ED 608 969 344 US</u>

Sheet 1 of 3 of List of References

ATTY. DOCKET NO. 8449-178-999

APPLICATION NO. 09/873,403

APPLICANT

Srivastava et al.

FILING DATE
June 4, 2001

art unit 1643

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
INITIAL	A01	09/393,652	9/10/99	Srivastava	
	A02	2001-0034042	10/01	Srivastava	
	A03	2002-0001841	1/03/02	Kaltoft et al.	
	A04	2002-0028207	6/4/01	Srivastava	
	A05	2002-0037290	03/28/02	Armen	
	A06	2002-0172682	11/21/02	Srivastava	
	A07	2002-0192230	12/19/02	Srivastava	
	A08	2003-0129296	07/10/03	Srivastava	
	A09	2003-0211971	11/13/03	Srivastava	
	A10	2004-0022796	02/05/04	Srivastava	
	A11	2004-0253228	12/16/04	Srivastava	
	A12	2006-0165710	07/26/06	Srivastava	
	A13	4,690,915	9/1/87	Rosenberg	
	A14	5,112,298	5/12/1992	Prince et al.	
	A15	5,188,964	2/23/93	McGuire et al.	
	A16	5,232,833	8/3/93	Sanders et al.	_
	A17	5,273,965	12/28/93	Kensil et al.	
	A18	5,348,945	9/20/94	Berberian et al.	
	A19	5,554,293	9/10/1996	Uhoch	
	A20	5,580,859	12/3/96	Felgner et al.	
	A21	5,637,082	6/10/1997	Pages et al.	
	A22	5,652,115	7/29/97	Marks et al.	
4.4	A23	5,736,146	4/7/98	Cohen	
	A24	5,747,332	5/5/98	Wallen et al	
	A25	5,750,119	05/12/98	Srivastava	
	A26	5,830,464	11/03/98	Srivastava et al.	
	A27	5,846,928	12/8/1998	Kishida	
	A28	5,869,058	2/9/99	Cohen	
	A29	5,891,653	4/6/99	Attfield	
	A30	5,910,306	06/99	Alving et al.	

EXAMINER

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 344 US</u>

Sheet 2 of 3 of List of References

TICT	ΔE	REFERENCES	CITED	$\mathbf{p}\mathbf{v}$	ADDI ICANT
LIS I	OF	REFERENCES	CHED	DІ	APPLICANT

(Use several sheets if necessary)

_		
	ATTY. DOCKET NO.	APPLICATION NO.
	8449-178-999	09/873,403
	APPLICANT	
	Srivastava et al.	
	FILING DATE	ART UNIT
	June 4, 2001	1643

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
INTIAL	A31	5,947,646	07/19/99	Srivastava et al.	
	A32	5,968,526	10/19/99	Garman et al.	
	A33	5,997,873	12/7/99	Srivastava et al.	
	A34	6,007,821	12/28/99	Srivastava et al.	
-	A35	6,027,731	2/22/2000	Pauza	
	A36	6,030,618	02/29/00	Srivastava	
	A37	6,033,561	3/7/2000	Schoendorfer	
	A38	6,048,530	4/11/00	Srivastava	
	A39	6,136,315	10/24/00	Srivastava	
	A40	6,156,311	12/05/00	Strickland et al.	
	A41	6,162,436	12/19/00	Srivastava	
7	A42	6,168,793	1/2/01	Srivastava et al.	
	A43	6,312,711	11/6/01	Duchateau et al.	
	A44	6,333,311	12/25/2001	Nuijens et al.	
· · · · · · · · · · · · · · · · · · ·	A45	6,338,945	01/15/02	Nicolette	
	A46	6,403,092	6/11/02	Pizzo et al.	
	A47	6,433,141	8/13/02	Wallen et al.	
	A48	6,689,363	02/10/04	Sette et al.	
	A49	6,709,672	3/23/04	Henot et al.	
	A50	6,713,608	3/30/04	Wallen et al.	
	A51	6,730,302	5/4/04	Fujihara et al.	
	A52	6,797,480	9/28/04	Srivastava	
	A53	6,986,389	01/06	Li	
	A54	7,176,515	03/06/07	Srivastava et al.	
	A55	7,179,462	02/20/07	Srivastava et al.	
	A56	7,132,109	11/07/06	Srivastava	

EXAMINER	Þ

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 344 US</u> Sheet 3 of 3 of List of References

ART UNIT

1643

ATTY. DOCKET NO.

8449-178-999

APPLICANT

Srivastava et al.

FILING DATE

June 4, 2001

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

		FOREIGN	PATENT DOCUMENTS	
B01	DE 196 02 985 A1	1/27/96	Germany	
B02	GB 2 251 186A	7/1/92	United Kingdom	
B03	WO 00/03003	1/20/00	University of Nottingham	
B04	WO 00/10597	03/02/00	Immunology Limited	
B05	WO 00/34494	6/15/00	The Government of the United States of America represented by the Secretary, Dept. of Health and Human Services	
B06	WO 00/38760	7/6/2000	Occulogix Corp	
B07	WO 00/46246	8/10/00	The General Hospital Corp.	
B08	WO 00/54801	9/21/2000	Entremed Inc	
B09	WO 01/91787	6/12/01	University of Conneticut Health Center	
B10	WO 01/92474	12/06/01	University of Conneticut Health Center	
B11	WO 02/07755	1/3/2002	The General Hospital Corporation	
B12	WO 02/11669	02/14/02	Antigenics, LLC	
B13	WO 02/15930	2/28/02	Duke University	
B14	WO 02/30434	4/18/02	University of Conneticut Health Center	
B15	WO 02/32923	4/25/02	University of Conneticut Health Center	
B16	WO 02/34205	5/2/02	University of Conneticut Health Center	
B17	WO 03/015712	02/27/03	University of Conneticut Health Center	
B18	WO 03/090686	11/06/03	University of Conneticut Health Center	
B19	WO 03/092624	11/13/03	University of Conneticut Health Center	
B20	WO 04/035602	04/29/04	University of Conneticut Health Center	
B21	WO 04/075636	09/10/04	University of Conneticut Health Center	
B22	WO 04/74454	09/02/04	University of Conneticut Health Center	
B23	WO 05/120558	12/22/05	University of Conneticut Health Center	
B24	WO 89/12455	12/28/89	Whitehead Institute for Biomedical Research Medical Research Council	

EXAMINER

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 1 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	art unit 1643

FOREIGN PATENT DOCUMENTS WO 90/02564 3/22/90 Codon Dragon B25 The Wellcome Foundation Limited 10/17/91 WO 91/15572 **B26** 2/6/92 Burnie, James et al. WO 92/01717 **B27** 5/29/92 University College London WO 92/08484 **B28** University College London 5/29/92 WO 92/08488 B29 7/22/93 Medical Research Council WO 93/14118 **B30** Biocine Sclavo Spa Rappuoli 9/16/93 WO 93/17712 B31 Institut National de la Sante et de la 9/16/93 WO 93/18146 B32 researche medicale Institute Nazionale per lo studio e la 9/16/93 WO 93/18147 **B33** cura dei tumori fondazione giovanni pascale Biocine S.P.A. WO 93/18150 9/16/93 **B34** WO 93/21529 10/28/93 **Duke University B35** WO 93/24136 12/9/93 Terman, David S. **B36** 2/17/94 Yeda Research and Development WO 94/03208 **B**37 Company, Ltd The Victoria University of Manchester 3/3/94 WO 94/04676 **B38** 5/26/94 Medical Research Council Colston WO 94/11513 **B**39 Washington University 7/7/1994 WO 94/14471 B40 Whitehead Institute for Biomedical WO 94/29459 12/22/94 B41 Research The American National Red Cross -2/13/97 WO 97/04794 **B42** The General Hospital Corporation WO 97/06685 2/27/97 Sloan-Kettering Institute for Cancer **B43** Research Sloan-Kettering Institute for Cancer WO 97/06821 2/27/97 **B44** Research Sloan-Kettering Institute for Cancer 2/27/97 WO 97/06828 B45 Research 03/20/97 Fordham University WO 97/10001 **B46** 7/31/97 Max-delbruck medizen milleck WO 97/26910 B47 10/01/98 Brigham and Woman's Hospital Inc. WO 98/42752 B48 7/23/97 Juridicial Foundation the Chemo-Sero-WO 98/46739 B49 therapeutic Research Institute 06/17/99 Fordham University WO 99/29834 B50

EXAMINER	CE CONSIDERED
----------	---------------

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
	APPLICANT		
	Srivastava et al.		
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т	
	C08	ABBAS et al., 1991, Cellular and Molecular Immunology, W.B. Saunders Co., Philadelphia (Chapters 15-18)	_	
	C09	AGOSTONI et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.		
	C10	ALDOVINI et al., 1992, "The New Vaccines", Technology Review pp. 24-31		
	CII	AMATO et al., 1999, "Active Specific Immunotherapy in Patients with Renal Cell Carcinoma (RCC) Using Autologous Tumor Derived Heat Shock Protein-Peptide Complex-96 (HSPP-96) Vaccine" American Society Clinical Oncology Meeting, abstract 1278		
	C12	ANDERSEN, P. 1994, "Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins," Infect. Immun. 62(6):2536-44		
-	C13	ANDUS et al., Synthesis of alpha 2-macroglobulin in rat hepatocytes and in a cell-free system. FEBS Lett. 1983 Jan 10;151(1):10-14		
	C14	ANTHONY et al., 1999, "Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule," Vaccine 17(4):373-83	<u> </u>	
	C15	BANCHEREAU et al., 1998, "Dendritic cells and the control of immunity," Nature 392:245-252	1	
	C16	BARRIOS et al., 1992, "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and BacillusCalmette Guerin priming," Eur. J. Immunol. 22(6):1365-72	ļ	
	C17	BARRIOS et al., 1994, "Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and Dna K proteins requires cross-linking with antigen," Clin. Exp. Immunol. 98(2):229-233		
	C18	BARRIOS et al., 1994, "Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD." Clin Exp Immunol. 98(2):224-8		
	C19	BARTLETT, 1972 "Effect Of Host Immunity On The Antigenic Strength Of Primary Tumors." J. Natl. Cancer Inst. 49:493-504		
	C20	BASOMBRÍO (1970) "Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene", <i>The Institute for Cancer Research</i> 30:2458-2462		
	C21	BASU and SRIVASTAVA, 1999, "Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity" J. Exp. Med. 189:797-802		
	C22	BASU et al., 2000, "Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway," Int. Immunol. 12(11):1539-46		
	C23	BASU et al., 2001, "CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin," Immunity 14:303-313		
	C24	BEDNAR et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.		
	C25	BELLONE et al., 1999, "Cancer Immunotherapy: synthetic and natural peptides in balance," Immunology Today 20(10): 457-462		
	C26	BEVERLY, 1988, "Tumour Immunology." In: <i>Immunology</i> , 3rd Edition, Roitt, Ed., Mosby, London, pp. 17.1-17.12		

EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation considered. Include copy of this form with next communication to applicant.		

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 3 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	filing date June 4, 2001	ART UNIT 1643	

Examiner		(I. I. I	Т
Initials	C27	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) BINDER and Srivastava, 2004, "Essential role of CD91 in re-presentation of gp96-chaperoned peptides," Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133	
	C28	BINDER et al., 2000, "CD91: a receptor for heat shock protein gp96," Nature Immunol. 1(2):151-155	
	C29	BINDER et al., 2001, "Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatability complex I molecules," J. Biol. Chem. 276(20): 17163-17171	
	C30	BIRKENMEIER G., 2001, "Targetting the Proteinase Inhibitor and Immune Modulatory Function of Human α2-Macroglobulin." Mod. Asp. Immunobiol. 2(1):32-36	
••••	C31	BLACHERE and SRIVASTAVA (1993) "Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells", J. Cellular Biochem. Keystone Symposia, 17D: pp. 124, Abstract NZ 502	
	C32	BLACHERE et al., 1993, "Heat Shock Protein Vaccines Against Cancer," Journal of Immunotherapy 14:352-356	
	C33	BLANDER et al., 1993, "Major cytoplasmic membrane protein of Legionella pnumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease," J. Clin. Invest. 91(2):717-23	
	C34	BODEY et al., 2000, Anticancer Res 20:2665-2676 Abs	I
	C35	BOSCH et al., 1999, "State of the art of therapeutic apheresis in Europe", Ther. Apher. 3(3):197-8	
	C36	BRELOER et al., 1999, "in vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins," J. Immunol. 162:3141-3147	
	C37	BUMOL et al., 1988 "Characterization Of The Human Tumor And Normal Tissue Reactivity Of The KS1/4 Monoclonal Antibody." Hybridoma 7:407-415	
	C38	CARSWELL et al., 1970, "Immunogenic Properties Of Reticulum Cell Sarcomas Of SJL/J Mice." Natl. Cancer Inst. 44:1281-1288	
	C39	CASSEL et al., 1977, "Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses," Cancer 40:672-679	
	C40	CASSEL et al., 1983 "A Phase II Study On The Postsurgical Management Of Stage II Malignant Melanoma With A Newcastle Disease Virus Oncolysate." Cancer, 52:856-860	
	C41	CASTELLI et al., 2001, "Human Heat Shock Protein 70 Peptide Complexes Specifically Active Antimelanoma T cells." Cancer Res 61:222-227	
	C42	CHANDAWARKAR et al., 2004, "Immune modulation with high-dose heat shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis," Int'l. Immunol. 16:315-324	
	C43	CHU et al., 1994, α ₂ -Macroglobulin: A Sensor for Proteolysis," Ann. N.Y. Acad. Sci. 737:291-307	
	C44	CLARKE et al. 1988, "Purification of Complexes of Nuclear Oncogene p53 with Rat and Escherichia coli Heat Shock Proteins: In Vitro Dissociation of hsc70 and dnaK from Murine p53 by ATP" Mol. and Cell. Biol. Vol. 8 (3) 1206-1215	
	C45	COLLEN et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.	
	C46	COSTANZO, 1996, "New monoclonal antibodies," Curr. Opin. Cardiol. 11(2):204-7	\top

EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 4 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	filing date June 4, 2001	ART UNIT 1643	

Examiner	1		Π
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C47	CRAIG, 1993, "Chaperones: Helpers Along the Pathways to Protein Folding," Science 260:1902-4	
	C48	D'ANDREA, 2005, "Add Alzheimer's disease to the list of autoimmune diseases," Med. Hypotheses 64(3):458-463	
	C49	DASH, et al., 2002 "Slow-Tight Binding Inhibition of Xylanase by an Aspartic Protease Inhibitor." J. Biol. Chem. 277:17978-17986	
	C50	DAVIDOFF et al., 1992, "Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers	
	C51	DEL GIUDICE et al., 1994, "Hsp70: a carrier molecule with built-in adjuvanticity", Experientia 30;50(11-12):1061-6	
	C52	DERMER, 1994, "Another Anniversary for the War on Cancer," Biotechnology 12:320	
	C53	DEUTSCHER et al., 1992 "Guide to protein purification." Meth. Enzymol., 182:610-611	
	C54	DUBOIS et al., 1980, "Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells," Cancer Res. 40:4204-4208	
	C55	DUBOIS, et al., 1982 "Purification and Biochemical Properties of Tumor-Associated Transplantation Antigens From Methylcholanthrene-Induced Murine Sarcomas." Proc. Natl. Acad. Sci USA, 79:7669-7673	
	C56	ELLGAARD ET AL., 1997,"Dissection of the domain architecture of the alpha2macrglobulin-receptor associated protein." Eur. J. Biochem 244:544-51	
	C57	EPPLEN et al., 1997, "Genetic predisposition to multiple sclerosis as revealed by immunoprinting," Ann. Neurol. 41(3):341-52.	Ī
	C58	ESPANA et al., 1996, Clin. Chem 42(3):545-550	
	C59	ESTIN et al., 1989, "Transfected mouse melanoma lines that express various levels of human melanoma-associated antigen p97," J. Natl. Cancer Inst. 81:445-448	
	C60	EVANS et al., 1999, O.J. Med 92:299-307	
	C61	FALK et al., 1990, "Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules", <i>Nature</i> 348:248-251	
	C62	FALK et al., 1991, "Identification of Naturally Processed Viral Nonapeptides Allows Their Quantification in Infected Cells and Suggests an Allele-specific T Cell Epitope Forecast". J Exp. Med 174:425-434	
	C63	FALK et al., 1991, "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC Molecules", Nature 351:290-296	
	C64	FALK et al., 1992, "Specificity of antigen processing for MHC class I restricted presentation is conserved between mouse and man", Eur. J. Immunol. 22:1323-1326	
	C65	FAY et al., 1979, "Leukopheresis Therapy of Leukemic Reticuloendotheliosis (Hairy Cell Leukemia)", Blood 54: 747-749	
	C66	FEDWEG and SRIVASTAVA "Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor rejection antigen", Mount Sinai School of Medicine NZ 206, p. 108	
	C67	FENG et al., 2002, "Exogenous heat shock proteins provide adjuvant effects on enhancing the immunogenicity of apoptotic tumor cells and inducing antitumor immunity," AACR 93 rd Annual Meeting, Vol. 43, April 6-10, Abstract #2214	
	C68	FERRERO et al., 1995, The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA 92(14):6499-503	

EXAMINER	DATE CONSIDERED
	id Marin (Co. D. F. d. L. india in Co. D. C. d. india in Co. D. d. india i

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 5 of 6 of List of References

·	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	art unit 1643	

Examiner		(7 1 1 Cd - dr. (2 CADITAL I ETTERS) Title Date Desirant Pages Etc.)	า
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	+'
	C69	FLYNN et al., 1989, "Peptide binding and release by proteins implicated as catalysts of protein assembly", Science 245:385-390	
	C70	FLYNN et al., 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", Nature 353:726-730	1
	C71	FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and chemotaxis", Immunology 50(2):251-9	
	C72	FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New York p4	
	C73	GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489	
	C74	GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-	
	C75	GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4	
	C76	GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5	
	C77	GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64	
	C78	GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71	
***	C79	GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95	
	C80	GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41	
	C81	GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416	†
	C82	GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909	
	C83	GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476	1
· <u>-</u>	C84	GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234	
	C85	GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846	
	C86	GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120	1
	C87	HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116	T
	C88	HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.	
	C89	HARLOW et al., 1988, "Antibodies: A Laboratory Manual" ch 6:139-243	十


EXAMINER	DATE CONSIDERED
*EVAMINED. Initial if reference considered whether or not citation is in confor	mance with MPEP 600: Draw line through citation if not in conformance and not.

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 6 of 6 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
	APPLICANT		
	Srivastava et al.		
·	FILING DATE	ART UNIT	
	June 4, 2001	1643	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
THE COLUMN TO TH	C90	HEEB et al., 1995, "Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera," Bjochem, Mol. Biol. Int. 37(5):917-23	
	C91	HEISKALA et al., 1988 "Characteristics Of Soluble Tumour-Derived Proteins That Inhibit Natural Killer Activity." Scand. J. Immunol. 28:19-27	
	C92	HENTTU AND VIHKO, 1989 "cDNA Coding For The Entire Human Prostate Specific Antigen Shows High Homologies To The Human Tissue Kallikrein Genes." <i>Biochem. Biophys. Res. Comm.</i> 160:903-910	
	C93	HERZ AND STRICKLAND, 2001, "LRP: a multifunctional scavenger and signaling receptor," J. Clin. Invest. 108:779-784	
	C94	HERZ et al., 1990, "Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver", J. of Biol. Chem. 265(34): 21355-21362.	
	C95	HERZ et al., 1991, "39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor." J.Biol.Chem. 266(31):21232-21238.	
	C96	HEY et al., 1988, "Cloning of a novel member of the low-density lipoprotein receptor family", Gene 216: 103-111.	
	C97	HINDS et al., 1987, "Immunological Evidence for the Association of p53 with a Heat Shock Protein, hsc70, in p53-plus-ras-Transformed Cell Lines" Mol. and Cell. Biol. Vol.7 (8) 2863-2869	

EXAMINER	DATE CONSIDERED





LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
APPLICANT	
Srivastava et al.	
FILING DATE Lune 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C98	HINDS et al., 1990, "Mutant p53 DNA Clones from Human Colon Carcinomas Cooperate with ras in Transforming Primary Rat Cells: A Comparison of the "Hot Spot" Mutant Phenotypes" Cell Growth and Differentiation Vol. 1 571-580
C99	HOLLINSHEAD, 1988, "Immunotherapy," in: Cancer: The Outlaw Cell, LaFond, ed., American Chemical Society, Washington, DC pp. 237-250 (Chapter 14)
C100	• • • • • • • • • • • • • • • • • • •
C101	HORWITZ et al., 1995, Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 92(5):1530-4
C102	
C103	
C104	
C105	
C106	HUMPHREY et al., 1984, "Adjuvant immunotherapy for melanoma," J. Surg. Concol. 25:303-305
C107	
C108	
C109	ISHII et al., 1999, "Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96", J Immunol. 162(3):1303-9
C110	
CIII	JAIN et al., 1994, "Barriers to drug delivery in solid tumors." Sc Am 171(1):58-65
C112	JAKOB et al., 1993, "Small Heat Shock Proteins Are Molecular Chaperones", J. Biol. Chem. 268:1517-1520
C113	Biol. Sci. p.43-47
C114	
C115	JANEWAY, Travers, Walport, and Shlomchick, 2001, Immunobiology, 5th ed., Garland Publishing, New York (Part V, Sections 13-1 to 13-15)
C116	JARDETZKY et al., 1991, "Identification of Self Peptides Bound to Purified HLA-B27", Nature 353:326-329
C117	JINDAL et al., 1989, "Primary structure of a human mitochondrial protein homologous to the bacterial and plant chaperonins and to the 65-kilodalton mycobacterial antigen. Mol Cell Biol. 9(5):2279-83
C118	

EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not		

considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 2 of 9 of List of References

•	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Srivastava et al.		
	FILING DATE	ART UNIT	
·	June 4, 2001	1643	

C119	KATSANIS et al., 2000, "Augmentation of Tumor Lysate Immunogencity by enrichment of Chaperone Proteins Using Free Solution Isoelectric Focusing (FS-IEF)" Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer, abstract 431
C120	KATSUTANI et al., 1992, "Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice." Fundam Appl Toxicol.19(4):555-62.
C121	KIM et al., 1998, "A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognized apolipoprotein E", J. Biochem. 124: 1072-1076.
C122	KIMBER et al., 2002, "Lactoferrin: influences on langerhans cells, epidermal cytokines, and cutaneous inflammation." Biochem Cell Biol. 2002;80(1):103-7.
C123	KOJIMA et al., 2002, "Combination therapy of tumor-derived gp96 and GM-CSF or IL-12-gene transduced tumor cells in the control of LLC tumor," AACR 93 rd Annual Meeting, Vol. 43, Abstract #5516
C124	KOL et al., 2000, "Cutting edge: heat shock protein (HSP)60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of monomuclear cells", J Immunol. 164(1):13-17
	KOO, 1982, "Characterization of growth-inhibitory activities associated with an alpha-macroglobulin of mice," Cancer Res. 42(5):1788-97
C126	KORNFELD et al., 1980, "Plasmapheresis in Myasthenia Gravis," Plasma Therapy, 2(3): 127-133
C127	KRIPKE, 1974 "Antigenicity Of Murine Skin Tumors Induced By Ultraviolet Light." J. Natl. Cancer Inst. 53:1333-1336
C128	KRISTENSEN et al., 1990, "Evidence that the newly cloned low-density-lipoprotein receptor related protein (LRP) is the alpha 2-macroglobulin receptor", FEBS Lett. 276(1-2):151-5
C129	KUHLMANN et al., 1997, "Drug Research: from the idea to the product," International Journal of Pharmacology and Therapeutics 35:541-552
C130	
C131	LANZAVECCHIA, 1993, "Identifying Strategies for Immune Intervention", Science 260:937-944
C132	LÉVY, 1991, "ATP is Required for In Vitro Assembly of MHC Class I Antigens but Not for Transfer of Peptides across the ER Membrane", Cell 67:265-274
	LI and SRIVASTAVA, 1993, "Tumor rejection antigen gp96/grp94 is an ATPase: Implications for protein folding and antigen presentation", EMBO J. 12(8):3143-3151
İ	LIVINGSTON et al. 1985, "Serological Response of Melanoma Patients to Vaccines Prepared from VSV Lysates of Autologous and Allogeneic Cultured Melanoma Cells." Cancer, 55:713-720
	LODISH et al., <i>Molecular Cell Biology</i> , ch. 17.3 "Overview of the Secretory Pathway". pp 691-696, W.H. Freeman and Company 2000
	LUESCHER et al., 1991, "Specific Binding of Antigenic Peptides to Cell-associated MHC Class I Molecules", Nature 351:72-77
	LUKACS et al., 1993, "Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors", J. Exp. Med. 178:343-348
C138	LUSSOW et al., 1991, "Mycobacterial heat-shock proteins as carrier molecules", Eur J Immunol. 21(10):2297-302
C139	
	Conformation", Nature 353:321-325

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not	

considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 3 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
	APPLICANT Srivastava et al.	
	filing date June 4, 2001	ART UNIT 1643

LC140	MAKI (1991) "The Human Homologue of the Mouse Tumor Rejection Antigen GP96", Ph.D. thesis,
10140	Cornell University
C141	MARTIN et al., 1986, "Role of Murine Tumor Models in Cancer Treatment Research", Cancer Research
	46:2189-2192
C142	MATSUTAKE et al., 2001, "The immunoprotective MHC II epitope of a chemically induced tumor
	harbors a unique mutation in a ribosomal protein," PNAS 98(7):3992-3997
C143	MELCHER et al., 1998, "Tumor immunogenicity is determined by the mechanism of cell death via
	induction of heat shock protein expression", Nat. Med. 5:581-7
C144	MELIEF et al., 1992, "Lessons from T Cell Responses to Virus Induced Tumours for Cancer Eradication
	in General", Career Surveys 13:81-99
C145	MELNICK, 1985, "Virus Vaccines: An Overview", Proceedings of the First Annual Southwest Foundation
	for Biomedical Research International Symposium, Houston, Texas, 8-10 November 1984, American
	Society for Microbiology pp. 1-13
C146	MÉNORET and CHANDAWARKAR, 1998, "Heat-shock protein-based anticancer immunotherapy: an
	idea whose time has come" Semin. in Oncology 25:654
C147	MENORET et al., 1995, "Co-segregation of tumor immunogenicity with expression of inducible but not
	constitutive hsp70 in rat colon carcinomas," J. Immunol. 155:740-7
C148	1
	Clin. Apheresis 1: 25-32
C149	1
	Biotherapy 10:173-185
C150	
	receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte
	differentiation antigen", Exper. Cell Res. 190: 195-203.
C151	
	receptor (low density lipoprotein receptor-related protein). J. Biol. Chem. 266(21):14011-14017.
C152	MOROI et al., 2000, "Induction of Cellular Immunity by Immunization with Novel Hybrid Peptides
	Complexed to Heat Shock PRotein 70." Proc. Natl. Acad. Sci. 97(7):3485-3490
C153	MSNBC News Services, 2000, "Mixed Results on new cancer drug."
C154	MULÉ et al., 1984, "Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and
	Recombinant Interleukin-2", Science 225:1487-1489
C155	
	and immunoglobulin heavy chain binding protein", Cell 46(2):291-300
C156	MURRAY et al., 1977 "Viral Oncolysate in the Management of Malignant Melanoma II, Clinical
	Studies." Cancer <u>40</u> :680-686
C157	1
	Potent Tumor Vaccines." Eur. J. Immunol. 27:589-597
C158	
	against bound peptides" J. Immunol. 162:6426
C159	NATALI et al., 1987 "Immunohistochemical Detection Of Antigen In Human Primary And Metastatic
	Melanomas By The Monoclonal Antibody 140.240 And Its Possible Prognostic Significance." Cancer,
	59:55-63

EXAMINER	DATE CONSIDERED
	<u> </u>

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

Cie	NIELAND et al., 1996, "Isolation of an immunodominant viral peptide that is endogenously bound to the
Cit	stress protein GP96/GRP94", Proc. Natl. Acad. Sci. USA 93:6135-6139
CIO	
	Spring Harbor, NY pp. 387-394
Cle	
	Therapy Of Cancer", Devitta et al., Eds., Lippincott, Philadelphia, PA, pp.87-119 (Chapter 6)
Cle	3 OFFICE ACTION mailed on 02/26/02 for U.S. Application No. 09/625,137 filed 07/25/00
	4 OFFICE ACTION mailed on 05/18/05 for U.S. Application No. 09/625,137 filed 07/25/00
C10	5 OFFICE ACTION mailed on 10/05/04 for U.S. Application No. 09/625,137 filed 07/25/00
	6 OFFICE ACTION mailed on 11/02/05 for U.S. Application No. 09/625,137 filed 07/25/00
CIO	OFFICE ACTION mailed on 12/31/02 for U.S. Application No. 09/625,137 filed 07/25/00
CIO	8 OFFICE ACTION mailed on 02/08/06 for U.S. Application No. 09/668,724 filed 09/22/00
Clo	
CI	
Cl	
C1'	
Cl	4 OFFICE ACTION mailed on 03/13/06 for U.S. Application No. 09/750,972 filed 12/28/00
C1	5 OFFICE ACTION mailed on 06/05/02 for U.S. Application No. 09/750,972 filed 12/28/00
C1	6 OFFICE ACTION mailed on 08/28/03 for U.S. Application No. 09/750,972 filed 12/28/00
C1	7 OFFICE ACTION mailed on 01/11/06 for U.S. Application No. 10/225,367 filed 08/20/02
Cl	8 OFFICE ACTION mailed on 03/30/05 for U.S. Application No. 10/225,367 filed 08/20/02
Cl	9 OFFICE ACTION mailed on 04/18/07 for U.S. Application No. 10/225,367 filed 08/20/02
Cli	OFFICE ACTION mailed on 09/25/06 for U.S. Application No. 10/225,367 filed 08/20/02
CI	OFFICE ACTION mailed on 10/19/07 for U.S. Application No. 10/225,367 filed 08/20/02
CI	OFFICE ACTION mailed on 01/03/06 for U.S. Application No. 10/427,857 filed 05/01/03
CI	3 OFFICE ACTION mailed on 10/15/07 for U.S. Application No. 10/546,106 filed 10/11/05
CI	
CI	
CI	6 OFFICE ACTION mailed on 11/02/07 for U.S. Application No. 10/784,012 filed 02/20/04
CI	OHASHI et al., 2000, Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J. Immunol. 164:558-561
CI	8 OLD et al., 1962 "Part II. Antigens Of Tumor Cells. Antigenic Properties Of Chemically-Induced Tumors." Ann. N.Y. Acad. Sci. 101:80-106
Ci	
CI	
	cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary
	tuberculosis." Infect Immun. 60(11):4781-92

EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 5 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	art unit 1643

	NON PATENT LITERATURE DOCUMENTS
C191	PALLADINO et al., 1987, "Expression of shared tumor-specific antigen by two chemically induced BALB/c sarcomas", Cancer Research 47:5074-5079
C192	
	PATTILLO, 1974 "Combination Chemotherapy-Immunotherapy Indirect Chemotherapy Sensitivity Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and Application: Proceedings of a Chicago Sumposium, Crispen, Ed. ITR, Chicago, IL, pp. 189-204
C194	PAUL, Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189- 220 Cited On pp.1173-1174
C195	PAUL. Fundamental Immunology. 1993 Third Edition, Raven PRess, NY
	6 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390
C197	PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098
	PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041
	PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573
C200	PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110
C20	PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110
C20:	PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13
C20:	PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667
C20-	
C20:	heat shock protiens", Nature Vol 320 (13) 182-184
C20	6 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787
C20	PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778
C20	PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82
C20	RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54
C21	REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80.
C21	Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882
C21	REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984
C21	

EXAMINER	DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 6 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS	
C214	ROTHMAN, 1989, "Polypeptide Chain Binding Proteins: Catalysts of Protein Folding and Related Processes in Cells", Cell 59:591-601	
C215	RÖTZSCHKE et al., 1990, "Isolation and Analysis of Naturally Processed Viral Peptides as Recognized by Cytotoxic T cells", <i>Nature</i> 348:248-251	
C216	ROTZSCHKE, 1990, "Characterization of Naturally Occurring Minor Histocompatibility Peptides including H-4 and H-Y" Science 249: 283-287	
C217	SALK et al., 1993, "A Strategy for Prophylactic Vaccination Against HIV", Science 260:1270-1272	
C218	SALLUSTO et al., 1994, "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha," J. Exp. Med. 179(4):1109-1118	
C219	SANO et al., 1987, "The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity," Cancer Immunol. Immunother. 25(3):180-184	
C220	SAUTER et al., 2000, "Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells", J. Exp. Med. 191:423-434	
	SCHREIBER, 1989 "Tumor Immunology." In: Fundamental Immunology, 2nd Edition, Paul, ed., pp; 923-955	
C222	SCHUMACHER et al., 1991, "Peptide Selection by MHC Class I Molecules", Nature 350:703-706	
C223	SENGUPTA et al., 2004, "Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA Class I and Class II," J. Immunol. 173:1987-1993	
C224	SILVA et al., 1994, "A single mycobacterial protein (hsp 65) expressed by a transgenic antigen-presenting cell vaccinates mice against tuberculosis", Immunology 82(2):244-8	
C225	43:79-94	
l l	SMORODIN et al., 1991, "The complex of α-2 Macroglobulin with CD2 in the Plasma of Gastric Carcinoma Patients." Scand J. Immunol 33:699-706	
C227	SORGER and PELHAM, 1987, "The glucose-regulated protein grp94 is related to heat shock protein hsp90", J. Mol. Biol. 194(2):341-4	
C228	Acta, Neurol, Scand, 98(5):314-7	
C229	111:1057-1062	
C230	SPERO et al., 1980, "Plasma Exchange in Preparation of Mild Factor IX Deficient Hemophiliacs for Surgical Procedures," 19-22	
C231	Convergence of two evolutionary pathways of antigen presentation?", Seminars in Immunology 3:57-64	
C232	Tumor Antigens and Specific Tumor Therapy, pages 63-71	
C233	Curr. Opin. Immunol. 6:728	
C234	SRIVASTAVA et al. (1990) "Immunization with Soluble Gp96 Antigens Elicits Tumor-Specific Cellular Immunity:, Cellular Immunity and the Immunotherapy of Cancer, pages 307-314	

Immunity:, Cellular Immunity and the Immunotherapy of Cancer, pages 307-314		
EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 7 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	filing date June 4, 2001	art unit 1643

		NON PATENT LITERATURE DOCUMENTS
	C235	
		is also its Tumor-Associated Transplantation Antigen", Int. J. Cancer 33:417-422
	C236	SRIVASTAVA et al., 1987, "5'-structural analysis of genes encoding polymorphic antigens of chemically
		induced tumors." Proc. Natl. Acad. Sci USA 84(11):3807-3811
	C237	SRIVASTAVA et al., 1988, "Individually distinct transplantation antigens of chemically induced mouse
2010		tumors," Immunol. Today 9:78-83
	C238	SRIVASTAVA et al., 1989, "Identification of a Human Homologue of the Murine Tumor Rejection
		Antigen GP96," Cancer Res. 49:1341-1343
	C239	SRIVASTAVA et al., 1991, "Protein Tumor Antigens", Curr. Opin. Immunol. 3:654-658
	C240	SRIVASTAVA et al., 1993, "Evidence for peptide-chaperoning by the endoplasmic reticular heat shock
		protein GP96: Implications for vaccination against cancer and infectious diseases", J Cell Biochem Suppl
		17D:94 (Abstract NZ014)
	C241	SRIVASTAVA et al., 1998, "Heat shock proteins come of age: primitive functions acquire new roles in an
		adaptive world", Immunity 8(6):657-65
	C242	SRIVASTAVA PK, 1994, "Heat shock proteins in immune response to cancer: the Fourth Paradigm",
	60.43	Experientia. (11-12):1054-60
	C243	SRIVASTAVA, 1993, "Peptide-Binding Heat Shock Proteins in the Endoplasmic Reticulum: Role in
		Immune Response to Cancer and in Antigen Presentation," Adv. Cancer Res. 62:153-177
	C244	SRIVASTAVA, 2002, "Roles of heat-shock proteins in innate and adaptive immunity," Nature Rev.
		Immunol. 2(3): 185-194
	C245	STACK et al., 1982, "Autologous x-irradiated tumour cells and percutaneous BCG in operable lung
		cancer," Thorax 37(8):588-593
	C246	
		encephalitis and multiple sclerosis," J. Exp. Med. 194:F27-F30
	C247	STENMAN et al., 1991, "A complex between prostate-specific antigen and alpha 1-antichymotrypsin is
		the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex
	52.10	improves clinical sensitivity for cancer," Cancer Res. 51(1):222-6
	C248	1
	C249	Review SUBBARAO et al., 1992, "A General Overview of Viral Vaccine Development," Genetically Engineered
	C249	
	C250	Vaccines 327:51-57 SUZUE et al., 1997, "Heat shock fusion proteins as vehicles for antigen delivery into the major
	C230	histocompatibility complex class I presentation pathway," Proc. Natl. Acad. Sci. USA 94(24):13146-51
	C251	
	(23)	Stress-Inducible Cellular Responses" (U. Feige, R. I. Morimoto, I. Yahara, B. S. Polla, eds.),
		Birkhauser/Springer, 77: 451-465
	C252	
	1 6232	immune responses to HIV-1" p24. J Immunol. 156(2):873-9
	C253	
	(233	Full-Length cDNA Clone." Nucl. Acids Res. 18:4928 (1990)
	C254	
	C255	THE MERCK MANUAL of Diagnosis and Therapy, 1999, Beers and Berkow eds., Merck Research
		Laboratories, Whitehouse Station N.J., pp. 1871 and 1872

EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not		

LIST OF REFERENCES CITED BY APPLICANT	ATTY. DOCKET NO. 8449-178-999 APPLICANT	APPLICATION NO. 09/873,403	
(Use several sheets if necessary)	Srivastava et al.		
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

	NON PATENT LITERATURE DOCUMENTS
C256	THOMAS et al., 1982, "Molecular and Cellular Effects of Heat Shock and Related Treatments of Mammalian Tissue-Culture Cells", Cold Springs Harbor Symp Quant Biol 46:985-996
C257	TODRYK et al., 1999, "Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake," J. Immunol. 163:1398-1408
C258	TWINING et al., 1977, "Large scale separation of protease inhibitors from malignant human breast tissue," Mol. Cell. Biochem. 18(2-3):101-7
C259	hsp90, and hsp70," J. Immunol., 152(11):5398-5403
C260	tumors from which they are isolated", J. Cell. Biochem. Suppl. 17D:113 (Abstract NZ225)
C261	ULLRICH et al., 1986, "A mouse tumor-specific transplantation antigen is a heat shock-related protein," Proc. Natl. Acad. Sci. USA 83(10):3121-3125
C262	URBANIAK AND ROBINSON, 1990, "ABC of transfusion. Therapeutic apheresis," BMJ 300(6725):662-5 Review
C263	
C264	
C265	
C266	
C267	
C268	ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054.
C269	WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33
C270	WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884
C271	257:14949-14959
C272	Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237
C273	in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211
C274	WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64
C275	WILLNOW et al., 1996, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro." The Biochemical Journal. England 313:71-76
C276	WONG et al., 1991, "Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus on chromosome 11," Clin. Exp. Immunol. 83(1):69-73
C277	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformations considered. Include copy of this form with next communication to applicant.	nance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 9 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	·
	FILING DATE June 4, 2001	ART UNIT 1643

NON PATENT LITERATURE DOCUMENTS			
C278	YAMAUCHI et al., 2000, "Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study." Mycoses.43(5):197-202.		
C279	YANG et al., 1999, "Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8+ and CD4+ T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity," Int. J. Cancer 83:532-540		
C280	YEDAVELLI et al., 1999, "Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model" Int. J. Mol. Med. 3:243		
C281			
C282	 		
C283	ZIMECKI et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." Arch Immunol Ther Exp (Warsz). 47(2):113-8.		

EXA	MI	NER
EAA	IVE I.	IND.

DATE CONSIDERED





Express Mail No.: <u>ED 608 969 344 US</u>

Sheet 1 of 3 of List of References

LIST OF REFERENCES	CITED BY APPLICANT
--------------------	--------------------

(Use several sheets if necessary)

	i
ATTY, DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403
APPLICANT	
Srivastava et al.	
FILING DATE	ART UNIT
	1642
June 4, 2001	1643

*EXAMINER					PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT
INITIAL	A01	DOCUMENT NUMBER 09/393,652	9/10/99	NAME Srivastava	FIGURES APPEAR
•					
	A02	2001-0034042	10/01	Srivastava	
	A03	2002-0001841	1/03/02	Kaltoft et al.	
	A04	2002-0028207	6/4/01	Srivastava	
	A05	2002-0037290	03/28/02	Armen	
	A06	2002-0172682	11/21/02	Srivastava	
	A07	2002-0192230	12/19/02	Srivastava	
	A08	2003-0129296	07/10/03	Srivastava	
	A09	2003-0211971	11/13/03	Srivastava	
	A10	2004-0022796	02/05/04	Srivastava	
	A11	2004-0253228	12/16/04	Srivastava	
	A12	2006-0165710	07/26/06	Srivastava	
	A13	4,690,915	9/1/87	Rosenberg	
	Al4	5,112,298	5/12/1992	Prince et al.	
	A15	5,188,964	2/23/93	McGuire et al.	
	A16	5,232,833	8/3/93	Sanders et al.	
	A17	5,273,965	12/28/93	Kensil et al.	
	A18	5,348,945	9/20/94	Berberian et al.	
	A19	5,554,293	9/10/1996	Uhoch	
	A20	5,580,859	12/3/96	Felgner et al.	
	A21	5,637,082	6/10/1997	Pages et al.	
	A22	5,652,115	7/29/97	Marks et al.	
	A23	5,736,146	4/7/98	Cohen	
	A24	5,747,332	5/5/98	Wallen et al	
	A25	5,750,119	05/12/98	Srivastava	
	A26	5,830,464	11/03/98	Srivastava et al.	
	A27	5,846,928	12/8/1998	Kishida	
	A27	5,869,058	2/9/99	Cohen	
	A29	5,891,653	4/6/99	Attfield	
	A29	5,910,306	06/99	Alving et al.	

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 2 of 3 of List of References

ATTY. DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT		
Srivastava et al.		
FILING DATE	ART UNIT	
June 4, 2001	1643	

			U.S. PA	TENT DOCUMENTS	
*EXAMINER			DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
INITIAL	A31	5,947,646	07/19/99	Srivastava et al.	PIOUNES AFFEAR
	A32	5,968,526	10/19/99	Garman et al.	
	· A33	5,997,873	12/7/99	Srivastava et al.	
	A34	6,007,821	12/28/99	Srivastava et al.	
	A35	6,027,731	2/22/2000	Pauza	
	A36	6,030,618	02/29/00	Srivastava	
	A37	6,033,561	3/7/2000	Schoendorfer	
	A38	6,048,530	4/11/00	Srivastava	
	A39	6,136,315	10/24/00	Srivastava	
	A40	6,156,311	12/05/00	Strickland et al.	
	A41	6,162,436	12/19/00	Srivastava	
	A42	6,168,793	1/2/01	Srivastava et al.	
	A43	6,312,711	11/6/01	Duchateau et al.	
	A44	6,333,311	12/25/2001	Nuijens et al.	
	A45	6,338,945	01/15/02	Nicolette	
	A46	6,403,092	6/11/02	Pizzo et al.	
	A47	6,433,141	8/13/02	Wallen et al.	
	A48	6,689,363	02/10/04	Sette et al.	
	A49	6,709,672	3/23/04	Henot et al.	
	A50	6,713,608	3/30/04	Wallen et al.	
	A51	6,730,302	5/4/04	Fujihara et al.	
	A52	6,797,480	9/28/04	Srivastava	
	A53	6,986,389	01/06	Li	
	A54	7,176,515	03/06/07	Srivastava et al.	
	A55	7,179,462	02/20/07	Srivastava et al.	
	A56	7,132,109	11/07/06	Srivastava	

EXAMINER	

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 3 of 3 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

- ·	APPLICATION NO. 09/873,403	ATTY. DOCKET NO. 8449-178-999
		APPLICANT Srivastava et al.
	ART UNIT	FILING DATE
	ARTUNIT 1643	Srivastava et al.

		FOREIGN	N PATENT DOCUMENTS	
B01	DE 196 02 985 A1	1/27/96	Germany	
B02	GB 2 251 186A	7/1/92	United Kingdom	
B03	WO 00/03003	1/20/00	University of Nottingham	
B04	WO 00/10597	03/02/00	Immunology Limited	
B05	WO 00/34494	6/15/00	The Government of the United States of America represented by the Secretary, Dept. of Health and Human Services	
B06	WO 00/38760	7/6/2000	Occulogix Corp	
B07	WO 00/46246	8/10/00	The General Hospital Corp.	
B08	WO 00/54801	9/21/2000	Entremed Inc	
В09	WO 01/91787	6/12/01	University of Conneticut Health Center	
B10	WO 01/924/4	12/06/01	University of Conneticut Health Center	
BII	WO 02/07755	1/3/2002	The General Hospital Corporation	
B12	WO 02/11669	02/14/02	Antigenics, LLC	
B13	WO 02/15930	2/28/02	Duke University	
B14	WO 02/30434	4/18/02	University of Conneticut Health Center	
B15	WO 02/32923	4/25/02	University of Conneticut Health Center	
B16	WO 02/34205	5/2/02	University of Conneticut Health Center	
B17	WO 03/015712	02/27/03	University of Conneticut Health Center	
B18	WO 03/090686	11/06/03	University of Conneticut Health Center	
B19	WO 03/092624	11/13/03	University of Conneticut Health Center	
B20	WO 04/035602	04/29/04	University of Conneticut Health Center	
B21	WO 04/075636	09/10/04	University of Conneticut Health Center	
B22	WO 04/74454	09/02/04	University of Conneticut Health Center	
B23	WO 05/120558	12/22/05	University of Conneticut Health Center	
B24	WO 89/12455	12/28/89	Whitehead Institute for Biomedical Research Medical Research Council	

DATE CONSIDERED

Sheet 1 of 3 of List of References

атту. docket no. 8449-178-999	APPLICATION NO. 09/873,403	
APPLICANT Srivastava et al.		
FILING DATE June 4, 2001	art unit 1643	

LIST OF REFERENCES CITED BY APPLICANT (Use several shorts fraccessary)

NOV 0 8 2007 W

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
INITIAL	A01	09/393,652	9/10/99	Srivastava	
	A02	2001-0034042	10/01	Srivastava	
	A03	2002-0001841	1/03/02	Kaltoft et al.	
· -	A04	2002-0028207	6/4/01	Srivastava	
	A05	2002-0037290	03/28/02	Armen	
	A06	2002-0172682	11/21/02	Srivastava	
	A07	2002-0192230	12/19/02	Srivastava	
"	A08	2003-0129296	07/10/03	Srivastava	
	A09	2003-0211971	11/13/03	Srivastava	
	A10	2004-0022796	02/05/04	Srivastava	
	All	2004-0253228	12/16/04	Srivastava	
	A12	2006-0165710	07/26/06	Srivastava	
	A13	4,690,915	9/1/87	Rosenberg	
	A14	5,112,298	5/12/1992	Prince et al.	
	A15	5,188,964	2/23/93	McGuire et al.	
	A16	5,232,833	8/3/93	Sanders et al.	
	A17	5,273,965	12/28/93	Kensil et al.	
. ,	A18	5,348,945	9/20/94	Berberian et al.	
	A19	5,554,293	9/10/1996	Uhoch	
	A20	5,580,859	12/3/96	Felgner et al.	
	A21	5,637,082	6/10/1997	Pages et al.	
	A22	5,652,115	7/29/97	Marks et al.	
	A23	5,736,146	4/7/98	Cohen	
···	A24	5,747,332	5/5/98	Wallen et al	
	A25	5,750,119	05/12/98	Srivastava	
	A26	5,830,464	11/03/98	Srivastava et al.	
	A27	5,846,928	12/8/1998	Kishida	
,	A28	5,869,058	2/9/99	Cohen	
7.5	A29	5,891,653	4/6/99	Attfield	
	A30	5,910,306	06/99	Alving et al.	

EXAMINER

DATE CONSIDERED

Sheet 2 of 3 of List of References

LIST OF REFERENCES	CITED BY APPLICANT
--------------------	--------------------

(Use several sheets if necessary)

APPLICATION NO.
09/873,403
ART UNIT
1643

	T			1	PAGES, COLUMNS, LINES, WHERE
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A31	5,947,646	07/19/99	Srivastava et al.	
	A32	5,968,526	10/19/99	Garman et al.	
	A33	5,997,873	12/7/99	Srivastava et al.	
	A34	6,007,821	12/28/99	Srivastava et al.	
	A35	6,027,731	2/22/2000	Pauza	
	A36	6,030,618	02/29/00	Srivastava	
	A37	6,033,561	3/7/2000	Schoendorfer	
	A38	6,048,530	4/11/00	Srivastava	
	A39	6,136,315	10/24/00	Srivastava	
	A40	6,156,311	12/05/00	Strickland et al.	
	A41	6,162,436	12/19/00	Srivastava	
	A42	6,168,793	1/2/01	Srivastava et al.	
	A43	6,312,711	11/6/01	Duchateau et al.	
	A44	6,333,311	12/25/2001	Nuijens et al.	
*****	A45	6,338,945	01/15/02	Nicolette	
	A46	6,403,092	6/11/02	Pizzo et al.	
	A47	6,433,141	8/13/02	Wallen et al.	
	A48	6,689,363	02/10/04	Sette et al.	
	A49	6,709,672	3/23/04	Henot et al.	
	A50	6,713,608	3/30/04	Wallen et al.	
	A51	6,730,302	5/4/04	Fujihara et al.	
	A52	6,797,480	9/28/04	Srivastava	
	A53	6,986,389	01/06	Li	
	A54	7,176,515	03/06/07	Srivastava et al.	
	A55	7,179,462	02/20/07	Srivastava et al.	
	A56	7,132,109	11/07/06	Srivastava	

EV	MI	TED
	ZIVL	AL:N

DATE CONSIDERED

Sheet 3 of 3 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403
APPLICANT	
Srivastava et al.	
FILING DATE	ARTUNIT
June 4, 2001	1643

		FOREIGN	PATENT DOCUMENTS	
B01	DE 196 02 985 A1	1/27/96	Germany	
B02	GB 2 251 186A	7/1/92	United Kingdom	
В03	WO 00/03003	1/20/00	University of Nottingham	
B04	WO 00/10597	03/02/00	Immunology Limited	
B05	WO 00/34494	6/15/00	The Government of the United States of America represented by the Secretary, Dept. of Health and Human Services	
B06	WO 00/38760	7/6/2000	Occulogix Corp	
B07	WO 00/46246	8/10/00	The General Hospital Corp.	
B08	WO 00/54801	9/21/2000	Entremed Inc	
B09	WO 01/91787	6/12/01	University of Conneticut Health Center	
B10	WO 01/92474	12/06/01	University of Conneticut Health Center	
B11	WO 02/07755	1/3/2002	The General Hospital Corporation	
B12	WO 02/11669	02/14/02	Antigenics, LLC	
B13	WO 02/15930	2/28/02	Duke University	
B14	WO 02/30434	4/18/02	University of Conneticut Health Center	
B15	WO 02/32923	4/25/02	University of Conneticut Health Center	
B16	WO 02/34205	5/2/02	University of Conneticut Health Center	
B17	WO 03/015712	02/27/03	University of Conneticut Health Center	
B18	WO 03/090686	11/06/03	University of Conneticut Health Center	
B19	WO 03/092624	11/13/03	University of Conneticut Health Center	
B20	WO 04/035602	04/29/04	University of Conneticut Health Center	
B21	WO 04/075636	09/10/04	University of Conneticut Health Center	
B22	WO 04/74454	09/02/04	University of Conneticut Health Center	
B23	WO 05/120558	12/22/05	University of Conneticut Health Center	
B24	WO 89/12455	12/28/89	Whitehead Institute for Biomedical Research Medical Research Council	

DATE CONSIDERED

Sheet 1 of 3 of List of References

ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
APPLICANT Srivastava et al.	_
FILING DATE June 4, 2001	ART UNIT

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

MOA 0 8 5001 E

			04 0 8 5001	TYPITE DOCUMENTS	
		No.	U.S. A	TENT DOCUMENTS	
*EXAMINER			ļ	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
INITIAL	A01	09/393,652	9/10/99	Srivastava	1,354,25
	A02	2001-0034042	10/01	Srivastava	
	A02	2002-0001841	1/03/02	Kaltoft et al.	
	A04	2002-0028207	6/4/01	Srivastava	
	A05	2002-0037290	03/28/02	Armen	
 	A06	2002-0172682	11/21/02	Srivastava	
	A07	2002-0192230	12/19/02	Srivastava	
	A08	2003-0129296	07/10/03	Srivastava	
	A09	2003-0211971	11/13/03	Srivastava	
•	A10	2004-0022796	02/05/04	Srivastava	
	All	2004-0253228	12/16/04	Srivastava	
	A12	2006-0165710	07/26/06	Srivastava	
	A13	4,690,915	9/1/87	Rosenberg	
	A14	5,112,298	5/12/1992	Prince et al.	
	A15	5,188,964	2/23/93	McGuire et al.	
-	A16	5,232,833	8/3/93	Sanders et al.	
	A17	5,273,965	12/28/93	Kensil et al.	
	A18	5,348,945	9/20/94	Berberian et al.	
	A19	5,554,293	9/10/1996	Uhoch	
	A20	5,580,859	12/3/96	Felgner et al.	
	A21	5,637,082	6/10/1997	Pages et al.	
	A22	5,652,115	7/29/97	Marks et al.	
	A23	5,736,146	4/7/98	Cohen	
	A24	5,747,332	5/5/98	Wallen et al	
	A25	5,750,119	05/12/98	Srivastava	
	A26	5,830,464	11/03/98	Srivastava et al.	
	A27	5,846,928	12/8/1998	Kishida	
***	A28	5,869,058	2/9/99	Cohen	
	A29	5,891,653	4/6/99	Attfield	
	A30	5,910,306	06/99	Alving et al.	

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 3 of List of References

ATTY. DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403
APPLICANT	
Srivastava et al.	
FILING DATE	ART UNIT
June 4, 2001	1643

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT *EXAMINER INITIAL DOCUMENT NUMBER DATE NAME FIGURES APPEAR 07/19/99 Srivastava et al. A31 5,947,646 A32 5,968,526 10/19/99 Garman et al. 5,997,873 12/7/99 Srivastava et al. A33 12/28/99 Srivastava et al. A34 6,007,821 6,027,731 2/22/2000 Pauza A35 6,030,618 02/29/00 Srivastava A36 3/7/2000 Schoendorfer 6,033,561 A37 4/11/00 6,048,530 Srivastava A38 10/24/00 Srivastava 6,136,315 A39 A40 Strickland et al. 6,156,311 12/05/00 6,162,436 12/19/00 Srivastava A41 1/2/01 Srivastava et al. 6,168,793 A42 11/6/01 Duchateau et al. 6,312,711 A43 12/25/2001 Nuijens et al. 6,333,311 A44 6,338,945 01/15/02 Nicolette A45 6/11/02 Pizzo et al. 6,403,092 A46 Wallen et al. 8/13/02 6,433,141 A47 02/10/04 Sette et al. 6,689,363 A48 3/23/04 Henot et al. 6,709,672 A49 3/30/04 Wallen et al. 6,713,608 A50 Fujihara et al. 6,730,302 5/4/04 A51 9/28/04 Srivastava 6,797,480 A52 01/06 Li 6,986,389 A53 03/06/07 Srivastava et al. 7,176,515 A54 02/20/07 Srivastava et al. 7,179,462 A55

EXAMIN	ER
--------	----

7,132,109

A56

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Srivastava

11/07/06

Express Mail No.: <u>ED 608 969 344 US</u> Sheet 3 of 3 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
	APPLICANT Srivastava et al.		
	June 4, 2001	1643	

		FOREIGN	N PATENT DOCUMENTS	
BOI	DE 196 02 985 A1	1/27/96	Germany	
B02	GB 2 251 186A	7/1/92	United Kingdom	
B03	WO 00/03003	1/20/00	University of Nottingham	
B04	WO 00/10597	03/02/00	Immunology Limited	
B05	WO 00/34494	6/15/00	The Government of the United States of America represented by the Secretary, Dept. of Health and Human Services	
B06	WO 00/38760	7/6/2000	Occulogix Corp	
B07	WO 00/46246	8/10/00	The General Hospital Corp.	
B08	WO 00/54801	9/21/2000	Entremed Inc	
B09	WO 01/91787	6/12/01	University of Conneticut Health Center	
B10	WO 01/92474	12/06/01	University of Conneticut Health Center	
B11	WO 02/07755	1/3/2002	The General Hospital Corporation	
B12	WO 02/11669	02/14/02	Antigenics, LLC	
B13	WO 02/15930	2/28/02	Duke University	
B14	WO 02/30434	4/18/02	University of Conneticut Health Center	
B15	WO 02/32923	4/25/02	University of Conneticut Health Center	
B16	WO 02/34205	5/2/02	University of Conneticut Health Center	
B17	WO 03/015712	02/27/03	University of Conneticut Health Center	
B18	WO 03/090686	11/06/03	University of Conneticut Health Center	
B19	WO 03/092624	11/13/03	University of Conneticut Health Center	
B20	WO 04/035602	04/29/04	University of Conneticut Health Center	
B21	WO 04/075636	09/10/04	University of Conneticut Health Center	
B22	WO 04/74454	09/02/04	University of Conneticut Health Center	
B23	WO 05/120558	12/22/05	University of Conneticut Health Center	
B24	WO 89/12455	12/28/89	Whitehead Institute for Biomedical Research Medical Research Council	

EXAMINER	DATE CONSIDERED
	1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Express Mail No.: <u>ED 608 969 358 US</u> Sheet 1 of 6 of List of References

ATTY. DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403
APPLICANT	
Srivastava et al.	
FILING DATE	ART UNIT
Tuno 4 2001	16/13

OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

	B25	WO 90/02564	3/22/90	Codon Dragon	
	B26	WO 91/15572	10/17/91	The Wellcome Foundation Limited	
	B27	WO 92/01717	2/6/92	Burnie, James et al.	
	B28	WO 92/08484	5/29/92	University College London	
	B29	WO 92/08488	5/29/92	University College London	
	B30	WO 93/14118	7/22/93	Medical Research Council	
	B31	WO 93/17712	9/16/93	Biocine Sclavo Spa Rappuoli	
	B32	WO 93/18146	9/16/93	Institut National de la Sante et de la researche medicale	
	В33	WO 93/18147	9/16/93	Institute Nazionale per lo studio e la cura dei tumori fondazione giovanni pascale	
	B34	WO 93/18150	9/16/93	Biocine S.P.A.	
	B35	WO 93/21529	10/28/93	Duke University	
	B36	WO 93/24136	12/9/93	Terman, David S.	
	B37	WO 94/03208	2/17/94	Yeda Research and Development Company, Ltd	
	B38	WO 94/04676	3/3/94	The Victoria University of Manchester	
	B39	WO 94/11513	5/26/94	Medical Research Council Colston	
	B40	WO 94/14471	7/7/1994	Washington University	
	B41	WO 94/29459	12/22/94	Whitehead Institute for Biomedical Research	
	B42	WO 97/04794	2/13/97	The American National Red Cross – The General Hospital Corporation	
	B43	WO 97/06685	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B44	WO 97/06821	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B45	WO 97/06828	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B46	WO 97/10001	03/20/97	Fordham University	
	B47	WO 97/26910	7/31/97	Max-delbruck medizen milleck	•
	B48	WO 98/42752	10/01/98	Brigham and Woman's Hospital Inc.	
_	B49	WO 98/46739	7/23/97	Juridicial Foundation the Chemo-Sero- therapeutic Research Institute	
	B50	WO 99/29834	06/17/99	Fordham University	

EX	A 1	M	IN	П	D

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Express Mail No.: <u>ED 608 969 358 US</u> Sheet 2 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C08	ABBAS et al., 1991, Cellular and Molecular Immunology, W.B. Saunders Co., Philadelphia (Chapters 15-18)	
	C09	AGOSTONI et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.	
	C10	ALDOVINI et al., 1992, "The New Vaccines", Technology Review pp. 24-31	1
	C11	AMATO et al., 1999, "Active Specific Immunotherapy in Patients with Renal Cell Carcinoma (RCC) Using Autologous Tumor Derived Heat Shock Protein-Peptide Complex-96 (HSPP-96) Vaccine" American Society Clinical Oncology Meeting, abstract 1278	
	C12	ANDERSEN, P. 1994, "Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins," Infect. Immun. 62(6):2536-44	
	C13	ANDUS et al., Synthesis of alpha 2-macroglobulin in rat hepatocytes and in a cell-free system. FEBS Lett. 1983 Jan 10;151(1):10-14	
	C14	ANTHONY et al., 1999, "Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule," Vaccine 17(4):373-83	
	C15	BANCHEREAU et al., 1998, "Dendritic cells and the control of immunity," Nature 392:245-252	
	C16	BARRIOS et al., 1992, "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and BacillusCalmette Guerin priming," Eur. J. Immunol. 22(6):1365-72	
	C17	BARRIOS et al., 1994, "Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and Dna K proteins requires cross-linking with antigen," Clin. Exp. Immunol. 98(2):229-233	
	C18	BARRIOS et al., 1994, "Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD." Clin Exp Immunol. 98(2):224-8	
	C19	BARTLETT, 1972 "Effect Of Host Immunity On The Antigenic Strength Of Primary Tumors." J. Natl. Cancer Inst. 49:493-504	
	C20	BASOMBRÍO (1970) "Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene", <i>The Institute for Cancer Research</i> 30:2458-2462	
	C21	BASU and SRIVASTAVA, 1999, "Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity" J. Exp. Med. 189:797-802	
	C22	BASU et al., 2000, "Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway," Int. Immunol. 12(11):1539-46	
	C23	BASU et al., 2001, "CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin," Immunity 14:303-313	
	C24	BEDNAR et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.	
	C25	BELLONE et al., 1999, "Cancer Immunotherapy: synthetic and natural peptides in balance," Immunology Today 20(10): 457-462	
	C26	BEVERLY, 1988, "Tumour Immunology." In: <i>Immunology</i> , 3rd Edition, Roitt, Ed., Mosby, London, pp. 17.1-17.12	

EXAMINER DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Express Mail No.: <u>ED 608 969 358 US</u> Sheet 3 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

		NON PATENT LITERATURE DOCUMENTS	
xaminer			Ţ,
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	17
	C27	BINDER and Srivastava, 2004, "Essential role of CD91 in re-presentation of gp96-chaperoned peptides,"	l
	C28	Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133 BINDER et al., 2000, "CD91: a receptor for heat shock protein gp96," Nature Immunol. 1(2):151-155	┝
			L
	C29	BINDER et al., 2001, "Heat shock protein-chaperoned peptides but not free peptides introduced into the	
		cytosol are presented efficiently by major histocompatability complex I molecules," J. Biol. Chem.	
	-	276(20): 17163-17171	l
	C30	BIRKENMEIER G., 2001, "Targetting the Proteinase Inhibitor and Immune Modulatory Function of	Γ
		Human α2-Macroglobulin." Mod. Asp. Immunobiol. 2(1):32-36	L
	C31	BLACHERE and SRIVASTAVA (1993) "Immunization with GP96 heat shock proteins isolated from	
		tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes	
		against the corresponding cells", J. Cellular Biochem. Keystone Symposia, 17D: pp. 124, Abstract NZ 502	L
	C32	BLACHERE et al., 1993, "Heat Shock Protein Vaccines Against Cancer," Journal of Immunotherapy	
		14:352-356	L
	C33	BLANDER et al., 1993, "Major cytoplasmic membrane protein of Legionella pnumophila, a genus	
		common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a	
	1024	guinea pig model of Legionnaires' disease," J. Clin. Invest. 91(2):717-23	╀
	C34	BODEY et al., 2000, Anticancer Res 20:2665-2676 Abs	┝
		BOSCH et al., 1999, "State of the art of therapeutic apheresis in Europe", Ther. Apher. 3(3):197-8	L
	C36	BRELOER et al., 1999, "in vivo and in vitro activation of T cells after administration of Ag-negative heat	l
		shock proteins," J. Immunol. 162:3141-3147	L
	C37	BUMOL et al., 1988 "Characterization Of The Human Tumor And Normal Tissue Reactivity Of The	
		KS1/4 Monoclonal Antibody." Hybridoma 7:407-415	L
	C38	CARSWELL et al., 1970, "Immunogenic Properties Of Reticulum Cell Sarcomas Of SJL/J Mice." Natl.	
	C39	CASSEL et al., 1977, "Viral oncolysate in the management of malignant melanoma. I. Preparation of the	╀
	C39	oncolysate and measurement of immunologic responses," Cancer 40:672-679	
	C40	CASSEL et al., 1983 "A Phase II Study On The Postsurgical Management Of Stage II Malignant	ł
	040	Melanoma With A Newcastle Disease Virus Oncolysate." Cancer, 52:856-860	١
	C41	CASTELLI et al., 2001, "Human Heat Shock Protein 70 Peptide Complexes Specifically Active	╁╴
	"	Antimelanoma T cells." Cancer Res 61:222-227	
	C42	CHANDAWARKAR et al., 2004, "Immune modulation with high-dose heat shock protein gp96: therapy	t
		of murine autoimmune diabetes and encephalomyelitis," Int'l. Immunol. 16:315-324	
,	C43	CHU et al., 1994, α ₂ -Macroglobulin: A Sensor for Proteolysis," Ann. N.Y. Acad. Sci. 737:291-307	T
	C44	CLARKE et al. 1988, "Purification of Complexes of Nuclear Oncogene p53 with Rat and Escherichia coli	t
	- ''	Heat Shock Proteins: In Vitro Dissociation of hsc70 and dnaK from Murine p53 by ATP" Mol. and Cell.	
		Biol. Vol. 8 (3) 1206-1215	
	C45	COLLEN et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic	T
		use as a thrombolytic agent." Drugs. 38(3):346-88.	ĺ
	C46	COSTANZO, 1996, "New monoclonal antibodies," Curr. Opin. Cardiol. 11(2):204-7	⊦
	C40	COSTATIZO, 1990, New monocional antibodies, Curt. Opin. Cardiol. 11(2):204-7	

EXAMINER	DATE CONSIDERED
	· · · · · · · · · · · · · · · · · · ·
#EVALUED. I id 116 - 6 id-ad - d - d - d - d - d - d - id-ad - id-	some with MDED 600. Draw line through situation if not in conformance and not



Sheet 4 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	filing date June 4, 2001	ART UNIT 1643

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
nitials	1017	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C47	CRAIG, 1993, "Chaperones: Helpers Along the Pathways to Protein Folding," Science 260:1902-4	
	C48	D'ANDREA, 2005, "Add Alzheimer's disease to the list of autoimmune diseases," Med. Hypotheses 64(3):458-463	
	C49	DASH, et al., 2002 "Slow-Tight Binding Inhibition of Xylanase by an Aspartic Protease Inhibitor." J. Biol. Chem. 277:17978-17986	
	C50	DAVIDOFF et al., 1992, "Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers	
	C51	DEL GIUDICE et al., 1994, "Hsp70: a carrier molecule with built-in adjuvanticity", Experientia 30;50(11-12):1061-6	
	C52	DERMER, 1994, "Another Anniversary for the War on Cancer," Biotechnology 12:320	T
	C53	DEUTSCHER et al., 1992 "Guide to protein purification." Meth. Enzymol., 182:610-611	T
	C54	DUBOIS et al., 1980, "Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells," Cancer Res. 40:4204-4208	
	C55	DUBOIS, et al., 1982 "Purification and Biochemical Properties of Tumor-Associated Transplantation Antigens From Methylcholanthrene-Induced Murine Sarcomas." Proc. Natl. Acad. Sci USA, 79:7669-7673	
	C56	ELLGAARD ET AL., 1997,"Dissection of the domain architecture of the alpha2macrglobulin-receptor associated protein." Eur. J. Biochem 244:544-51	
	C57	EPPLEN et al., 1997, "Genetic predisposition to multiple sclerosis as revealed by immunoprinting," Ann. Neurol. 41(3):341-52.	
	C58	ESPANA et al., 1996, Clin. Chem 42(3):545-550	Т
	C59	ESTIN et al., 1989, "Transfected mouse melanoma lines that express various levels of human melanoma- associated antigen p97," J. Natl. Cancer Inst. 81:445-448	
	C60	EVANS et al., 1999, Q.J. Med 92:299-307	Τ
	C61	FALK et al., 1990, "Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules", Nature 348:248-251	
	C62	FALK et al., 1991, "Identification of Naturally Processed Viral Nonapeptides Allows Their Quantification in Infected Cells and Suggests an Allele-specific T Cell Epitope Forecast". J Exp. Med 174:425-434	
	C63	FALK et al., 1991, "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC Molecules", Nature 351:290-296	
	C64	FALK et al., 1992, "Specificity of antigen processing for MHC class I restricted presentation is conserved between mouse and man", Eur. J. Immunol. 22:1323-1326	
	C65	FAY et al., 1979, "Leukopheresis Therapy of Leukemic Reticuloendotheliosis (Hairy Cell Leukemia)", Blood 54: 747-749	
	C66	FEDWEG and SRIVASTAVA "Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor rejection antigen", Mount Sinai School of Medicine NZ 206, p. 108	
	C67	FENG et al., 2002, "Exogenous heat shock proteins provide adjuvant effects on enhancing the immunogenicity of apoptotic tumor cells and inducing antitumor immunity," AACR 93 rd Annual Meeting, Vol. 43, April 6-10, Abstract #2214	
***	C68	FERRERO et al., 1995, The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA 92(14):6499-503	

EXAMINER	DATE CONSIDERED
*EVAMINED. Initial if and annual annual subathor or not situation is in any form	ADED 600. Describe the state of

Sheet 5 of 6 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Srivastava et al.		
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

		NON PATENT LITERATURE DOCUMENTS	
Examiner	Τ	(7. 1. 1	Т
nitials	000	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	┼∸
	C69	FLYNN et al., 1989, "Peptide binding and release by proteins implicated as catalysts of protein assembly",	ŀ
	670	Science 245:385-390	╁
	C70	FLYNN et al., 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", Nature 353:726-730	+
	C71	FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and chemotaxis", Immunology 50(2):251-9	
	C72	FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New York p4	
	C73	GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489	
	C74	GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55	
	C75	GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4	
	C76	GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5	
<u> </u>	C77	GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64	-
	C78	GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat	╁╴
	C/8	shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71	
	C79	GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum	+
	"	protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95	
	C80	GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in	+
	1 600	Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41	
	C81	GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416	+
 ,	C82	GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine	╁
	Coz	B-cell leukemia/lymphoma" Clin. Can. Res.6:909	L
	C83	GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476	
	C84	GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234	
- 11 <u>-</u> 111 - 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	C85	GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846	
	C86	GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120	
	C87	HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites",	
***	Coo	Science Vol. 250 113-116 HANOVER et al. 1986 "Managinari entitlediae against a glycoprotein localized in costed pits and	+
	C88	HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.	
ı	C89	HARLOW et al., 1988, "Antibodies: A Laboratory Manual" ch 6:139-243	+

EXAMINER	DATE CONSIDERED

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 6 of 6 of List of References

ATTY. DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403
APPLICANT	
Srivastava et al.	
FILING DATE	ART UNIT
June 4, 2001	1643

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

			Т
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
Intrais_	C90	HEEB et al., 1995, "Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera." Biochem, Mol. Biol. Int. 37(5):917-23	
100	C91	HEISKALA et al., 1988 "Characteristics Of Soluble Tumour-Derived Proteins That Inhibit Natural Killer Activity." Scand. J. Immunol. 28:19-27	
	C92	HENTTU AND VIHKO, 1989 "cDNA Coding For The Entire Human Prostate Specific Antigen Shows High Homologies To The Human Tissue Kallikrein Genes." Biochem. Biophys. Res. Comm. 160:903-910	
	C93	HERZ AND STRICKLAND, 2001, "LRP: a multifunctional scavenger and signaling receptor," J. Clin. Invest. 108:779-784	
	C94	HERZ et al., 1990, "Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver", J. of Biol. Chem. 265(34): 21355-21362.	
	C95	HERZ et al., 1991, "39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor." J.Biol.Chem. 266(31):21232-21238.	
-	C96	HEY et al., 1988, "Cloning of a novel member of the low-density lipoprotein receptor family", Gene 216: 103-111.	
	C97	HINDS et al., 1987, "Immunological Evidence for the Association of p53 with a Heat Shock Protein, hsc70, in p53-plus-ras-Transformed Cell Lines" Mol. and Cell. Biol. Vol.7 (8) 2863-2869	

EXAMINER	DATE CONSIDERED
----------	-----------------



Express Mail No.: <u>ED 608 969 358 US</u> Sheet 1 of 6 of List of References

ATTY. DOCKET NO.

8449-178-999

APPLICANT

Srivastava et al.

FILING DATE

June 4, 2001

APPLICATION NO.

09/873,403

ART UNIT

1643

IST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

	B25	WO 90/02564	3/22/90	Codon Dragon	
	B26	WO 91/15572	10/17/91	The Wellcome Foundation Limited	
	B27	WO 92/01717	2/6/92	Burnie, James et al.	
	B28	WO 92/08484	5/29/92	University College London	
	B29	WO 92/08488	5/29/92	University College London	
	B30	WO 93/14118	7/22/93	Medical Research Council	
	B31	WO 93/17712	9/16/93	Biocine Sclavo Spa Rappuoli	
-	B32	WO 93/18146	9/16/93	Institut National de la Sante et de la researche medicale	
	B33	WO 93/18147	9/16/93	Institute Nazionale per lo studio e la cura dei tumori fondazione giovanni pascale	
	B34	WO 93/18150	9/16/93	Biocine S.P.A.	
	B35	WO 93/21529	10/28/93	Duke University	
<u> </u>	B36	WO 93/24136	12/9/93	Terman, David S.	
	B37	WO 94/03208	2/17/94	Yeda Research and Development Company, Ltd	·
	B38	WO 94/04676	3/3/94	The Victoria University of Manchester	
	B39	WO 94/11513	5/26/94	Medical Research Council Colston	
	B40	WO 94/14471	7/7/1994	Washington University	
	B41	WO 94/29459	12/22/94	Whitehead Institute for Biomedical Research	
	B42	WO 97/04794	2/13/97	The American National Red Cross – The General Hospital Corporation	
	B43	WO 97/06685	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B44	WO 97/06821	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B45	WO 97/06828	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B46	WO 97/10001	03/20/97	Fordham University	
	B47	WO 97/26910	7/31/97	Max-delbruck medizen milleck	
	B48	WO 98/42752	10/01/98	Brigham and Woman's Hospital Inc.	
	B49	WO 98/46739	7/23/97	Juridicial Foundation the Chemo-Sero- therapeutic Research Institute	
	B50	WO 99/29834	06/17/99	Fordham University	

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 2 of 6 of List of References

ATTY. DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403
APPLICANT	
Srivastava et al.	
FILING DATE	ART UNIT
June 4, 2001	1643

LIST OF REFERENCES CITED BY APPLICANT


(Use several sheets if necessary)

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
Initials	C08	ABBAS et al., 1991, Cellular and Molecular Immunology, W.B. Saunders Co., Philadelphia (Chapters 15-18)	
	C09	AGOSTONI et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.	
	C10	ALDOVINI et al., 1992, "The New Vaccines", Technology Review pp. 24-31	
	CII	AMATO et al., 1999, "Active Specific Immunotherapy in Patients with Renal Cell Carcinoma (RCC) Using Autologous Tumor Derived Heat Shock Protein-Peptide Complex-96 (HSPP-96) Vaccine" American Society Clinical Oncology Meeting, abstract 1278	
	C12	ANDERSEN, P. 1994, "Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins," Infect. Immun. 62(6):2536-44	
	C13	ANDUS et al., Synthesis of alpha 2-macroglobulin in rat hepatocytes and in a cell-free system. FEBS Lett. 1983 Jan 10;151(1):10-14	
	C14	ANTHONY et al., 1999, "Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule," Vaccine 17(4):373-83	
	C15	BANCHEREAU et al., 1998, "Dendritic cells and the control of immunity," Nature 392:245-252	
	C16	BARRIOS et al., 1992, "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and BacillusCalmette Guerin priming," Eur. J. Immunol. 22(6):1365-72	
	C17	BARRIOS et al., 1994, "Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and Dna K proteins requires cross-linking with antigen," Clin. Exp. Immunol. 98(2):229-233	
	C18	BARRIOS et al., 1994, "Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD." Clin Exp Immunol. 98(2):224-8	
	C19	BARTLETT, 1972 "Effect Of Host Immunity On The Antigenic Strength Of Primary Tumors." J. Natl. Cancer Inst. 49:493-504	
	C20	BASOMBRÍO (1970) "Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene", <i>The Institute for Cancer Research</i> 30:2458-2462	
	C21	BASU and SRIVASTAVA, 1999, "Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity" J. Exp. Med. 189:797-802	
	C22	BASU et al., 2000, "Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway," Int. Immunol. 12(11):1539-46	
	C23	BASU et al., 2001, "CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin," Immunity 14:303-313	
	C24	BEDNAR et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.	
	C25	BELLONE et al., 1999, "Cancer Immunotherapy: synthetic and natural peptides in balance," Immunology Today 20(10): 457-462	
	C26	BEVERLY, 1988, "Tumour Immunology." In: <i>Immunology</i> , 3rd Edition, Roitt, Ed., Mosby, London, pp. 17.1-17.12	

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 3 of 6 of List of References

	ATTY. DOCKETNO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Srivastava et al.		
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

		NON PATENT LITERATURE DOCUMENTS	
Examiner	1	(1 1 1 1 Col Alex Co CADITAL LETTERS) Title Date Particent Borge Etc.)	Т
Initials	C27	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) BINDER and Srivastava, 2004, "Essential role of CD91 in re-presentation of gp96-chaperoned peptides," Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133	1
	C28	BINDER et al., 2000, "CD91: a receptor for heat shock protein gp96," Nature Immunol. 1(2):151-155	
	C29	BINDER et al., 2001, "Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatability complex I molecules," J. Biol. Chem. 276(20): 17163-17171	
	C30	BIRKENMEIER G., 2001, "Targetting the Proteinase Inhibitor and Immune Modulatory Function of Human a2-Macroglobulin." Mod. Asp. Immunobiol. 2(1):32-36	
	C31	BLACHERE and SRIVASTAVA (1993) "Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells", J. Cellular Biochem. Keystone Symposia, 17D: pp. 124, Abstract NZ 502	
	C32	BLACHERE et al., 1993, "Heat Shock Protein Vaccines Against Cancer," Journal of Immunotherapy 14:352-356	
	C33	BLANDER et al., 1993, "Major cytoplasmic membrane protein of Legionella pnumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease," J. Clin. Invest. 91(2):717-23	
	C34	BODEY et al., 2000, Anticancer Res 20:2665-2676 Abs	
	C35	BOSCH et al., 1999, "State of the art of therapeutic apheresis in Europe", Ther. Apher. 3(3):197-8	
	C36	BRELOER et al., 1999, "in vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins," J. Immunol. 162:3141-3147	
	C37	BUMOL et al., 1988 "Characterization Of The Human Tumor And Normal Tissue Reactivity Of The KS1/4 Monoclonal Antibody." Hybridoma 7:407-415	
	C38	CARSWELL et al., 1970, "Immunogenic Properties Of Reticulum Cell Sarcomas Of SJL/J Mice." Natl. Cancer Inst. 44:1281-1288	
	C39	CASSEL et al., 1977, "Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses," Cancer 40:672-679	
	C40	CASSEL et al., 1983 "A Phase II Study On The Postsurgical Management Of Stage II Malignant Melanoma With A Newcastle Disease Virus Oncolysate." Cancer, 52:856-860	
- 12-21	C41	CASTELLI et al., 2001, "Human Heat Shock Protein 70 Peptide Complexes Specifically Active Antimelanoma T cells." Cancer Res 61:222-227	
	C42	CHANDAWARKAR et al., 2004, "Immune modulation with high-dose heat shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis," Int'l. Immunol. 16:315-324	
	C43	CHU et al., 1994, α ₂ -Macroglobulin: A Sensor for Proteolysis," Ann. N.Y. Acad. Sci. 737:291-307	1
	C44	CLARKE et al. 1988, "Purification of Complexes of Nuclear Oncogene p53 with Rat and Escherichia coli Heat Shock Proteins: In Vitro Dissociation of hsc70 and dnaK from Murine p53 by ATP" Mol. and Cell. Biol. Vol. 8 (3) 1206-1215	
	C45	COLLEN et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.	
	C46	COSTANZO, 1996, "New monoclonal antibodies," Curr. Opin. Cardiol. 11(2):204-7	


|--|

Sheet 4 of 6 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT		
	Srivastava et al.		
	FILING DATE	ART UNIT	
•	June 4, 2001	1643	

		NON PATENT LITERATURE DOCUMENTS	
Examiner			T
Initials	C47	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) CRAIG, 1993, "Chaperones: Helpers Along the Pathways to Protein Folding," Science 260:1902-4	T
			╄
	C48	D'ANDREA, 2005, "Add Alzheimer's disease to the list of autoimmune diseases," Med. Hypotheses 64(3):458-463	
	C49	DASH, et al., 2002 "Slow-Tight Binding Inhibition of Xylanase by an Aspartic Protease Inhibitor." J. Biol. Chem. 277:17978-17986	
	C50	DAVIDOFF et al., 1992, "Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers	
	C51	DEL GIUDICE et al., 1994, "Hsp70: a carrier molecule with built-in adjuvanticity", Experientia 30;50(11-12):1061-6	
	C52	DERMER, 1994, "Another Anniversary for the War on Cancer," Biotechnology 12:320	
	C53	DEUTSCHER et al., 1992 "Guide to protein purification." Meth. Enzymol., 182:610-611	
	C54	DUBOIS et al., 1980, "Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells," Cancer Res. 40:4204-4208	
	C55	DUBOIS, et al., 1982 "Purification and Biochemical Properties of Tumor-Associated Transplantation Antigens From Methylcholanthrene-Induced Murine Sarcomas." Proc. Natl. Acad. Sci USA, 79:7669-7673	
	C56	ELLGAARD ET AL., 1997,"Dissection of the domain architecture of the alpha2macrglobulin-receptor associated protein." Eur. J. Biochem 244:544-51	
	C57	EPPLEN et al., 1997, "Genetic predisposition to multiple sclerosis as revealed by immunoprinting," Ann. Neurol. 41(3):341-52.	
	C58	ESPANA et al., 1996, Clin. Chem 42(3):545-550	
	C59	ESTIN et al., 1989, "Transfected mouse melanoma lines that express various levels of human melanoma- associated antigen p97," J. Natl. Cancer Inst. 81:445-448	
	C60	EVANS et al., 1999, Q.J. Med 92:299-307	
	C61	FALK et al., 1990, "Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules", Nature 348:248-251	
	C62	FALK et al., 1991, "Identification of Naturally Processed Viral Nonapeptides Allows Their Quantification in Infected Cells and Suggests an Allele-specific T Cell Epitope Forecast". J Exp. Med 174:425-434	
	C63	FALK et al., 1991, "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC Molecules", Nature 351:290-296	
	C64	FALK et al., 1992, "Specificity of antigen processing for MHC class I restricted presentation is conserved between mouse and man", Eur. J. Immunol. 22:1323-1326	
	C65	FAY et al., 1979, "Leukopheresis Therapy of Leukemic Reticuloendotheliosis (Hairy Cell Leukemia)", Blood 54: 747-749	
***************************************	C66	FEDWEG and SRIVASTAVA "Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor rejection antigen", Mount Sinai School of Medicine NZ 206, p. 108	
	C67	FENG et al., 2002, "Exogenous heat shock proteins provide adjuvant effects on enhancing the immunogenicity of apoptotic tumor cells and inducing antitumor immunity," AACR 93 rd Annual Meeting, Vol. 43, April 6-10, Abstract #2214	
	C68	FERRERO et al., 1995, The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA 92(14):6499-503	

EXAMINER	DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not				



Sheet 5 of 6 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Srivastava et al.		
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	_	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C69	FLYNN et al., 1989, "Peptide binding and release by proteins implicated as catalysts of protein assembly", Science 245:385-390	
	C70	FLYNN et al., 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", Nature 353:726-730	
	C71	FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and chemotaxis", Immunology 50(2):251-9	
	C72	FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New York p4	
	C73	GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489	
	C74	GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55	
	C75	GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4	
	C76	GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5	
	C77	GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64	
	C78	GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71	
	C79	GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95	
	C80	GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41	
	C81	GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416	Π
	C82	GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909	
	C83	GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476	
	C84	GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234	
	C85	GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846	
	C86	GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120	
	C87	HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116	
	C88	HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.	
	C89	HARLOW et al., 1988, "Antibodies: A Laboratory Manual" ch 6:139-243	

EXAMINER		•	DATE CONSIDERED	
EXAMINER			DATE CONSIDERED	
+ 273 2 / 4 3 / 23 / 27 / 27 / 27	1 1		 C :1 14DED (00 D 1:	

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 6 of 6 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.
	8449-178-999	09/873,403
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT	
(Use several sheets if necessary)	Srivastava et al.	
	FILING DATE	ART UNIT
	June 4, 2001	1643

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т		
	C90	HEEB et al., 1995, "Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera" Biochem, Mol. Biol. Int. 37(5):917-23			
	C91	HEISKALA et al., 1988 "Characteristics Of Soluble Tumour-Derived Proteins That Inhibit Natural Killer Activity." Scand. J. Immunol. 28:19-27			
	C92	HENTTU AND VIHKO, 1989 "cDNA Coding For The Entire Human Prostate Specific Antigen Shows High Homologies To The Human Tissue Kallikrein Genes." Biochem. Biophys. Res. Comm. 160:903-910			
	C93	HERZ AND STRICKLAND, 2001, "LRP: a multifunctional scavenger and signaling receptor," J. Clin. Invest. 108:779-784			
	C94	HERZ et al., 1990, "Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver", J. of Biol. Chem. 265(34): 21355-21362.			
	C95	HERZ et al., 1991, "39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor." J.Biol.Chem. 266(31):21232-21238.			
	C96	HEY et al., 1988, "Cloning of a novel member of the low-density lipoprotein receptor family", Gene 216: 103-111.			
	C97	HINDS et al., 1987, "Immunological Evidence for the Association of p53 with a Heat Shock Protein, hsc70, in p53-plus-ras-Transformed Cell Lines" Mol. and Cell. Biol. Vol.7 (8) 2863-2869			

EXAMINER	DATE CONSIDERED	





Express Mail No.: ED 608 969 358 US Sheet 1 of 6 of List of References

APPLICATION NO. ATTY. DOCKET NO. 09/873,403 8449-178-999

APPLICANT

Srivastava et al.

ART UNIT FILING DATE 1643 June 4, 2001

REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

	B25	WO 90/02564	3/22/90	Codon Dragon	
	B26	WO 91/15572	10/17/91	The Wellcome Foundation Limited	
	B27	WO 92/01717	2/6/92	Burnie, James et al.	
	B28	WO 92/08484	5/29/92	University College London	
	B29	WO 92/08488	5/29/92	University College London	
	B30	WO 93/14118	7/22/93	Medical Research Council	
	B31	WO 93/17712	9/16/93	Biocine Sclavo Spa Rappuoli	
	B32	WO 93/18146	9/16/93	Institut National de la Sante et de la researche medicale	
	B33	WO 93/18147	9/16/93	Institute Nazionale per lo studio e la cura dei tumori fondazione giovanni pascale	
-	B34	WO 93/18150	9/16/93	Biocine S.P.A.	
	B35	WO 93/21529	10/28/93	Duke University	
	B36	WO 93/24136	12/9/93	Terman, David S.	
-	B37	WO 94/03208	2/17/94	Yeda Research and Development Company, Ltd	
	B38	WO 94/04676	3/3/94	The Victoria University of Manchester	
	B39	WO 94/11513	5/26/94	Medical Research Council Colston	
	B40	WO 94/14471	7/7/1994	Washington University	
	B41	WO 94/29459	12/22/94	Whitehead Institute for Biomedical Research	
	B42	WO 97/04794	2/13/97	The American National Red Cross – The General Hospital Corporation	
	B43	WO 97/06685	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B44	WO 97/06821	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B45	WO 97/06828	2/27/97	Sloan-Kettering Institute for Cancer Research	
-	B46	WO 97/10001	03/20/97	Fordham University	
	B47	WO 97/26910	7/31/97	Max-delbruck medizen milleck	
	B48	WO 98/42752	10/01/98	Brigham and Woman's Hospital Inc.	
	B49	WO 98/46739	7/23/97	Juridicial Foundation the Chemo-Sero- therapeutic Research Institute	
	B50	WO 99/29834	06/17/99	Fordham University	

EXAMINER

DATE CONSIDERED



Express Mail No.: <u>ED 608 969 358 US</u> Sheet 1 of 6 of List of References

ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403

APPLICANT

Srivastava et al.

FILING DATE ART UNIT
June 4, 2001 1643

REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

	B25	WO 90/02564	3/22/90	Codon Dragon	
	B26	WO 91/15572	10/17/91	The Wellcome Foundation Limited	
	B27	WO 92/01717	2/6/92	Burnie, James et al.	
	B28	WO 92/08484	5/29/92	University College London	
	B29	WO 92/08488	5/29/92	University College London	
	B30	WO 93/14118	7/22/93	Medical Research Council	
	B31	WO 93/17712	9/16/93	Biocine Sclavo Spa Rappuoli	
	B32	WO 93/18146	9/16/93	Institut National de la Sante et de la researche medicale	
	B33	WO 93/18147	9/16/93	Institute Nazionale per lo studio e la cura dei tumori fondazione giovanni pascale	
	B34	WO 93/18150	9/16/93	Biocine S.P.A.	
	B35	WO 93/21529	10/28/93	Duke University	
	B36	WO 93/24136	12/9/93	Terman, David S.	
	B37	WO 94/03208	2/17/94	Yeda Research and Development Company, Ltd	
	B38	WO 94/04676	3/3/94	The Victoria University of Manchester	
	B39	WO 94/11513	5/26/94	Medical Research Council Colston	
	B40	WO 94/14471	7/7/1994	Washington University	
	B41	WO 94/29459	12/22/94	Whitehead Institute for Biomedical Research	
	B42	WO 97/04794	2/13/97	The American National Red Cross – The General Hospital Corporation	
	B43	WO 97/06685	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B44	WO 97/06821	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B45	WO 97/06828	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B46	WO 97/10001	03/20/97	Fordham University	
	B47	WO 97/26910	7/31/97	Max-delbruck medizen milleck	
	B48	WO 98/42752	10/01/98	Brigham and Woman's Hospital Inc.	
-	B49	WO 98/46739	7/23/97	Juridicial Foundation the Chemo-Sero- therapeutic Research Institute	
	B50	WO 99/29834	06/17/99	Fordham University	

EXAMINER	
-----------------	--

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





Express Mail No.: <u>ED 608 969 358 US</u> Sheet 2 of 6 of List of References

	ATTY. DOCKET NO. APPLICATION NO. 09/873,403		
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	filing date June 4, 2001	ART UNIT 1643	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	1	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
THE COLUMN TO TH	C08	ABBAS et al., 1991, Cellular and Molecular Immunology, W.B. Saunders Co., Philadelphia (Chapters 15-18)	Ī
	C09	AGOSTONI et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.	
	C10	ALDOVINI et al., 1992, "The New Vaccines", Technology Review pp. 24-31	
,	CII	AMATO et al., 1999, "Active Specific Immunotherapy in Patients with Renal Cell Carcinoma (RCC) Using Autologous Tumor Derived Heat Shock Protein-Peptide Complex-96 (HSPP-96) Vaccine" American Society Clinical Oncology Meeting, abstract 1278	
	C12	ANDERSEN, P. 1994, "Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins," Infect. Immun. 62(6):2536-44	
	C13	ANDUS et al., Synthesis of alpha 2-macroglobulin in rat hepatocytes and in a cell-free system. FEBS Lett. 1983 Jan 10;151(1):10-14	
	C14	ANTHONY et al., 1999, "Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule," Vaccine 17(4):373-83	
		BANCHEREAU et al., 1998, "Dendritic cells and the control of immunity," Nature 392:245-252	Γ
	C16	BARRIOS et al., 1992, "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and BacillusCalmette Guerin priming," Eur. J. Immunol. 22(6):1365-72	
	C17	BARRIOS et al., 1994, "Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and Dna K proteins requires cross-linking with antigen," Clin. Exp. Immunol. 98(2):229-233	
	C18	BARRIOS et al., 1994, "Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD." Clin Exp Immunol. 98(2):224-8	
	C19	BARTLETT, 1972 "Effect Of Host Immunity On The Antigenic Strength Of Primary Tumors." J. Natl. Cancer Inst. 49:493-504	
	C20	BASOMBRÍO (1970) "Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene", <i>The Institute for Cancer Research</i> 30:2458-2462	
	C21	BASU and SRIVASTAVA, 1999, "Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity" J. Exp. Med. 189:797-802	
	C22	BASU et al., 2000, "Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway," Int. Immunol. 12(11):1539-46	
	C23	BASU et al., 2001, "CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin," Immunity 14:303-313	
	C24	BEDNAR et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.	
• ,	C25	BELLONE et al., 1999, "Cancer Immunotherapy: synthetic and natural peptides in balance," Immunology Today 20(10): 457-462	
	C26	BEVERLY, 1988, "Tumour Immunology." In: <i>Immunology</i> , 3rd Edition, Roitt, Ed., Mosby, London, pp. 17.1-17.12	

EXAMINE	R	DATE CONSIDERED
*EVALUNE	D. Initial if reference considered whether or not citation is in conform	age of with MDED 600s Drown line through citation if not in conformance and not





Sheet 3 of 6 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
APPLICANT Srivastava et al.		
FILING DATE June 4, 2001	ART UNIT 1643	

		NON PATENT LITERATURE DOCUMENTS	
Examiner nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	т
	C27	BINDER and Srivastava, 2004, "Essential role of CD91 in re-presentation of gp96-chaperoned peptides," Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133	
	C28	BINDER et al., 2000, "CD91: a receptor for heat shock protein gp96," Nature Immunol. 1(2):151-155	
	C29	BINDER et al., 2001, "Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatability complex I molecules," J. Biol. Chem. 276(20): 17163-17171	
	C30	BIRKENMEIER G., 2001, "Targetting the Proteinase Inhibitor and Immune Modulatory Function of Human α2-Macroglobulin." Mod. Asp. Immunobiol. 2(1):32-36	
	C31	BLACHERE and SRIVASTAVA (1993) "Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells", J. Cellular Biochem. Keystone Symposia, 17D: pp. 124, Abstract NZ 502	
	C32	BLACHERE et al., 1993, "Heat Shock Protein Vaccines Against Cancer," Journal of Immunotherapy 14:352-356	
	C33	BLANDER et al., 1993, "Major cytoplasmic membrane protein of Legionella pnumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease," J. Clin. Invest. 91(2):717-23	
	C34	BODEY et al., 2000, Anticancer Res 20:2665-2676 Abs	
	C35	BOSCH et al., 1999, "State of the art of therapeutic apheresis in Europe", Ther. Apher. 3(3):197-8	
		BRELOER et al., 1999, "in vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins," J. Immunol. 162:3141-3147	
	C37	BUMOL et al., 1988 "Characterization Of The Human Tumor And Normal Tissue Reactivity Of The KS1/4 Monoclonal Antibody." Hybridoma 7:407-415	
	C38	CARSWELL et al., 1970, "Immunogenic Properties Of Reticulum Cell Sarcomas Of SJL/J Mice." Natl. Cancer Inst. 44:1281-1288	
• •	C39	CASSEL et al., 1977, "Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses," Cancer 40:672-679	
	C40	CASSEL et al., 1983 "A Phase II Study On The Postsurgical Management Of Stage II Malignant Melanoma With A Newcastle Disease Virus Oncolysate." Cancer, 52:856-860	
	C41	CASTELLI et al., 2001, "Human Heat Shock Protein 70 Peptide Complexes Specifically Active Antimelanoma T cells." Cancer Res 61:222-227	
	C42	CHANDAWARKAR et al., 2004, "Immune modulation with high-dose heat shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis," Int'l. Immunol. 16:315-324	
	C43	CHU et al., 1994, \(\alpha_2\)-Macroglobulin: A Sensor for Proteolysis," Ann. N.Y. Acad. Sci. 737:291-307	\top
	C44	CLARKE et al. 1988, "Purification of Complexes of Nuclear Oncogene p53 with Rat and Escherichia coli Heat Shock Proteins: In Vitro Dissociation of hsc70 and dnaK from Murine p53 by ATP" Mol. and Cell. Biol. Vol. 8 (3) 1206-1215	
•	C45	COLLEN et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.	
	C46	COSTANZO, 1996, "New monoclonal antibodies," Curr. Opin. Cardiol. 11(2):204-7	1

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





Express Mail No.: <u>ED 608 969 358 US</u> Sheet 4 of 6 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403
APPLICANT	
Srivastava et al.	
FILING DATE	ART UNIT
June 4, 2001	1642

NON PATENT LITERATURE DOCUMENTS			
Examiner		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
Initials	C47	CRAIG, 1993, "Chaperones: Helpers Along the Pathways to Protein Folding," Science 260:1902-4	╁
	C48	D'ANDREA, 2005, "Add Alzheimer's disease to the list of autoimmune diseases," Med. Hypotheses	┢
	C40	64(3):458-463	
	C49	DASH, et al., 2002 "Slow-Tight Binding Inhibition of Xylanase by an Aspartic Protease Inhibitor." J. Biol.	<u> </u>
		Chem. 277:17978-17986	
	C50	DAVIDOFF et al., 1992, "Immune response to p53 is dependent upon p53/HSP70 complexes in breast	
		cancers	ļ.,
	C51	DEL GIUDICE et al., 1994, "Hsp70: a carrier molecule with built-in adjuvanticity", Experientia 30;50(11-12):1061-6	
	C52	DERMER, 1994, "Another Anniversary for the War on Cancer," Biotechnology 12:320	
	C53	DEUTSCHER et al., 1992 "Guide to protein purification." Meth. Enzymol., 182:610-611	+
	C54	DUBOIS et al., 1980, "Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells,"	t
	034	Cancer Res. 40:4204-4208	1
	C55	DUBOIS, et al., 1982 "Purification and Biochemical Properties of Tumor-Associated Transplantation	Т
		Antigens From Methylcholanthrene-Induced Murine Sarcomas." Proc. Natl. Acad. Sci USA, 79:7669-7673	
	C56	ELLGAARD ET AL., 1997,"Dissection of the domain architecture of the alpha2macrglobulin-receptor	
		associated protein." Eur. J. Biochem 244:544-51	L
	C57	EPPLEN et al., 1997, "Genetic predisposition to multiple sclerosis as revealed by immunoprinting," Ann.	1
		Neurol. 41(3):341-52.	L
	C58	ESPANA et al., 1996, Clin. Chem 42(3):545-550	L
	C59	ESTIN et al., 1989, "Transfected mouse melanoma lines that express various levels of human melanoma-	l
		associated antigen p97," J. Natl. Cancer Inst. 81:445-448	┝
	C60	EVANS et al., 1999, Q.J. Med 92:299-307 FALK et al., 1990, "Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I	⊦
	C61	Molecules", Nature 348:248-251	
	C62	FALK et al., 1991, "Identification of Naturally Processed Viral Nonapeptides Allows Their Quantification	t
	002	in Infected Cells and Suggests an Allele-specific T Cell Epitope Forecast". J Exp. Med 174:425-434	1
	C63	FALK et al., 1991, "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC	T
		Molecules", <i>Nature</i> 351:290-296	
	C64	FALK et al., 1992, "Specificity of antigen processing for MHC class I restricted presentation is conserved	
		between mouse and man", Eur. J. Immunol. 22:1323-1326	L
	C65	FAY et al., 1979, "Leukopheresis Therapy of Leukemic Reticuloendotheliosis (Hairy Cell Leukemia)",	ļ
		Blood 54: 747-749	L
	C66	FEDWEG and SRIVASTAVA "Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor	
	1055	rejection antigen", Mount Sinai School of Medicine NZ 206, p. 108	╀
	C67	FENG et al., 2002, "Exogenous heat shock proteins provide adjuvant effects on enhancing the	
		immunogenicity of apoptotic tumor cells and inducing antitumor immunity," AACR 93 rd Annual Meeting,	
	C68	Vol. 43, April 6-10, Abstract #2214 FERRERO et al., 1995, The GroES homolog of Helicobacter pylori confers protective immunity against	╁
	C08	mucosal infection in mice. Proc Natl Acad Sci USA 92(14):6499-503	
		mucosai infection in fince. Fluc than Acad Sci USA 72(14).0477-303	Щ

	EXAMINER	DATE CONSIDERED	
ĺ	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not		





Express Mail No.: ED 608 969 358 US

Sheet 5 of 6 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403
APPLICANT	
Srivastava et al.	
FILING DATE	ART UNIT
Tune 4 2001	1643

		NON PATENT LITERATURE DOCUMENTS	
Examiner	1	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
nitials	C69	FLYNN et al., 1989, "Peptide binding and release by proteins implicated as catalysts of protein assembly",	╁
		Science 245:385-390	<u> </u>
	C70	FLYNN et al., 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", Nature 353:726-730	$oxed{oxed}$
	C71	FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and chemotaxis", Immunology 50(2):251-9	
	C72	FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New York p4	
	C73	GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489	
	C74	GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-	
//	C75	GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4	
	C76	GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5	
	C77	GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64	
	C78	GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71	
	C79	GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95	
	C80	GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41	
	C81	GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416	
	C82	GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909	
	C83	GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476	
	C84	GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234	
	C85	GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846	
3 2 11	C86	GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120	
	C87	HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116	
	C88	HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.	
-	C89	HARLOW et al., 1988, "Antibodies: A Laboratory Manual" ch 6:139-243	

EXAMINER D	DATE CONSIDERED
------------	-----------------





Express Mail No.: <u>ED 608 969 358 US</u> Sheet 6 of 6 of List of References

LIST OF REFERENCES	CITED BY	APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
APPLICANT Srivastava et al.	
FILING DATE June 4, 2001	ART UNIT

C			Т
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	1
	C90	HEEB et al., 1995, "Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera." Biochem, Mol. Biol. Int. 37(5):917-23	
	C91	HEISKALA et al., 1988 "Characteristics Of Soluble Tumour-Derived Proteins That Inhibit Natural Killer Activity." Scand. J. Immunol. 28:19-27	
	C92	HENTTU AND VIHKO, 1989 "cDNA Coding For The Entire Human Prostate Specific Antigen Shows High Homologies To The Human Tissue Kallikrein Genes." Biochem. Biophys. Res. Comm. 160:903-910	
	C93	HERZ AND STRICKLAND, 2001, "LRP: a multifunctional scavenger and signaling receptor," J. Clin. Invest. 108:779-784	
	C94	HERZ et al., 1990, "Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver", J. of Biol. Chem. 265(34): 21355-21362.	
	C95	HERZ et al., 1991, "39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor." J.Biol.Chem. 266(31):21232-21238.	
-	C96	HEY et al., 1988, "Cloning of a novel member of the low-density lipoprotein receptor family", Gene 216: 103-111.	
	C97	HINDS et al., 1987, "Immunological Evidence for the Association of p53 with a Heat Shock Protein, hsc70, in p53-plus-ras-Transformed Cell Lines" Mol. and Cell. Biol. Vol.7 (8) 2863-2869	

EXAMINER DATE CONSIDERED

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 1 of 6 of List of References

ATTY. DOCKET NO.

8449-178-999

APPLICATION NO.

09/873,403

APPLICANT

Srivastava et al.

FILING DATE

June 4, 2001

ART UNIT

1643

T OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

	B25	WO 90/02564	3/22/90	Codon Dragon	
	B26	WO 91/15572	10/17/91	The Wellcome Foundation Limited	
	B27	WO 92/01717	2/6/92	Burnie, James et al.	
	B28	WO 92/08484	5/29/92	University College London	
	B29	WO 92/08488	5/29/92	University College London	
	B30	WO 93/14118	7/22/93	Medical Research Council	
-	B31	WO 93/17712	9/16/93	Biocine Sclavo Spa Rappuoli	
	B32	WO 93/18146	9/16/93	Institut National de la Sante et de la researche medicale	
	В33	WO 93/18147	9/16/93	Institute Nazionale per lo studio e la cura dei tumori fondazione giovanni pascale	
	B34	WO 93/18150	9/16/93	Biocine S.P.A.	
	B35	WO 93/21529	10/28/93	Duke University	
	. В36	WO 93/24136	12/9/93	Terman, David S.	
•••	B37	WO 94/03208	2/17/94	Yeda Research and Development Company, Ltd	
	B38	WO 94/04676	3/3/94	The Victoria University of Manchester	
	B39	WO 94/11513	5/26/94	Medical Research Council Colston	
	B40	WO 94/14471	7/7/1994	Washington University	
	B41	WO 94/29459	12/22/94	Whitehead Institute for Biomedical Research	
	B42	WO 97/04794	2/13/97	The American National Red Cross – The General Hospital Corporation	
	B43	WO 97/06685	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B44	WO 97/06821	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B45	WO 97/06828	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B46	WO 97/10001	03/20/97	Fordham University	
	B47	WO 97/26910	7/31/97	Max-delbruck medizen milleck	
	B48	WO 98/42752	10/01/98	Brigham and Woman's Hospital Inc.	
	B49	WO 98/46739	7/23/97	Juridicial Foundation the Chemo-Sero- therapeutic Research Institute	
	B50	WO 99/29834	06/17/99	Fordham University	

EXAMINER

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 2 of 6 of List of References

	ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403				
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.				
	FILING DATE June 4, 2001	art unit 1643			

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т		
mitiais	C08	ABBAS et al., 1991, Cellular and Molecular Immunology, W.B. Saunders Co., Philadelphia (Chapters 15-18)			
	C09	AGOSTONI et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.			
	C10	ALDOVINI et al., 1992, "The New Vaccines", Technology Review pp. 24-31			
,	C11	AMATO et al., 1999, "Active Specific Immunotherapy in Patients with Renal Cell Carcinoma (RCC) Using Autologous Tumor Derived Heat Shock Protein-Peptide Complex-96 (HSPP-96) Vaccine" American Society Clinical Oncology Meeting, abstract 1278			
	C12	ANDERSEN, P. 1994, "Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins," Infect. Immun. 62(6):2536-44			
	C13	ANDUS et al., Synthesis of alpha 2-macroglobulin in rat hepatocytes and in a cell-free system. FEBS Lett. 1983 Jan 10;151(1):10-14			
	C14	ANTHONY et al., 1999, "Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule," Vaccine 17(4):373-83			
	C15	BANCHEREAU et al., 1998, "Dendritic cells and the control of immunity," Nature 392:245-252			
	C16	BARRIOS et al., 1992, "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and BacillusCalmette Guerin priming," Eur. J. Immunol. 22(6):1365-72			
, , , , , , , , , , , , , , , , , , ,	C17	BARRIOS et al., 1994, "Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and Dna K proteins requires cross-linking with antigen," Clin. Exp. Immunol. 98(2):229-233			
	C18	BARRIOS et al., 1994, "Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD." Clin Exp Immunol. 98(2):224-8			
	C19	BARTLETT, 1972 "Effect Of Host Immunity On The Antigenic Strength Of Primary Tumors." J. Natl. Cancer Inst. 49:493-504			
	C20	BASOMBRÍO (1970) "Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene", <i>The Institute for Cancer Research</i> 30:2458-2462			
	C21	BASU and SRIVASTAVA, 1999, "Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity" <i>J. Exp. Med.</i> 189:797-802			
	C22	BASU et al., 2000, "Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway," Int. Immunol. 12(11):1539-46			
	C23	BASU et al., 2001, "CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin," Immunity 14:303-313			
	C24	BEDNAR et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.			
	C25	BELLONE et al., 1999, "Cancer Immunotherapy: synthetic and natural peptides in balance," Immunology Today 20(10): 457-462			
	C26	BEVERLY, 1988, "Tumour Immunology." In: <i>Immunology</i> , 3rd Edition, Roitt, Ed., Mosby, London, pp. 17.1-17.12			

EXAMINER	DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 3 of 6 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Srivastava et al.		
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C27	BINDER and Srivastava, 2004, "Essential role of CD91 in re-presentation of gp96-chaperoned peptides," Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133	
	C28	BINDER et al., 2000, "CD91: a receptor for heat shock protein gp96," Nature Immunol. 1(2):151-155	
	C29	BINDER et al., 2001, "Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatability complex I molecules," J. Biol. Chem. 276(20): 17163-17171	
	C30	BIRKENMEIER G., 2001, "Targetting the Proteinase Inhibitor and Immune Modulatory Function of Human α2-Macroglobulin." Mod. Asp. Immunobiol. 2(1):32-36	
	C31	BLACHERE and SRIVASTAVA (1993) "Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells", J. Cellular Biochem. Keystone Symposia, 17D: pp. 124, Abstract NZ 502	
	C32	BLACHERE et al., 1993, "Heat Shock Protein Vaccines Against Cancer," Journal of Immunotherapy 14:352-356	
	C33	BLANDER et al., 1993, "Major cytoplasmic membrane protein of Legionella pnumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease," J. Clin. Invest. 91(2):717-23	
	C34	BODEY et al., 2000, Anticancer Res 20:2665-2676 Abs	
	C35	BOSCH et al., 1999, "State of the art of therapeutic apheresis in Europe", Ther. Apher. 3(3):197-8	
	C36	BRELOER et al., 1999, "in vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins," J. Immunol. 162:3141-3147	
	C37	BUMOL et al., 1988 "Characterization Of The Human Tumor And Normal Tissue Reactivity Of The KS1/4 Monoclonal Antibody." Hybridoma 7:407-415	
	C38	CARSWELL et al., 1970, "Immunogenic Properties Of Reticulum Cell Sarcomas Of SJL/J Mice." Natl. Cancer Inst. 44:1281-1288	
	C39	CASSEL et al., 1977, "Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses," Cancer 40:672-679	
	C40	CASSEL et al., 1983 "A Phase II Study On The Postsurgical Management Of Stage II Malignant Melanoma With A Newcastle Disease Virus Oncolysate." Cancer, 52:856-860	
	C41	CASTELLI et al., 2001, "Human Heat Shock Protein 70 Peptide Complexes Specifically Active Antimelanoma T cells." Cancer Res 61:222-227	
	C42	CHANDAWARKAR et al., 2004, "Immune modulation with high-dose heat shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis," Int'l. Immunol. 16:315-324	
	C43	CHU et al., 1994, α ₂ -Macroglobulin: A Sensor for Proteolysis," Ann. N.Y. Acad. Sci. 737:291-307	
	C44	CLARKE et al. 1988, "Purification of Complexes of Nuclear Oncogene p53 with Rat and Escherichia coli Heat Shock Proteins: In Vitro Dissociation of hsc70 and dnaK from Murine p53 by ATP" Mol. and Cell. Biol. Vol. 8 (3) 1206-1215	
	C45	COLLEN et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.	
	C46	COSTANZO, 1996, "New monoclonal antibodies," Curr. Opin. Cardiol. 11(2):204-7	1

1	
EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformation considered. Include copy of this form with next communication to applicant.	nance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 4 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	art unit 1643	

		NON PATENT LITERATURE DOCUMENTS	
Examiner	1	(CARITTAL LETTERS) Title Date Participal Record Page Page	Т
Initials	C17	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) CRAIG, 1993, "Chaperones: Helpers Along the Pathways to Protein Folding," Science 260:1902-4	┿
	C47		L
	C48	D'ANDREA, 2005, "Add Alzheimer's disease to the list of autoimmune diseases," Med. Hypotheses 64(3):458-463	
	C49	DASH, et al., 2002 "Slow-Tight Binding Inhibition of Xylanase by an Aspartic Protease Inhibitor." J. Biol. Chem. 277:17978-17986	
	C50	DAVIDOFF et al., 1992, "Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers	
	C51	DEL GIUDICE et al., 1994, "Hsp70: a carrier molecule with built-in adjuvanticity", Experientia 30;50(11-12):1061-6	
	C52	DERMER, 1994, "Another Anniversary for the War on Cancer," Biotechnology 12:320	
	C53	DEUTSCHER et al., 1992 "Guide to protein purification." Meth. Enzymol., 182:610-611	Т
	C54	DUBOIS et al., 1980, "Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells," Cancer Res. 40:4204-4208	
	C55	DUBOIS, et al., 1982 "Purification and Biochemical Properties of Tumor-Associated Transplantation Antigens From Methylcholanthrene-Induced Murine Sarcomas." Proc. Natl. Acad. Sci USA, 79:7669-7673	
	C56	ELLGAARD ET AL., 1997,"Dissection of the domain architecture of the alpha2macrglobulin-receptor associated protein." Eur. J. Biochem 244:544-51	
	C57	EPPLEN et al., 1997, "Genetic predisposition to multiple sclerosis as revealed by immunoprinting," Ann. Neurol. 41(3):341-52.	
	C58	ESPANA et al., 1996, Clin. Chem 42(3):545-550	Τ
	C59	ESTIN et al., 1989, "Transfected mouse melanoma lines that express various levels of human melanoma-associated antigen p97," J. Natl. Cancer Inst. 81:445-448	
	C60	EVANS et al., 1999, Q.J. Med 92:299-307	Τ
·-	C61	FALK et al., 1990, "Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules", Nature 348:248-251	
	C62	FALK et al., 1991, "Identification of Naturally Processed Viral Nonapeptides Allows Their Quantification in Infected Cells and Suggests an Allele-specific T Cell Epitope Forecast". J Exp. Med 174:425-434	T
	C63	FALK et al., 1991, "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC Molecules", Nature 351:290-296	
	C64	FALK et al., 1992, "Specificity of antigen processing for MHC class I restricted presentation is conserved between mouse and man", Eur. J. Immunol. 22:1323-1326	
	C65	FAY et al., 1979, "Leukopheresis Therapy of Leukemic Reticuloendotheliosis (Hairy Cell Leukemia)", Blood 54: 747-749	
	C66	FEDWEG and SRIVASTAVA "Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor rejection antigen", Mount Sinai School of Medicine NZ 206, p. 108	
	C67	FENG et al., 2002, "Exogenous heat shock proteins provide adjuvant effects on enhancing the immunogenicity of apoptotic tumor cells and inducing antitumor immunity," AACR 93 rd Annual Meeting, Vol. 43, April 6-10, Abstract #2214	
_	C68	FERRERO et al., 1995, The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA 92(14):6499-503	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformation considered. Include copy of this form with next communication to applicant.	nance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 5 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	7
	C69	FLYNN et al., 1989, "Peptide binding and release by proteins implicated as catalysts of protein assembly", Science 245:385-390	
	C70	FLYNN et al., 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", Nature 353:726-730	
	C71	FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and chemotaxis", Immunology 50(2):251-9	
11.5	C72	FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New York p4	
	C73	GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489	
	C74	GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55	
	C75	GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4	
	C76	GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5	
	C77	GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64	
	C78	GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71	
	C79	GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95	
	C80	GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41	
	C81	GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416	
	C82	GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909	
	C83	GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476	
	C84	GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234	
	C85	GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846	
	C86	GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120	
	C87	HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116	
	C88	HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.	
	C89	HARLOW et al., 1988, "Antibodies: A Laboratory Manual" ch 6:139-243	\top


EXAMINER	DATE CONSIDERED
	ist A (DED COO). Describing the such situation if not in conformance and not

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 6 of 6 of List of References

	ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403		
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	filing date June 4, 2001	ART UNIT 1643	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T		
Initials	C 90	HEEB et al., 1995, "Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera," Biochem. Mol. Biol. Int. 37(5):917-23			
	C91	HEISKALA et al., 1988 "Characteristics Of Soluble Tumour-Derived Proteins That Inhibit Natural Killer Activity." Scand. J. Immunol. 28:19-27			
	C92	HENTTU AND VIHKO, 1989 "cDNA Coding For The Entire Human Prostate Specific Antigen Shows High Homologies To The Human Tissue Kallikrein Genes." <i>Biochem. Biophys. Res. Comm.</i> 160:903-910			
	C93	HERZ AND STRICKLAND, 2001, "LRP: a multifunctional scavenger and signaling receptor," J. Clin. Invest. 108:779-784			
	C94	HERZ et al., 1990, "Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver", J. of Biol. Chem. 265(34): 21355-21362.			
	C95	HERZ et al., 1991, "39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor." J.Biol.Chem. 266(31):21232-21238.			
	C96	HEY et al., 1988, "Cloning of a novel member of the low-density lipoprotein receptor family", Gene 216: 103-111.			
	C97	HINDS et al., 1987, "Immunological Evidence for the Association of p53 with a Heat Shock Protein, hsc70, in p53-plus-ras-Transformed Cell Lines" Mol. and Cell. Biol. Vol.7 (8) 2863-2869			

EXAMINER	DATE CONSIDERED





1643 IFW

Express Mail No.: *ED 608 969 344 US*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Srivastava et al.

Confirmation No.: 1802

Application No.: 09/873,403

Art Unit: 1643

Filed: June 4, 2001

Examiner: Christopher H. Yaen

For: COMPLEXES OF ALPHA (2)

Attorney Docket No:

8449-178-999

MACROGLOBULIN AND ANTIGENIC MOLECULES FOR IMMUNOTHERAPY

(CAM No:

708584-999177)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56 AND § 1.97

MAIL STOP RCE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 COPY

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the United States Patent and Trademark Office ("USPTO") of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicant hereby invite the Examiner's attention to references A01-A56, B01-B50, and C08 to C283 listed on the attached form entitled "List of References Cited by Applicant."

Copies of references A01, B01-B50 and C08-C283 are enclosed herewith. Copies of references A02-A56 are not submitted herewith because they are U.S. patents or U.S. patent application publications. Pursuant to 37 C.F.R. § 1.98 (a)(2)(i) as amended (see Fed. Reg. vol. 69, no. 182, Sept. 21, 2004), the requirement for providing a copy of each U.S. patent or U.S. patent application publication listed in an Information Disclosure Statement in a patent application, regardless of the filing date of the application, is eliminated.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Pursuant to 37 C.F.R. §1.98(a)(3)(i), a concise explanation of the relevance of non-English documents (references B01 and B47) is provided herewith. The relevance of reference B01, German Patent DE 19602985, can be explained by the English translation of

sheet 2 of 2 Attorney Docket No.: 8449-178-999 Application No.: 09/873,403 Applicant: Srivastava

the abstract: Tumor vaccine, for immune therapy of tumors, comprises tumor cells which also contain a gene for an exogenic heat shock protein. The relevance of reference B47, PCT Application No. WO 97/26910, can be explained by the English translation of the abstract:

The invention concerns a tumor vaccine in which the immunogenicity of tumor cells, tumor associated antigens or antigen partial structures are reinforced through genetic modification or through chemical bonding to an exogenous thermal shock protein. The use of microbial thermal shock proteins or their genes is preferred which are derived from mycobacteria, Escherichia coli or from Chlamydia trachomatis.

While not to be construed as indicating that the Examiner should not review and consider fully all the listed references, Attorneys for Applicant particularly direct the Examiner's attention to references A05, A08, A11, C177-C181, and C184-C186.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97 (b)(4), Applicants believe that no fee is due in connection with the filing of this Supplemental Information Disclosure Statement. However, if the Patent Office determines otherwise, the Commissioner is authorized to charge any required fees to Jones Day deposit account no. 50-3013.

Respectfully submitted,

Date: November 8, 2007

Adriane M. Antler (Reg. No.)

JONES DAY

222 East 41st Street

New York, New York 10017

Phone: (212) 326-3939



COPY

FILING DATE

June 4, 2001

Express Mail No.: <u>ED 608 969 344 US</u> Sheet 1 of 3 of List of References

ARTUNIT

ATTY. DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403
APPLICANT	
Srivastava et al.	

REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT *EXAMINER FIGURES APPEAR DOCUMENT NUMBER INITIAL DATE NAME 9/10/99 A01 09/393,652 Srivastava 2001-0034042 10/01 Srivastava A02 1/03/02 A03 2002-0001841 Kaltoft et al. 6/4/01 Srivastava 2002-0028207 A04 A05 03/28/02 2002-0037290 Armen 2002-0172682 11/21/02 Srivastava A06 12/19/02 2002-0192230 Srivastava A07 A08 07/10/03 2003-0129296 Srivastava 2003-0211971 11/13/03 Srivastava A09 A10 2004-0022796 02/05/04 Srivastava A11 12/16/04 Srivastava 2004-0253228 A12 07/26/06 2006-0165710 Srivastava 9/1/87 4,690,915 Rosenberg A13 5/12/1992 Prince et al. A14 5,112,298 2/23/93 McGuire et al. 5,188,964 A15 8/3/93 Sanders et al. 5,232,833 A16 5,273,965 12/28/93 Kensil et al. A17 5,348,945 9/20/94 Berberian et al. A18 9/10/1996 Uhoch 5,554,293 A19 12/3/96 Felgner et al. 5,580,859 A20 6/10/1997 Pages et al. 5,637,082 A21 Marks et al. 7/29/97 A22 5,652,115 4/7/98 Cohen 5,736,146 A23 5,747,332 5/5/98 Wallen et al A24 5,750,119 05/12/98 Srivastava A25 A26 5,830,464 11/03/98 Srivastava et al. 12/8/1998 Kishida 5,846,928 A27 Cohen 2/9/99 5,869,058 A28 5,891,653 4/6/99 Attfield A29 5,910,306 06/99 Alving et al. A30

EXAMINER

DATE CONSIDERED

Express Mail No.: ED 608 969 344 US

Sheet 2 of 3 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403
APPLICANT	
Srivastava et al.	
FILING DATE	ARTUNIT
June 4, 2001	1643

*EXAMINER INITIAL	1	DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
INTTAL	A31	5,947,646	07/19/99	Srivastava et al.	116011257117257
	A32	5,968,526	10/19/99	Garman et al.	
	A33	5,997,873	12/7/99	Srivastava et al.	
	A34	6,007,821	12/28/99	Srivastava et al.	
	A35	6,027,731	2/22/2000	Pauza	
	A36	6,030,618	02/29/00	Srivastava	
	A37	6,033,561	3/7/2000	Schoendorfer	
	A38	6,048,530	4/11/00	Srivastava	
	A39	6,136,315	10/24/00	Srivastava	
	A40	6,156,311	12/05/00	Strickland et al.	
	A41	6,162,436	12/19/00	Srivastava	
	A42	6,168,793	1/2/01	Srivastava et al.	
	A43	6,312,711	11/6/01	Duchateau et al.	
	A44	6,333,311	12/25/2001	Nuijens et al.	
	A45	6,338,945	01/15/02	Nicolette	
	A46	6,403,092	6/11/02	Pizzo et al.	
	A47	6,433,141	8/13/02	Wallen et al.	
	A48	6,689,363	02/10/04	Sette et al.	
	A49	6,709,672	3/23/04	Henot et al.	
	A50	6,713,608	3/30/04	Wallen et al.	
	A51	6,730,302	5/4/04	Fujihara et al.	
	A52	6,797,480	9/28/04	Srivastava	
	A53	6,986,389	01/06	Li	
	A54	7,176,515	03/06/07	Srivastava et al.	
	A55	7,179,462	02/20/07	Srivastava et al.	
	A56	7,132,109	11/07/06	Srivastava	

TO WAR A TRAITED	
	EXAMINER

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 344 US</u> Sheet 3 of 3 of List of References

LIST OF REFERENCES CITED BY APPLICANT	ATTY. DOCKET NO. APPLICATION NO. 09/873,403 APPLICANT	
(Use several sheets if necessary)	Srivastava et al. FILING DATE June 4, 2001	art unit

		FOREIGN	PATENT DOCUMENTS	
B01	DE 196 02 985 A1	1/27/96	Germany	
B02	GB 2 251 186A	7/1/92	United Kingdom	
B03	WO 00/03003	1/20/00	University of Nottingham	
B04	WO 00/10597	03/02/00	Immunology Limited	
B05		6/15/00	The Government of the United States of America represented by the Secretary, Dept. of Health and Human Services	
B06	WO 00/38760	7/6/2000	Occulogix Corp	
B07	WO 00/46246	8/10/00	The General Hospital Corp.	
B08	WO 00/54801	9/21/2000	Entremed Inc	
B09	WO 01/91787	6/12/01	University of Conneticut Health Center	
B10	WO 01/92474	12/06/01	University of Conneticut Health Center	
B11	WO 02/07755	1/3/2002	The General Hospital Corporation	
B12	WO 02/11669	02/14/02	Antigenics, LLC	
B13	WO 02/15930	2/28/02	Duke University	
B14	WO 02/30434	4/18/02	University of Conneticut Health Center	
B15	WO 02/32923	4/25/02	University of Conneticut Health Center	
B16	WO 02/34205	5/2/02	University of Conneticut Health Center	
B17	WO 03/015712	02/27/03	University of Conneticut Health Center	
B18		11/06/03	University of Conneticut Health Center	
B19	WO 03/092624	11/13/03	University of Conneticut Health Center	
B20	WO 04/035602	04/29/04	University of Conneticut Health Center	
B21	WO 04/075636	09/10/04	University of Conneticut Health Center	
B22	WO 04/74434	09/02/04	University of Conneticut Health Center	
B23		12/22/05	University of Conneticut Health Center	
B24	WO 89/12455	12/28/89	Whitehead Institute for Biomedical Research Medical Research Council	

EX	AM	IN	FR

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 1 of 6 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.
	8449-178-999	09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE	ART UNIT

FOREIGN PATENT DOCUMENTS 3/22/90 Codon Dragon WO 90/02564 B25 The Wellcome Foundation Limited WQ 91/15572 10/17/91 **B26** Burnie, James et al. WO 92/01717 2/6/92 B27 WO 92/08484 5/29/92 University College London **B28** 5/29/92 University College London WO 92/08488 B29 Medical Research Council WO 93/14118 7/22/93 **B30** WO 93/17712 9/16/93 Biocine Sclavo Spa Rappuoli B31 Institut National de la Sante et de la WO 93/18146 9/16/93 B32 researche medicale Institute Nazionale per lo studio e la 9/16/93 WO 93/18147 **B33** cura dei tumori fondazione giovanni pascale Biocine S.P.A. WO 93/18150 9/16/93 **B34** WO 93/21529 10/28/93 **Duke University B35** Terman, David S. WO 93/24136 12/9/93 **B36** WO 94/03208 2/17/94 Yeda Research and Development **B37** Company, Ltd The Victoria University of Manchester WO 94/04676 3/3/94 Medical Research Council Colston WO 94/11513 5/26/94 **B39** WO 94/14471 7/7/1994 Washington University **B40** 12/22/94 Whitehead Institute for Biomedical WO 94/29459 B41 Research The American National Red Cross -WO 97/04794 2/13/97 B42 The General Hospital Corporation 2/27/97 Sloan-Kettering Institute for Cancer WO 97/06685 B43 Research WO 97/06821 2/27/97 Sloan-Kettering Institute for Cancer **B44** Research WO 97/06828 2/27/97 Sloan-Kettering Institute for Cancer B45 Research WO 97/10001 03/20/97 Fordham University **B46** WO 97/26910 7/31/97 Max-delbruck medizen milleck **B47** 10/01/98 WO 98/42752 Brigham and Woman's Hospital Inc. **B48** Juridicial Foundation the Chemo-Sero-7/23/97 WO 98/46739 B49 therapeutic Research Institute Fordham University WO 99/29834 06/17/99 **B50**

EXAMINER DATE	E CONSIDERED
---------------	--------------

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
minais	C08	ABBAS et al., 1991, Cellular and Molecular Immunology, W.B. Saunders Co., Philadelphia (Chapters 15-18)	
	C09	AGOSTONI et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.	
	C10	ALDOVINI et al., 1992, "The New Vaccines", Technology Review pp. 24-31	
	CII	AMATO et al., 1999, "Active Specific Immunotherapy in Patients with Renal Cell Carcinoma (RCC) Using Autologous Tumor Derived Heat Shock Protein-Peptide Complex-96 (HSPP-96) Vaccine" American Society Clinical Oncology Meeting, abstract 1278	
	C12	ANDERSEN, P. 1994, "Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins," Infect. Immun. 62(6):2536-44	
	C13	ANDUS et al., Synthesis of alpha 2-macroglobulin in rat hepatocytes and in a cell-free system. FEBS Lett. 1983 Jan 10:151(1):10-14	
	C14	ANTHONY et al., 1999, "Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule," Vaccine 17(4):373-83	
	C15	BANCHEREAU et al., 1998, "Dendritic cells and the control of immunity," Nature 392:245-252	
	C16	BARRIOS et al., 1992, "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and BacillusCalmette Guerin priming," Eur. J. Immunol. 22(6):1365-72	
	C17	BARRIOS et al., 1994, "Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and Dna K proteins requires cross-linking with antigen," Clin. Exp. Immunol. 98(2):229-233	
	C18	BARRIOS et al., 1994, "Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD." Clin Exp Immunol. 98(2):224-8	
	C19	BARTLETT, 1972 "Effect Of Host Immunity On The Antigenic Strength Of Primary Tumors." J. Natl. Cancer Inst. 49:493-504	
	C20	BASOMBRÍO (1970) "Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene", <i>The Institute for Cancer Research</i> 30:2458-2462	
	C21	BASU and SRIVASTAVA, 1999, "Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity" J. Exp. Med. 189:797-802	
	C22	BASU et al., 2000, "Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway," Int. Immunol. 12(11):1539-46	
	C23	BASU et al., 2001, "CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin," Immunity 14:303-313	
	C24	BEDNAR et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.	
	C25	BELLONE et al., 1999, "Cancer Immunotherapy: synthetic and natural peptides in balance," Immunology Today 20(10): 457-462	
·	C26	BEVERLY, 1988, "Tumour Immunology." In: <i>Immunology</i> , 3rd Edition, Roitt, Ed., Mosby, London, pp. 17.1-17.12	

EXAMINER	DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 3 of 6 of List of References

	ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403		
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	filing date June 4, 2001	ART UNIT 1643	

		NON PATENT LITERATURE DOCUMENTS	
Examiner nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C27	BINDER and Srivastava, 2004, "Essential role of CD91 in re-presentation of gp96-chaperoned peptides," Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133	
	C28	BINDER et al., 2000, "CD91: a receptor for heat shock protein gp96," Nature Immunol. 1(2):151-155	
•	C29	BINDER et al., 2001, "Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatability complex I molecules," J. Biol. Chem. 276(20): 17163-17171	
	C30	BIRKENMEIER G., 2001, "Targetting the Proteinase Inhibitor and Immune Modulatory Function of Human α2-Macroglobulin." Mod. Asp. Immunobiol. 2(1):32-36	
	C31	BLACHERE and SRIVASTAVA (1993) "Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells", J. Cellular Biochem. Keystone Symposia, 17D: pp. 124, Abstract NZ 502	
	C32	BLACHERE et al., 1993, "Heat Shock Protein Vaccines Against Cancer," Journal of Immunotherapy 14:352-356	
	C33	BLANDER et al., 1993, "Major cytoplasmic membrane protein of Legionella pnumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease," J. Clin. Invest. 91(2):717-23	
	C34	BODEY et al., 2000, Anticancer Res 20:2665-2676 Abs	
	C35	BOSCH et al., 1999, "State of the art of therapeutic apheresis in Europe", Ther. Apher. 3(3):197-8	
	C36	BRELOER et al., 1999, "in vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins," J. Immunol. 162:3141-3147	
	C37	BUMOL et al., 1988 "Characterization Of The Human Tumor And Normal Tissue Reactivity Of The KS1/4 Monoclonal Antibody." Hybridoma 7:407-415	
	C38	CARSWELL et al., 1970, "Immunogenic Properties Of Reticulum Cell Sarcomas Of SJL/J Mice." Natl. Cancer Inst. 44:1281-1288	
	C39	CASSEL et al., 1977, "Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses," Cancer 40:672-679	
	C40	CASSEL et al., 1983 "A Phase II Study On The Postsurgical Management Of Stage II Malignant Melanoma With A Newcastle Disease Virus Oncolysate." Cancer, 52:856-860	
	C41	CASTELLI et al., 2001, "Human Heat Shock Protein 70 Peptide Complexes Specifically Active Antimelanoma T cells." Cancer Res 61:222-227	
	C42	CHANDAWARKAR et al., 2004, "Immune modulation with high-dose heat shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis," Int'l. Immunol. 16:315-324	
_,, ,,,,,	C43	CHU et al., 1994, α ₂ -Macroglobulin: A Sensor for Proteolysis," Ann. N.Y. Acad. Sci. 737:291-307	Τ
	C44	CLARKE et al. 1988, "Purification of Complexes of Nuclear Oncogene p53 with Rat and Escherichia coli Heat Shock Proteins: In Vitro Dissociation of hsc70 and dnaK from Murine p53 by ATP" Mol. and Cell. Biol. Vol. 8 (3) 1206-1215	
	C45	COLLEN et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.	
	C46	COSTANZO, 1996, "New monoclonal antibodies," Curr. Opin. Cardiol. 11(2):204-7	T

	C45	Biol. Vol. 8 (3) 1206-1215 COLLEN et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.		
	C46	COSTANZO, 1996, "New monoclonal antibodies," Curr. Opin. Cardiol. 11(2):204-7		
EXAMINE	ER	DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 4 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	art unit 1643	

Examiner	1		Π
Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C47	CRAIG, 1993, "Chaperones: Helpers Along the Pathways to Protein Folding," Science 260:1902-4	
. 17***	C48	D'ANDREA, 2005, "Add Alzheimer's disease to the list of autoimmune diseases," Med. Hypotheses 64(3):458-463	
	C49	DASH, et al., 2002 "Slow-Tight Binding Inhibition of Xylanase by an Aspartic Protease Inhibitor." J. Biol. Chem. 277: 17978-17986	
* ***	C50	DAVIDOFF et al., 1992, "Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers	
	C51	DEL GIUDICE et al., 1994, "Hsp70: a carrier molecule with built-in adjuvanticity", Experientia 30;50(11-12):1061-6	
	C52	DERMER, 1994, "Another Anniversary for the War on Cancer," Biotechnology 12:320	
	C53	DEUTSCHER et al., 1992 "Guide to protein purification." Meth. Enzymol., 182:610-611	Τ
	C54	DUBOIS et al., 1980, "Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells," Cancer Res. 40:4204-4208	
	C55	DUBOIS, et al., 1982 "Purification and Biochemical Properties of Tumor-Associated Transplantation Antigens From Methylcholanthrene-Induced Murine Sarcomas." Proc. Natl. Acad. Sci USA, 79:7669-7673	
	C56	ELLGAARD ET AL., 1997,"Dissection of the domain architecture of the alpha2macrglobulin-receptor associated protein." Fur. J. Biochem 244:544-51	1
	C57	EPPLEN et al., 1997, "Genetic predisposition to multiple sclerosis as revealed by immunoprinting," Ann. Neurol. 41(3):341-52.	
	C58	ESPANA et al., 1996, Clin. Chem 42(3):545-550	
	C59	ESTIN et al., 1989, "Transfected mouse melanoma lines that express various levels of human melanoma-associated antigen p97," J. Natl. Cancer Inst. 81:445-448	
	C60	EVANS et al., 1999, Q.J. Med 92:299-307	┸
	C61	FALK et al., 1990, "Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules", <i>Nature</i> 348:248-251	1
	C62	FALK et al., 1991, "Identification of Naturally Processed Viral Nonapeptides Allows Their Quantification in Infected Cells and Suggests an Allele-specific T Cell Epitope Forecast". J Exp. Med 174:425-434	
	C63	FALK et al., 1991, "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC Molecules", <i>Nature</i> 351:290-296	
	C64	FALK et al., 1992, "Specificity of antigen processing for MHC class I restricted presentation is conserved between mouse and man", Eur. J. Immunol. 22:1323-1326	
	C65	FAY et al., 1979, "Leukopheresis Therapy of Leukemic Reticuloendotheliosis (Hairy Cell Leukemia)", Blood 54: 747-749	
	C66	FEDWEG and SRIVASTAVA "Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor rejection antigen", Mount Sinai School of Medicine NZ 206, p. 108	
	C67	FENG et al., 2002, "Exogenous heat shock proteins provide adjuvant effects on enhancing the immunogenicity of apoptotic tumor cells and inducing antitumor immunity," AACR 93 rd Annual Meeting, Vol. 43, April 6-10, Abstract #2214	
	C68	FERRERO et al., 1995, The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA 92(14):6499-503	

	mucosal infection in mice. Proc Natl Acad Sci	USA 92(14):6499-503
EXAMINER		DATE CONSIDERED
*EXAMINER: I considered. Incl	Initial if reference considered, whether or not citation is in conforude copy of this form with next communication to applicant.	mance with MPEP 609; Draw line through citation if not in conformance and not

	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Srivastava et al.		
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

		NON PATENT LITERATURE DOCUMENTS	
Examiner nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
IIIIais	C69	FLYNN et al., 1989, "Peptide binding and release by proteins implicated as catalysts of protein assembly",	T
	007	Science 245:385-390	ı
	C70	FLYNN et al., 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", Nature 353:726-730	1
	C71	FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and	Τ
	0,1	chemotaxis", Immunology 50(2):251-9	
	C72	FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New	
		York p4	
	C73	GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid	Τ
		leukemia," Blood 96(4):1480-1489	
	C74	GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-	Т
		55	
	C75	GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae	
		provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4	
	C76	GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae	
		multiplication in mouse footpads," Infect Immun. 62(10):4250-5	L
	C77	GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell	
	1	membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64	L
	C78	GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat	1
		shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun.	
		60(7):2565-71	4
,	C79	GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum	İ
		protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95	1
	C80	GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in	
		Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41	+
	C81	GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416	╀
	C82	GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine	
		B-cell leukemia/lymphoma" Clin. Can. Res.6:909	\perp
	C83	GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric	
		focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476	+
	C84	GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines	
		against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234	4
	C85	GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North	1
		America, Vol. 52:839-846	+
	C86	GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of	
		Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120	+
	C87	HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites",	
		Science Vol. 250 113-116	+
	C88	HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and	
		endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-	
		16737.	\perp
	C89	HARLOW et al., 1988, "Antibodies: A Laboratory Manual" ch 6:139-243	

	289	HARLOW et al., 1988, "Antibodies: A Laboratory Manual" ch 6:139-243
EXAMINER		DATE CONSIDERED
		if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not py of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 6 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т		
	C90	HEEB et al., 1995, "Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera," Biochem. Mol. Biol. Int. 37(5):917-23			
	C91	HEISKALA et al., 1988 "Characteristics Of Soluble Tumour-Derived Proteins That Inhibit Natural Killer Activity." Scand. J. Immunol. 28:19-27			
	C92	HENTTU AND VIHKO, 1989 "cDNA Coding For The Entire Human Prostate Specific Antigen Shows High Homologies To The Human Tissue Kallikrein Genes." <i>Biochem. Biophys. Res. Comm.</i> 160:903-910			
	C93	HERZ AND STRICKLAND, 2001, "LRP: a multifunctional scavenger and signaling receptor," J. Clin. Invest. 108:779-784			
	C94	HERZ et al., 1990, "Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver", J. of Biol. Chem. 265(34): 21355-21362.			
	C95	HERZ et al., 1991, "39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor." J.Biol.Chem. 266(31):21232-21238.			
	C96	HEY et al., 1988, "Cloning of a novel member of the low-density lipoprotein receptor family", Gene 216: 103-111.			
	C97	HINDS et al., 1987, "Immunological Evidence for the Association of p53 with a Heat Shock Protein, hsc70, in p53-plus-ras-Transformed Cell Lines" Mol. and Cell. Biol. Vol.7 (8) 2863-2869			

EXAMINER	DATE CONSIDERED
----------	-----------------

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 1 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

	NON PATENT LITERATURE DOCUMENTS
C98	HINDS et al., 1990, "Mutant p53 DNA Clones from Human Colon Carcinomas Cooperate with ras in Transforming Primary Rat Cells: A Comparison of the "Hot Spot" Mutant Phenotypes" Cell Growth and Differentiation Vol. 1 571-580
C99	HOLLINSHEAD, 1988, "Immunotherapy," in: Cancer: The Outlaw Cell, LaFond, ed., American Chemical Society, Washington, DC pp. 237-250 (Chapter 14)
C100	HORN et al., 1995, "Analysis of the binding of Pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library", J. of Biol. Chem. 270 (20): 11770-11775.
C101	HORWITZ et al., 1995, Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 92(5):1530-4
C102	
C103	HUBBARD et al., 1992, "Immunization of mice with mycobacterial culture filtrate proteins," Clin. Exp. Immunol. 87(1):94-8
C104	HUGHES et al., 1970, "A Study In Clinical Cancer Immunotherapy", Cancer, 26:269-278
	HUGHES et al., 1981, "Characterization of plasma membrane proteins identified by monoclonal antibodies", J. of Biol./ Chem. 256(2): 664-671.
C106	HUMPHREY et al., 1984, "Adjuvant immunotherapy for melanoma," J. Surg. Concol. 25:303-305
C107	HUNTER, N. et al., 1991, "Suppression of experimental allergic encephalomyelitis by alpha(2)-macroglobulin," Immunology 73:58-63
C108	ISAACS et al., 1988, "Use of anti-idiotypic antibodies to establish that monoclonal antibody 7H11D6 binds to the alpha2-macroglobulin receptor recognition site", J. Biol. Chem. 263(14): 6709-6714.
C109	ISHII et al., 1999, "Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96", J Immunol. 162(3):1303-9
C110	ISRAELI et al., 1993, "Molecular Cloning Of A Complementary DNA Encoding A Prostate-Specific Membrane Antigen." Cancer Res. 53:227-230
C111	JAIN et al., 1994, "Barriers to drug delivery in solid tumors." Sc Am 171(1):58-65
C112	JAKOB et al., 1993, "Small Heat Shock Proteins Are Molecular Chaperones", J. Biol. Chem. 268:1517-1520
. C113	Biol. Sci. p.43-47
C114	protein gp96 preparations: a pilot study" Int. J. of Cancer 88:232-238
C115	JANEWAY, Travers, Walport, and Shlomchick, 2001, Immunobiology, 5th ed., Garland Publishing, New York (Part V. Sections 13-1 to 13-15)
C116	JARDETZKY et al., 1991, "Identification of Self Peptides Bound to Purified HLA-B27", Nature 353:326-329
C117	plant chaperonins and to the 65-kilodalton mycobacterial antigen. Mol Cell Biol. 9(5):2279-83
C118	

EXAMINER DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 2 of 9 of List of References

	ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403		
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	artunit 1643	

	NON PATENT LITERATURE DOCUMENTS
C119	KATSANIS et al., 2000, "Augmentation of Tumor Lysate Immunogencity by enrichment of Chaperone Proteins Using Free Solution Isoelectric Focusing (FS-IEF)" Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer, abstract 431
C120	KATSUTANI et al., 1992, "Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice." Fundam Appl Toxicol.19(4):555-62.
C121	KIM et al., 1998, "A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognized apolipoprotein E", J. Biochem. 124: 1072-1076.
C122	KIMBER et al., 2002, "Lactoferrin: influences on langerhans cells, epidermal cytokines, and cutaneous inflammation." Biochem Cell Biol. 2002;80(1):103-7.
C123	KOJIMA et al., 2002, "Combination therapy of tumor-derived gp96 and GM-CSF or IL-12-gene transduced tumor cells in the control of LLC tumor," AACR 93 rd Annual Meeting, Vol. 43, Abstract #5516
C124	KOL et al., 2000, "Cutting edge: heat shock protein (HSP)60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of monomuclear cells", J Immunol. 164(1):13-17
C125	mice," Cancer Res. 42(5):1788-97
C126	
C127	53:1333-1336
C128	protein (LRP) is the alpha 2-macroglobulin receptor", FEBS Lett. 276(1-2):151-5
C129	KUHLMANN et al., 1997, "Drug Research: from the idea to the product," International Journal of Pharmacology and Therapeutics 35:541-552
	LAKEY et al., 1987, "Identification of a peptide binding protein that plays a role in antigen presentation",
C131	LANZAVECCHIA, 1993, "Identifying Strategies for Immune Intervention", Science 260:937-944
C132	LÉVY, 1991, "ATP is Required for In Vitro Assembly of MHC Class I Antigens but Not for Transfer of Pentides across the ER Membrane". Cell 67:265-274
C133	folding and antigen presentation", EMBO J. 12(8):3143-3151
C134	LIVINGSTON et al. 1985, "Serological Response of Melanoma Patients to Vaccines Prepared from VSV Lysates of Autologous and Allogeneic Cultured Melanoma Cells." Cancer, 55:713-720
C135	LODISH et al., <i>Molecular Cell Biology</i> , ch. 17.3 "Overview of the Secretory Pathway". pp 691-696, W.H.
C136	LUESCHER et al., 1991, "Specific Binding of Antigenic Peptides to Cell-associated MHC Class I Molecules", <i>Nature</i> 351:72-77
C137	LUKACS et al., 1993, "Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors", J. Exp. Med. 178:343-348
C138	LUSSOW et al., 1991, "Mycobacterial heat-shock proteins as carrier molecules", Eur J Immunol. 21(10):2297-302
C139	

EXAMINER	DATE CONSIDERED
	the temporary of the temporary and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 3 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	filing date June 4, 2001	art unit 1643

C140	MAKI (1991) "The Human Homologue of the Mouse Tumor Rejection Antigen GP96", Ph.D. thesis,
CIAI	Cornell University MARTIN et al., 1986, "Role of Murine Tumor Models in Cancer Treatment Research", Cancer Research
C141	46:2189-2192
C142	MATSUTAKE et al., 2001, "The immunoprotective MHC II epitope of a chemically induced tumor
	harbors a unique mutation in a ribosomal protein," PNAS 98(7):3992-3997
C143	MELCHER et al., 1998, "Tumor immunogenicity is determined by the mechanism of cell death via
	induction of heat shock protein expression", Nat. Med. 5:581-7
C144	MELIEF et al., 1992, "Lessons from T Cell Responses to Virus Induced Tumours for Cancer Eradication
	in General", Career Surveys 13:81-99
C145	MELNICK, 1985, "Virus Vaccines: An Overview", Proceedings of the First Annual Southwest Foundation
	for Biomedical Research International Symposium, Houston, Texas, 8-10 November 1984, American
	Society for Microbiology pp. 1-13
C146	· · · · · · · · · · · · · · · · · · ·
	idea whose time has come" Semin. in Oncology 25:654
C147	MENORET et al., 1995, "Co-segregation of tumor immunogenicity with expression of inducible but not
	constitutive hsp70 in rat colon carcinomas," J. Immunol. 155:740-7
C148	
	Clin. Apheresis 1: 25-32
C149	MIZZEN et al., 1998, "Immune responses to stress proteins: applications to infectious disease and cancer," Biotherapy 10:173-185
C150	MOESTRUP et al., 1990, "Immunocytochemical identification of the human aplpha 2-macroglobulin
	receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte
ļ.	differentiation antigen", Exper. Cell Res. 190: 195-203.
C151	MOESTRUP et al., 1991, "Analysis of Ligand Recognition by the purified alpha-2M- macroglobulin
	receptor (low density lipoprotein receptor-related protein). J. Biol. Chem. 266(21):14011-14017.
C152	MOROI et al., 2000, "Induction of Cellular Immunity by Immunization with Novel Hybrid Peptides
1	Complexed to Heat Shock PRotein 70." Proc. Natl. Acad. Sci. 97(7):3485-3490
C153	
C154	
	Recombinant Interleukin-2", Science 225:1487-1489
C155	
i	and immunoglobulin heavy chain binding protein", Cell 46(2):291-300
C156	
	Studies." Cancer 40:680-686
C157	
	Potent Tumor Vaccines." Eur. J. Immunol. 27:589-597
C158	NAIR et al., 1999, "Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses
	against bound peptides" J. Immunol. 162:6426
C159	NATALI et al., 1987 "Immunohistochemical Detection Of Antigen In Human Primary And Metastatic
1	Melanomas By The Monoclonal Antibody 140.240 And Its Possible Prognostic Significance." Cancer,

EXAMINER	DATE CONSIDERED
*FXAMINER: Initial if reference considered, whether or not citation is in conform	mance with MPEP 609: Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 4 of 9 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.
	8449-178-999	09/873,403
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT	
(Use several sheets if necessary)	Srivastava et al.	
	FILING DATE	ART UNIT
	June 4, 2001	1643

	NON PATENT LITERATURE DOCUMENTS	
C160	NIELAND et al., 1996, "Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94", Proc. Natl. Acad. Sci. USA 93:6135-6139	
C161	NORRBY, 1985, "Summary," in: <i>Vaccines 85</i> , Lerner <i>et al.</i> , eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY pp. 387-394	
C162		
C163	OFFICE ACTION mailed on 02/26/02 for U.S. Application No. 09/625,137 filed 07/25/00	
C164	OFFICE ACTION mailed on 05/18/05 for U.S. Application No. 09/625,137 filed 07/25/00	
C165		
C166		
C167	OFFICE ACTION mailed on 12/31/02 for U.S. Application No. 09/625,137 filed 07/25/00	
C168	OFFICE ACTION mailed on 02/08/06 for U.S. Application No. 09/668,724 filed 09/22/00	
C169		
C170	OFFICE ACTION mailed on 05/07/02 for U.S. Application No. 09/668,724 filed 09/22/00	
C171	OFFICE ACTION mailed on 06/20/07 for U.S. Application No. 09/668,724 filed 09/22/00	
C172		
C173		
C174	OFFICE ACTION mailed on 03/13/06 for U.S. Application No. 09/750,972 filed 12/28/00	
C175	OFFICE ACTION mailed on 06/05/02 for U.S. Application No. 09/750,972 filed 12/28/00	
C176	OFFICE ACTION mailed on 08/28/03 for U.S. Application No. 09/750,972 filed 12/28/00	
C177	OFFICE ACTION mailed on 01/11/06 for U.S. Application No. 10/225,367 filed 08/20/02	
C178	OFFICE ACTION mailed on 03/30/05 for U.S. Application No. 10/225,367 filed 08/20/02	
C179	,	
C180	OFFICE ACTION mailed on 09/25/06 for U.S. Application No. 10/225,367 filed 08/20/02	
C181	OFFICE ACTION mailed on 10/19/07 for U.S. Application No. 10/225,367 filed 08/20/02	
C182	OFFICE ACTION mailed on 01/03/06 for U.S. Application No. 10/427,857 filed 05/01/03	
C183		
C184		
C185	OFFICE ACTION mailed on 08/07/06 for U.S. Application No. 10/784,012 filed 02/20/04	
C186	OFFICE ACTION mailed on 11/02/07 for U.S. Application No. 10/784,012 filed 02/20/04	
C187	receptor-4 complex. J. Immunol. 164:558-561	
C188	OLD et al., 1962 "Part II. Antigens Of Tumor Cells. Antigenic Properties Of Chemically-Induced Tumors." Ann. N.Y. Acad. Sci. 101:80-106	
C189	OPEKUN et al., 1999, "Novel therapies for Helicobacter pylori infection." Aliment Pharmacol Ther. 13(1):35-42.	
C190	PAL P.G., et al., 1992, "Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis." Infect Immun. 60(11):4781-92	

EXAMINER .	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformation considered. Include copy of this form with next communication to applicant.	nance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 5 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	filing date June 4, 2001	ART UNIT 1643

C191 PALLADINO et al., 1987, "Expression of shared tumor-specific antigen by two chemically induced BALB/c sarcomas", Cancer Research 47:5074-5079 C192 PARDOLL, 2000, "Therapeutic vaccination for cancer", Clin. Immunol. 95(1 Pt 2): S44-62 C193 PATTILLO, 1974 "Combination Chemotherapy-Immunotherapy Indirect Chemotherapy Sensitivity Testing and Specific and Non-Specific Immunositimulation." In: Neoplasm Immunity: Theory and Application: Proceedings of a Chicago Sumposium. Crispen. Ed. ITR, Chicago, IL., pp. 189-204 C194 PAUL, Ed., 1993 Fundamental Immunology. 3rd Edition, Raven Press, NY, p. 1158 and References 189-220 Cited On pp.1173-1174 C195 PAUL Fundamental Immunology. 1993 Third Edition, Raven Press, NY, p. 1158 and References 189-220 Cited On pp.1173-1174 PC196 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390 C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C203 PERG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. 142;3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMH et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINHASI-KIMH et al. 1986, "Specific interaction between the p53 cellular tumour antigen and monogene breakpoint fusion	C192 PARDOLL, 2000. "Therapeutic vaccination for cancer", Clin. Immunol. 95(1 Pt 2): S44-62 C193 PATTILLO, 1974 "Combination Chemotherapy-Immunotherapy Indirect Chemotherapy Sensitivity Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and Application: Proceedings of a Chicago Sumposium. Crispen, Ed. ITR. Chicago, IL., pp. 189-204 C194 PAUL, Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189-220 Cited On pp.1173-1174 C195 PAUL. Fundamental Immunology. 1993 Third Edition, Raven Press, NY, p. 1158 and References 189-220 Cited On pp.1173-1174 C196 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/IUS03/14390 C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/IUS03/123098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/IUS01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US02/26573 C200 PCT Usernational Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US02/26573 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker" J. Immunol. 143:662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock proteins", Nature Vol 320 (13) 182-184 C206 PINILA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-		
 C192 PARDOLL, 2000. "Therapeutic vaccination for cancer". Clin. Immunol. 95(1 Pt.2): S44-62 C193 PATTILLO, 1974 "Combination Chemotherapy-Immunotherapy Indirect Chemotherapy Sensitivity Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and Application: Proceedings of a Chicago Sumposium. Crispen. Ed. TIR. Chicago, L., pp. 189-204 C194 PAUL, Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189-220 Cited On pp.1173-1174 C195 PAUL Fundamental Immunology. 1993 Third Edition, Raven Press, NY C196 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390 C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18/041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography". J. Immunol. Meth. 204:13 C203 PERG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography". J. Immunol. Meth. 204:13 C204 PINEDa et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PROUD, G. et al., 1997, "Blood transfusion and renal transplan	C192 PARDOLL, 2000. "Therapeutic vaccination for cancer", Cliin. Immunol. 95(1 Pt.2): S44-62 C193 PATTILLO, 1974 "Combination Chemotherapy-Immunotherapy Indirect Chemotherapy Sensitivity Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and Application: Proceedings of a Chicago Sumposium. Crispen, Ed. ITR. Chicago, IL., pp. 189-204 C194 PAUL, Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189-220 Cited On pp.1173-1174 C195 PAUL. Fundamental Immunology. 1993 Third Edition, Raven PRess, NY PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. Meth. 204:13 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINIL-A-Ibarz et al., 2000, "Vaccination of	C191	PALLADINO et al., 1987, "Expression of shared tumor-specific antigen by two chemically induced
C193 PATTILLO, 1974 "Combination Chemotherapy-Immunotherapy Individual Chemotherapy Sensitivity Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and Application: Proceedings of a Chicago Sumposium. Crispen, Ed. ITR, Chicago, IL., pp. 189-204 C194 PAUL., Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189-220 Cited On pp. 1173-1174 C195 PAUL., Fundamental Immunology, 1993 Third Edition, Raven Press, NY C196 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390 C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/18041 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US01/18041 C209 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PCT of et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker". J. Immunol. Meth. 204:13 C204 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock proteins", Nature Vol 320 (13) 182-184 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock proteins", Nature Vol 320 (13) 182-184 C207 PREHN AND MAIN, 1957 "Immunol. Methylcholanthrene-Induced Sarcomas," J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1997, "Bood transfusion and renal t	C193 PATTILLO, 1974 "Combination Chemotherapy-Immunotherapy Indirect Chemotherapy Sensitivity Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and Application: Proceedings of a Chicago Sumposium, Crispen, Ed. 1TR, Chicago, IL, pp. 189-204 C194 PAUL, Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189-220 Cited On pp.1173-1174 C195 PAUL, Fundamental Immunology. 1993 Third Edition, Raven PRess, NY C196 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390 C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US01/18041 C209 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock proteins", Nature Vol 320 (13) 182-184 C206 PINHASI-KIMH et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock proteins", Nature Vol 320 (13) 182-184 C207 PREEDA and MAIN, 1957 "Immunol. Therapeutic Plasmaplantation," Br. J. Sur. 66:678-82 PROUD, G. et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen act	C102	BALB/c sarcomas", Cancer Research 47:3074-3079 DARDOLL 2000 "Therepowie veceinties for concer" Clin Immunol 95(1 Pt 2): \$44-62
Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and Application: Proceedings of a Chicago Sumposium, Crispen, Ed. ITR, Chicago, IL., pp. 189-204 C194 PAUL, Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189-220 Cited On pp. 1173-1174 C195 PAUL, Ed., 1993 Fundamental Immunology, 1993 Third Edition, Raven PRess, NY C196 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390 C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US01/28073 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Mark. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. Mark. 204:13 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock proteins", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1997, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C210 REED et al., 1990	Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and Application: Proceedings of a Chicago Sumposium, Crispen, Ed. ITR, Chicago, IL, pp. 189-204 C194 PAUL, Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189-220 Cited On pp. 1173-1174 C195 PAUL, Fundamental Immunology. 1993 Third Edition, Raven Press, NY, p. 1158 and References 189-220 Cited On pp. 1173-1174 C196 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390 C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US02/06/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock proteins", Nature Vol 320 (13) 182-184 C205 PINHASI-KIMHI et al., 1986, "Specific interaction between the p53 cellular unurual mitted and concepte breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 R209 PROUD, G. et al., 1999, "Blood transfusion and renal transplantation," Br. J	C192	PARDULL, 2000, Therapeutic vaccination for cancer, Chin. Hillington. 95(1712). 544-02
Application: Proceedings of a Chicago Sumposium. Crispen. Ed. ITR, Chicago, IL., pp. 189-204 C194 PAUL., Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189-220 Cited On pp. 1173-1174 C195 PAUL., Fundamental Immunology. 1993 Third Edition, Raven PRess, NY C196 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390 C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/18041 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker". J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with ber-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 PREBIN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas," J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1999, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REPO	Application: Proceedings of a Chicago Sumposium, Crispen, Ed. ITR, Chicago, IL., pp. 189-204 C194 PAUL, Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189-220 Cited On pp.1173-1174 C195 PAUL, Fundamental Immunology, 1993 Third Edition, Raven Press, NY C196 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390 C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US02/26573 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/06110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PEEHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1999, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REPD ANN	C193	PATTILLO, 1974 "Combination Chemotherapy-Infinition interapy Indirect Chemotherapy Sensitivity
C194 PAUL. Ed., 1993 Fundamental Immunology. 3rd Edition, Raven Press, NY, p. 1158 and References 189-220 Cited On pp.1173-1174 C195 PAUL. Fundamental Immunology. 1993 Third Edition, Raven PRess, NY C196 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390 C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US02/26573 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. Meth. 204:13 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PRINIASI-KIMHI et al. 1996, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C207 PREHN AND MAIN, 1957 "Immunol, 1958 "Immunol, 1958 "Immunol, 1958 "Immunol, 1	C194 PAUL, Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189-220 Cited On pp.1173-1174 C195 PAUL, Fundamental Immunology, 1993 Third Edition, Raven PRess, NY C196 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390 C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US02/26573 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1999, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activat		Testing and Specific and Non-Specific Infinitionstitutiation. In: Neoplasm Immunity. Theory and
C195 PAUL. Fundamental Immunology. 1993 Third Edition, Raven PRess, NY C196 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390 C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/23098 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US01/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142;3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with ber-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, Dec	220 Cited On pp.1173-1174 C195 PAUL. Fundamental Immunology. 1993 Third Edition, Raven PRess, NY C196 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390 C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US02/26573 C201 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1999, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REPO et al., 1990, "Low incidence of antibodies to recombinant human tissue-type pla	G104	Application: Proceedings of a Chicago Sumpostum, Clispell, Ed. 11K, Chicago, IL, pp. 165-204
C195 PAUL. Fundamental Immunology. 1993 Third Edition, Raven PRess, NY C196 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390 C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associ	C195 PAUL. Fundamental Immunology. 1993 Third Edition, Raven PRess, NY C196 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390 C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bor-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis.	C194	
C196 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390 C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 RCOGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antiquent CaTA) obtained in soluble form or solubilized from two m	C196 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US01/4390 C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 PRED AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 PRED AND MAIN, 1957 "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REPD et al., 1999, "Tow incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of	C105	
C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US02/06573 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142;3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas," J. Natl. Cancer Inst. 18:769-778 C208 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine," Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated	C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US02/26573 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas," J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic	C195	PAUL. Fundamental immunology. 1995 Third Edition, Raven Press, N1
C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US020/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas," J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapher	C197 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098 C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmaphere	C196	
C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" <i>J. Immunol. Meth.</i> 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker". <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 REPGED et al., 1981, "Some immunogenic acid bio	C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography". Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	0107	PCT/USU3/14390
C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" <i>J. Immunol. Meth.</i> 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PERHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." *Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid	C198 PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041 C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" <i>J. Immunol. Meth.</i> 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker". <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." <i>Anticancer Res.</i> 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	C197	
PCT/US01/18041 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" <i>J. Immunol. Meth.</i> 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1999, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." *Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or so	C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" <i>J. Immunol. Meth.</i> 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." <i>Anticancer Res.</i> 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	C109	PCT/USU1/23098 DCT I variable and Profine in conv. Examination Report model on 00/23/04 for Intl. Application No.
C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US202/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" <i>J. Immunol. Meth.</i> 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	C199 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US202/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" <i>J. Immunol. Meth.</i> 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPORANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	C198	
C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" <i>J. Immunol. Meth.</i> 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	PCT/US20/26573 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" <i>J. Immunol. Meth.</i> 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." <i>Anticancer Res.</i> 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	CIO	PCT International Proliminary Examination Percent mailed on 10/06/2005 for Intl. Application No.
 C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" <i>J. Immunol. Meth.</i> 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antige	C200 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" <i>J. Immunol. Meth.</i> 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." <i>Anticancer Res.</i> 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	(199	
PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	PCT/US2004/005110 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	C200	
C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	 C201 PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110 C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis 	C200	•
C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" <i>J. Immunol. Meth.</i> 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." <i>Anticancer Res.</i> 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	C202 PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" <i>J. Immunol. Meth.</i> 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN <i>et al.</i> 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." <i>Anticancer Res.</i> 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	C201	
ADP-affinity chromatography" <i>J. Immunol. Meth.</i> 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN <i>et al.</i> 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." <i>Anticancer Res.</i> 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS <i>et al.</i> , 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	ADP-affinity chromatography" <i>J. Immunol. Meth.</i> 204:13 C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN <i>et al.</i> 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." <i>Anticancer Res.</i> 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis		DENC et al. 1907 "Durification of immunogenic heat shock protein 70-nentide complexes by
C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	C203 PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." <i>Anticancer Res.</i> 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	C202	
Epithelial Carcinoma Marker", <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with ber-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN <i>et al.</i> 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." <i>Anticancer Res.</i> 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS <i>et al.</i> , 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	Epithelial Carcinoma Marker", <i>J. Immunol.</i> 142:3662-3667 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN <i>et al.</i> 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." <i>Anticancer Res.</i> 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	C203	DEDET AND WALKER 1989 "Isolation And Characterization Of A CoDNA Encoding The KS1/4
 C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene- 	C204 PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4 C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	C203	Enithelial Carcinoma Marker" I Immunol 142:3667
C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." <i>J. Natl. Cancer Inst.</i> 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	C205 PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	C204	DINIEDA et al. 1904 "Applications of therepoutic apheresis" Mayo Clin. Proc. 60(0):803-4
heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	heat shock protiens", Nature Vol 320 (13) 182-184 C206 PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis		
oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	C205	heat shock protiens", Nature Vol 320 (13) 182-184
 C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene- 	C207 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778 C208 PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	C206	PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl
18:769-778	18:769-778		oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787
C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	 C209 RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis 	C207	18:769-778
3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	C208	PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82
3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	3(2):139-54 C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	C209	PAPI FY 1995 "The biotechnology and applications of antibody engineering." Mol. Biotechnol.
C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	C210 REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	(20)	
in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	in treated patients." Thromb Haemost. 64(2):276-80. C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	C210	
C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	C211 REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis		
Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882 C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	6211	•
C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	C212 REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	C211	REPMANN et al. 1997 Adjuvant Therapy Of Renai Cell Carchiolia with Active-Specific-
and Related Techniques, December 1984 C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-		6212	DEPODE - 6th - AMA Parel or Therapoutic Plasmopheresis Current Status of Therapoutic Plasmopheresis
transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	and Related Techniques, December 1984		and Related Techniques, December 1984
transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	C213 ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated	C213	ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated
	transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-induced sarcomas, Meth A and CI-4," Int. J. Cancer 27:789-796		transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conform	nance with MPEP 609; Draw line through citation if not in conformance and not
considered. Include copy of this form with next communication to applicant.	

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 6 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C214	ROTHMAN, 1989, "Polypeptide Chain Binding Proteins: Catalysts of Protein Folding and Related Processes in Cells", Cell 59:591-601
C215	by Cytotoxic T cells", Nature 348:248-251
C216	including H-4 and H-Y" Science 249: 283-287
C217	SALK et al., 1993, "A Strategy for Prophylactic Vaccination Against HIV", Science 260:1270-1272
C218	SALLUSTO et al., 1994, "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha," J. Exp. Med. 179(4):1109-1118
C219	(MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten- reactive helper T cell activity," Cancer Immunol. Immunother. 25(3):180-184
C220	tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells", J. Exp. Med. 191:423-434
C221	923-955
C222	
C223	HLA Class I and Class II," J. Immunol. 173:1987-1993
C224	cell vaccinates mice against tuberculosis", Immunology 82(2):244-8
C225	43:79-94
C226	Carcinoma Patients." Scand J. Immunol 33:699-706
C227	SORGER and PELHAM, 1987, "The glucose-regulated protein grp94 is related to heat shock protein hsp90". J. Mol. Biol. 194(2):341-4
C228	SOTGIU et al., 1998, "Genetic susceptibility to multiple sclerosis in Sardinians: an immunological study," Acta. Neurol. Scand. 98(5):314-7
C229	SPARKS et al., 1976, "Immunology and adjuvant chemoimmunotherapy of breast cancer," Arch. Surg. 111:1057-1062
C230	SPERO et al., 1980, "Plasma Exchange in Preparation of Mild Factor IX Deficient Hemophiliacs for Surgical Procedures," 19-22
C231	Convergence of two evolutionary pathways of antigen presentation?", Seminars in Immunology 3:57-64
C232	Tumor Antigens and Specific Tumor Therapy, pages 63-71
C233	Curr. Opin. Immunol. 6:728
C234	SRIVASTAVA et al. (1990) "Immunization with Soluble Gp96 Antigens Elicits Tumor-Specific Cellular Immunity:, Cellular Immunity and the Immunotherapy of Cancer, pages 307-314

EXAMINER	DATE CONSIDERED
*EVAMINED: Initial if reference considered, whether or not citation is in conform	sance with MPEP 609. Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 7 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C235	SRIVASTAVA et al., 1984, "The Serologically Unique Cell Surface Antigen of Zajdela Ascitic Hepatoma
	is also its Tumor-Associated Transplantation Antigen", Int. J. Cancer 33:417-422
C236	SRIVASTAVA et al., 1987, "5'-structural analysis of genes encoding polymorphic antigens of chemically
	induced tumors." Proc. Natl. Acad. Sci USA 84(11):3807-3811
C237	SRIVASTAVA et al., 1988, "Individually distinct transplantation antigens of chemically induced mouse
	tumors," Immunol. Today 9:78-83
C238	SRIVASTAVA et al., 1989, "Identification of a Human Homologue of the Murine Tumor Rejection
	Antigen GP96," Cancer Res. 49:1341-1343
C239	SRIVASTAVA et al., 1991, "Protein Tumor Antigens", Curr. Opin. Immunol. 3:654-658
C240	SRIVASTAVA et al., 1993, "Evidence for peptide-chaperoning by the endoplasmic reticular heat shock
	protein GP96: Implications for vaccination against cancer and infectious diseases", J Cell Biochem Suppl
	17D:94 (Abstract NZ014)
C241	SRIVASTAVA et al., 1998, "Heat shock proteins come of age: primitive functions acquire new roles in an
	adaptive world", Immunity 8(6):657-65
C242	SRIVASTAVA PK, 1994, "Heat shock proteins in immune response to cancer: the Fourth Paradigm",
	Experientia. (11-12):1054-60
C243	SRIVASTAVA, 1993, "Peptide-Binding Heat Shock Proteins in the Endoplasmic Reticulum: Role in
	Immune Response to Cancer and in Antigen Presentation," Adv. Cancer Res. 62:153-177
C244	SRIVASTAVA, 2002, "Roles of heat-shock proteins in innate and adaptive immunity," Nature Rev.
	Immunol. 2(3): 185-194
C245	STACK et al., 1982, "Autologous x-irradiated tumour cells and percutaneous BCG in operable lung
	cancer," Thorax 37(8):588-593
C246	
	encephalitis and multiple sclerosis," J. Exp. Med. 194:F27-F30
C247	STENMAN et al., 1991, "A complex between prostate-specific antigen and alpha 1-antichymotrypsin is
	the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex
6240	improves clinical sensitivity for cancer," Cancer Res. 51(1):222-6
C248	STEVENSON, 1999, "DNA vaccines against cancer: from genes to therapy," Ann. Oncol. 10:1413-8
- 6240	Review
C249	SUBBARAO et al., 1992, "A General Overview of Viral Vaccine Development," Genetically Engineered Vaccines 327:51-57
C250	SUZUE et al., 1997, "Heat shock fusion proteins as vehicles for antigen delivery into the major
1	histocompatibility complex class I presentation pathway," Proc. Natl. Acad. Sci. USA 94(24):13146-51
C251	SUZUE K., Young R.A., 1996, "Heat shock proteins as immunological carriers and vaccines. in:
525 .	Stress-Inducible Cellular Responses" (U. Feige, R. I. Morimoto, I. Yahara, B. S. Polla, eds.),
	Birkhauser/Springer, 77: 451-465
C252	SUZUE K., Young R.A., 1996, "Adjuvant-free hsp70 fusion protein system elicits humoral and cellular
3402	immune responses to HIV-1" p24. J Immunol. 156(2):873-9
C253	
3233	Full-Length cDNA Clone." Nucl. Acids Res. 18:4928 (1990)
C254	
C255	
3233	Laboratories, Whitehouse Station N.J., pp. 1871 and 1872

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

•	NON PATENT LITERATURE DOCUMENTS
C256	THOMAS et al., 1982, "Molecular and Cellular Effects of Heat Shock and Related Treatments of
	Mammalian Tissue-Culture Cells", Cold Springs Harbor Symp Quant Biol 46:985-996
C257	TODRYK et al., 1999, "Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines
	and targets immature dendritic cell precursors to enhance antigen uptake," J. Immunol. 163:1398-1408
C258	
	tissue," Mol. Cell. Biochem. 18(2-3):101-7
C259	
	hsp90, and hsp70," J. Immunol., 152(11):5398-5403
C260	
	tumors from which they are isolated", J. Cell. Biochem. Suppl. 17D:113 (Abstract NZ225)
C261	
	Proc. Natl. Acad. Sci. USA 83(10):3121-3125
C262	
	300(6725):662-5 Review
C263	
(203	28:2477-2483
C264	
6265	the hsp70 heat shock family", J. Exp. Med. 170:1799-1809 VIJAYASARADHI et al., 1990 "The Melanoma Antigen gp75 Is The Human Homologue Of The Mouse
C265	b (Brown) Locus Gene Product." J. Exp. Med. 171:1375-1380
624	b (Brown) Locus Gene Product. J. Exp. Med. 171.1373-1380
C266	
	complex class I molecules in cellular peptide processing". Eur. J. Immunol 22:655-659
C267	WANG et al., 2001, "Characterization of heat shock protein 110 and glucose-regulated protein 170 as
	cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-
6269	497
C268	
	ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054.
C269	WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33
C270	WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884
C271	WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem.
	257:14949-14959
C272	
	Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237
C273	
	in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat
	fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211
C274	
C275	
	in vivo and in vitro." The Biochemical Journal. England 313:71-76
C276	
	on chromosome 11," Clin. Exp. Immunol. 83(1):69-73
C277	
C277	
L	of human thyroglobulin." Arch Biochem Biophys. 20;320(1):96-105

EXAMINER DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 9 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
	APPLICANT Srivastava et al.	
	filing date June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS		
C278	YAMAUCHI et al., 2000, "Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study." Mycoses.43(5):197-202.		
	YANG et al., 1999, "Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8+ and CD4+ T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity," Int. J. Cancer 83:532-540		
C280	YEDAVELLI et al., 1999, "Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model" Int. J. Mol. Med. 3:243		
C281	YU et al., 1991, "Sequence Analysis of Peptides Bound to MHC Class II Molecules", Nature 353:622-627		
C282			
C283	ZIMECKI et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." Arch Immunol Ther Exp (Warsz). 47(2):113-8.		

EXAMINER	DATE CONSIDERED
----------	-----------------

box 3 of 3

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 1 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
(Use several sheets if necessary)	APPLICANT Srivastava et al.	
NOV 0 8 2007	FILING DATE June 4, 2001	ART UNIT 1643
WATER TRANSPORTER OF THE PARTY		

	NON PATENT LITERATURE DOCUMENTS
C98	HINDS et al., 1990, "Mutant p53 DNA Clones from Human Colon Carcinomas Cooperate with ras in Transforming Primary Rat Cells: A Comparison of the "Hot Spot" Mutant Phenotypes" Cell Growth and Differentiation Vol. 1 571-580
C99	HOLLINSHEAD, 1988, "Immunotherapy," in: Cancer: The Outlaw Cell, LaFond, ed., American Chemical Society, Washington, DC pp. 237-250 (Chapter 14)
C100	
C101	
C102	
C103	
C104	HUGHES et al., 1970, "A Study In Clinical Cancer Immunotherapy", Cancer, 26:269-278
C105	
C106	
C107	
C108	ISAACS et al., 1988, "Use of anti-idiotypic antibodies to establish that monoclonal antibody 7H11D6 binds to the alpha2-macroglobulin receptor recognition site", J. Biol. Chem. 263(14): 6709-6714.
C109	ISHII et al., 1999, "Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96", J Immunol. 162(3):1303-9
C110	
CIII	JAIN et al., 1994, "Barriers to drug delivery in solid tumors." Sc Am 171(1):58-65
C112	JAKOB et al., 1993, "Small Heat Shock Proteins Are Molecular Chaperones", J. Biol. Chem. 268:1517-1520
C113	JAMES, K., 1980, "Alpha (2) macroglobulin and its possible importance in immune systems," Trends in Biol. Sci. p.43-47
C114	<u> </u>
C115	1
C116	
C117	JINDAL et al., 1989, "Primary structure of a human mitochondrial protein homologous to the bacterial and plant chaperonins and to the 65-kilodalton mycobacterial antigen. Mol Cell Biol. 9(5):2279-83
C118	

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 2 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C119	Proteins Using Free Solution Isoelectric Focusing (FS-IEF)" Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer, abstract 431
C120	
C121	KIM et al., 1998, "A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognized apolipoprotein E", J. Biochem. 124: 1072-1076.
C122	inflammation." Biochem Cell Biol. 2002;80(1):103-7.
C123	transduced tumor cells in the control of LLC tumor," AACR 93 rd Annual Meeting, Vol. 43, Abstract #5516
C124	KOL et al., 2000, "Cutting edge: heat shock protein (HSP)60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of monomuclear cells", J Immunol. 164(1):13-17
C125	mice." Cancer Res. 42(5):1788-97
C126	1
C127	53:1333-1336
C128	protein (LRP) is the alpha 2-macroglobulin receptor", FEBS Lett. 276(1-2):151-5
C129	KUHLMANN et al., 1997, "Drug Research: from the idea to the product," International Journal of Pharmacology and Therapeutics 35:541-552
ŀ	LAKEY et al., 1987, "Identification of a peptide binding protein that plays a role in antigen presentation", Proc. Natl. Acad. Sci. USA 84:1659-1663
C131	LANZAVECCHIA, 1993, "Identifying Strategies for Immune Intervention", Science 260:937-944
C132	LÉVY, 1991, "ATP is Required for In Vitro Assembly of MHC Class I Antigens but Not for Transfer of Pentides across the ER Membrane", Cell 67:265-274
C133	folding and antigen presentation", EMBO J. 12(8):3143-3151
C134	LIVINGSTON et al. 1985, "Serological Response of Melanoma Patients to Vaccines Prepared from VSV Lysates of Autologous and Allogeneic Cultured Melanoma Cells." Cancer, 55:713-720
C135	LODISH et al., <i>Molecular Cell Biology</i> , ch. 17.3 "Overview of the Secretory Pathway". pp 691-696, W.H. Freeman and Company 2000
C136	LUESCHER et al., 1991, "Specific Binding of Antigenic Peptides to Cell-associated MHC Class I Molecules", Nature 351:72-77
C137	LUKACS et al., 1993, "Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors", J. Exp. Med. 178:343-348
C138	LUSSOW et al., 1991, "Mycobacterial heat-shock proteins as carrier molecules", Eur J Immunol. 21(10):2297-302
C139	

EXAMINER	DATE CONSIDERED
	id MADED (00. Decelling through situation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 3 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

Tar	The state of the s
C140	MAKI (1991) "The Human Homologue of the Mouse Tumor Rejection Antigen GP96", Ph.D. thesis, Cornell University
C141	
6141	46:2189-2192
C142	<u></u>
"	harbors a unique mutation in a ribosomal protein," PNAS 98(7):3992-3997
C143	<u> </u>
	induction of heat shock protein expression", Nat. Med. 5:581-7
C144	
	in General", Career Surveys 13:81-99
C145	
	for Biomedical Research International Symposium, Houston, Texas, 8-10 November 1984, American
	Society for Microbiology pp. 1-13
C146	
	idea whose time has come" Semin. in Oncology 25:654
C147	·
	constitutive hsp70 in rat colon carcinomas," J. Immunol. 155:740-7
C148	MILLWARD AND HOELTGE, 1982, "The Historical Development of Automated Hemapheresis", J. of
	Clin. Apheresis 1: 25-32
C149	MIZZEN et al., 1998, "Immune responses to stress proteins: applications to infectious disease and cancer,"
	Biotherapy 10:173-185
C150	1.102011101 01411, 1570, 11111111100, 10111111111111111111111
	receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte
	differentiation antigen", Exper. Cell Res. 190: 195-203.
C151	MOESTRUP et al., 1991, "Analysis of Ligand Recognition by the purified alpha-2M- macroglobulin
	receptor (low density lipoprotein receptor-related protein). J. Biol. Chem. 266(21):14011-14017.
C152	MOROI et al., 2000, "Induction of Cellular Immunity by Immunization with Novel Hybrid Peptides
	Complexed to Heat Shock PRotein 70." Proc. Natl. Acad. Sci. 97(7):3485-3490
C153	MSNBC News Services, 2000, "Mixed Results on new cancer drug."
C154	
	Recombinant Interleukin-2", Science 225:1487-1489
C155	
	and immunoglobulin heavy chain binding protein", Cell 46(2):291-300
C156	MURRAY et al 1977 "Viral Oncolysate in the Management of Malignant Melanoma II, Clinical
	Studies." Cancer 40:680-686
C157	NAIR et al., 1977 "Antigen-Presenting Cells Pulsed With Unfractionated Tumor-Derived Peptides Are
	Potent Tumor Vaccines." Eur. J. Immunol. 27:589-597
C158	NAIR et al., 1999, "Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses
	against bound peptides" J. Immunol. 162:6426
C159	NATALI et al., 1987 "Immunohistochemical Detection Of Antigen In Human Primary And Metastatic
ĺ	Melanomas By The Monoclonal Antibody 140.240 And Its Possible Prognostic Significance." Cancer,

	EXAMINER	DATE CONSIDERED
ı	*EXAMINER: Initial if reference considered, whether or not citation is in confor	mance with MPEP 609: Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 4 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

C160	NIELAND et al., 1996, "Isolation of an immunodominant viral peptide that is endogenously bound to the
	stress protein GP96/GRP94", Proc. Natl. Acad. Sci. USA 93:6135-6139
C161	
	Spring Harbor, NY pp. 387-394
C162	OETTGEN AND OLD, 1991 "The History Of Cancer Immunotherapy." In: Introduction To The Biologic
	Therapy Of Cancer", Devitta et al., Eds., Lippincott, Philadelphia, PA, pp.87-119 (Chapter 6)
C163	OFFICE ACTION mailed on 02/26/02 for U.S. Application No. 09/625,137 filed 07/25/00
	OFFICE ACTION mailed on 05/18/05 for U.S. Application No. 09/625,137 filed 07/25/00 OFFICE ACTION mailed on 10/05/04 for U.S. Application No. 09/625,137 filed 07/25/00
	OFFICE ACTION mailed on 10/03/04 for U.S. Application No. 09/025,137 filed 07/25/00 OFFICE ACTION mailed on 11/02/05 for U.S. Application No. 09/625,137 filed 07/25/00
C166	
C107	
C168	
C169	OFFICE ACTION mailed on 02/25/03 for U.S. Application No. 09/668,724 filed 09/22/00
C170	OFFICE ACTION mailed on 05/07/02 for U.S. Application No. 09/668,724 filed 09/22/00
C171	OFFICE ACTION mailed on 06/20/07 for U.S. Application No. 09/668,724 filed 09/22/00
C172	OFFICE ACTION mailed on 07/07/04 for U.S. Application No. 09/668,724 filed 09/22/00
C173	OFFICE ACTION mailed on 09/21/06 for U.S. Application No. 09/668,724 filed 09/22/00
C174	OFFICE ACTION mailed on 03/13/06 for U.S. Application No. 09/750,972 filed 12/28/00
C175	OFFICE ACTION mailed on 06/05/02 for U.S. Application No. 09/750,972 filed 12/28/00
	OFFICE ACTION mailed on 08/28/03 for U.S. Application No. 09/750,972 filed 12/28/00
C177	OFFICE ACTION mailed on 01/11/06 for U.S. Application No. 10/225,367 filed 08/20/02
C178	OFFICE ACTION mailed on 03/30/05 for U.S. Application No. 10/225,367 filed 08/20/02
C179	OFFICE ACTION mailed on 04/18/07 for U.S. Application No. 10/225,367 filed 08/20/02
C180	OFFICE ACTION mailed on 09/25/06 for U.S. Application No. 10/225,367 filed 08/20/02
C181	OFFICE ACTION mailed on 10/19/07 for U.S. Application No. 10/225,367 filed 08/20/02
C182	OFFICE ACTION mailed on 01/03/06 for U.S. Application No. 10/427,857 filed 05/01/03
C183	OFFICE ACTION mailed on 10/15/07 for U.S. Application No. 10/546,106 filed 10/11/05
C184	
C185	OFFICE ACTION mailed on 08/07/06 for U.S. Application No. 10/784,012 filed 02/20/04
C186	OFFICE ACTION mailed on 11/02/07 for U.S. Application No. 10/784,012 filed 02/20/04
C187	OHASHI et al., 2000, Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like
	receptor-4 complex. J. Immunol. 164:558-561
C188	OLD et al., 1962 "Part II. Antigens Of Tumor Cells. Antigenic Properties Of Chemically-Induced
	Tumors." Ann. N.Y. Acad. Sci. <u>101</u> :80-106
C189	OPEKUN et al., 1999, "Novel therapies for Helicobacter pylori infection."
	Aliment Pharmacol Ther. 13(1):35-42.
C190	PAL P.G., et al., 1992, "Immunization with extracellular proteins of Mycobacterium tuberculosis induces
	cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary
	tuberculosis." Infect Immun. 60(11):4781-92

EXAMINER		DATE CONSIDERED
*EYAMINED	Initial if reference considered, whether or not citation is in conform	nance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 5 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-178-999 APPLICANT	APPLICATION NO. 09/873,403
	Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

C101	PALLADINO et al., 1987, "Expression of shared tumor-specific antigen by two chemically induced
C191	BALB/c sarcomas", Cancer Research 47:5074-5079
C192	
C193	PATTILLO, 1974 "Combination Chemotherapy-Immunotherapy Indirect Chemotherapy Sensitivity Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and Application: Proceedings of a Chicago Sumposium, Crispen, Ed. ITR, Chicago, IL, pp. 189-204
C194	PAUL, Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189- 220 Cited On pp.1173-1174
C195	PAUL. Fundamental Immunology. 1993 Third Edition, Raven PRess, NY
C196	PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390
C197	PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098
C198	PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041
	PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573
C200	PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110
C201	PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110
C202	PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13
C203	PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667
C204	PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4
C205	PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184
C206	PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787
C207	PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778
C208	PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82
C209	RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54
C210	\$
C211	REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882
C212	
C213	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conform	nance with MPEP 609: Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 6 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT

C214	ROTHMAN, 1989, "Polypeptide Chain Binding Proteins: Catalysts of Protein Folding and Related	
	Processes in Cells". Cell 59:591-601	
C215	RÖTZSCHKE et al., 1990, "Isolation and Analysis of Naturally Processed Viral Peptides as Recognized	
Ì	by Cytotoxic T cells", Nature 348:248-251	
C216		
	including H-4 and H-Y" Science 249: 283-287	
C217	SALK et al., 1993, "A Strategy for Prophylactic Vaccination Against HIV", Science 260:1270-1272	
C218	SALLUSTO et al., 1994, "Efficient presentation of soluble antigen by cultured human dendritic cells is	
	maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by	
	tumor necrosis factor alpha," J. Exp. Med. 179(4):1109-1118	
C219	SANO et al., 1987, "The augmentation of tumor-specific immunity using haptenic muramyl dipeptide	
	(MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-	
	reactive helper T cell activity," Cancer Immunol. Immunother. 25(3):180-184	
C220	SAUTER et al., 2000, "Consequences of cell death: exposure to necrotic tumor cells, but not primary	
	tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells", J. Exp. Med.	
	191:423-434	
C221	[
	923-955	
C222		
C223		
	HLA Class I and Class II," J. Immunol. 173:1987-1993	
C224	SILVA et al., 1994, "A single mycobacterial protein (hsp 65) expressed by a transgenic antigen-presenting	
	cell vaccinates mice against tuberculosis", Immunology 82(2):244-8	
C225	1 == : == - : : : : : : : : : : : : : : :	
	43:79-94	
C226		
	Carcinoma Patients." Scand J. Immunol 33:699-706	
C227		
	hsp90", J. Mol. Biol. 194(2):341-4	
C228		
	Acta. Neurol. Scand. 98(5):314-7 SPARKS et al., 1976, "Immunology and adjuvant chemoimmunotherapy of breast cancer," Arch. Surg.	
C229		
C220	111:1057-1062 SPERO et al., 1980, "Plasma Exchange in Preparation of Mild Factor IX Deficient Hemophiliacs for	
C230	Surgical Procedures," 19-22	
C231		
1231	Convergence of two evolutionary pathways of antigen presentation?", Seminars in Immunology 3:57-64	
C232	SRIVASTAVA and OLD (1989) "Gp96 Molecules: Recognition Elements in Tumor Immunity", Human	
1232	Tumor Antigens and Specific Tumor Therapy, pages 63-71	
C233		
1233	Curr. Opin. Immunol. 6:728	
	LUII. Ovii. minutio. 0.740	

EXAMINER	DATE CONSIDERED
	to the property of the state of

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 7 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON I	PATENT LITERATURE DOCUMENTS
	5 SRIVASTAVA et al., 198	34, "The Serologically Unique Cell Surface Antigen of Zajdela Ascitic Hepatoma
	is also its Tumor-Associate	ted Transplantation Antigen", Int. J. Cancer 33:417-422
C	6 SRIVASTAVA et al., 198	37, "5'-structural analysis of genes encoding polymorphic antigens of chemically
	induced tumors." Proc. N	atl. Acad. Sci USA 84(11):3807-3811
(7 SRIVASTAVA et al., 198	38, "Individually distinct transplantation antigens of chemically induced mouse
	tumors," Immunol. Today	9:78-83
(8 SRIVASTAVA et al., 198	39, "Identification of a Human Homologue of the Murine Tumor Rejection
	Antigen GP96," Cancer I	Res. 49:1341-1343
	9 SRIVASTAVA et al., 199	91, "Protein Tumor Antigens", Curr. Opin. Immunol. 3:654-658
(0 SRIVASTAVA et al., 199	33, "Evidence for peptide-chaperoning by the endoplasmic reticular heat shock
	protein GP96: Implication	ns for vaccination against cancer and infectious diseases", J Cell Biochem Suppl
l	17D:94 (Abstract NZ014)	
		98, "Heat shock proteins come of age: primitive functions acquire new roles in an
İ	adaptive world", Immun	ity 8(6):657-65
(2 SRIVASTAVA PK, 1994	4, "Heat shock proteins in immune response to cancer: the Fourth Paradigm",
	Experientia. (11-12):1054	-60
(3 SRIVASTAVA, 1993, "P	Peptide-Binding Heat Shock Proteins in the Endoplasmic Reticulum: Role in
	Immune Response to Can	cer and in Antigen Presentation," Adv. Cancer Res. 62:153-177
(4 SRIVASTAVA, 2002, "R	toles of heat-shock proteins in innate and adaptive immunity," Nature Rev.
i	Immunol. 2(3): 185-194	
	5 STACK et al., 1982, "Au	tologous x-irradiated tumour cells and percutaneous BCG in operable lung
ŀ	cancer," Thorax 37(8):58	
(Myelin-specific CD8+ T cells in the pathogenesis of experimental allergic
1	encephalitis and multiple	sclerosis," J. Exp. Med. 194:F27-F30
(7 STENMAN et al., 1991,	'A complex between prostate-specific antigen and alpha 1-antichymotrypsin is
1		e-specific antigen in serum of patients with prostatic cancer: assay of the complex
	improves clinical sensitiv	ity for cancer," Cancer Res. 51(1):222-6
(8 STEVENSON, 1999, "DI	NA vaccines against cancer: from genes to therapy," Ann. Oncol. 10:1413-8
	Review	
(9 SUBBARAO et al., 1992	, "A General Overview of Viral Vaccine Development," Genetically Engineered
	Vaccines 327:51-57	
(0 SUZUE et al., 1997, "He	at shock fusion proteins as vehicles for antigen delivery into the major
		ex class I presentation pathway," Proc. Natl. Acad. Sci. USA 94(24):13146-51
		1996, "Heat shock proteins as immunological carriers and vaccines. in:
		Responses" (U. Feige, R. I. Morimoto, I. Yahara, B. S. Polla, eds.),
	Birkhauser/Springer, 77:	451-465
(1996, "Adjuvant-free hsp70 fusion protein system elicits humoral and cellular
	immune responses to HI	V-1" p24. J Immunol. 156(2):873-9
(ucleotide Sequence Of Human Prostatic Acid Phosphatase Determined From A
		." Nucl. Acids Res. 18:4928 (1990)
(4 TAIT, BD, 1990, "Geneti	c susceptibility to type I diabetes: a review," J. Autoimmun. 3 Suppl. 1:3-11
	5 THE MERCK MANUAL	of Diagnosis and Therapy, 1999, Beers and Berkow eds., Merck Research
\	Laboratories Whitehouse	e Station N.J., pp. 1871 and 1872

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conform	nance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 8 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C256	Mammalian Tissue-Culture Cells", Cold Springs Harbor Symp Quant Biol 46:985-996
C257	TODRYK et al., 1999, "Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake," J. Immunol. 163:1398-1408
C258	TWINING et al., 1977, "Large scale separation of protease inhibitors from malignant human breast tissue," Mol. Cell. Biochem. 18(2-3):101-7
C259	UDONO et al., 1994, "Comparison of Tumor-Specific Immunogenicities of Stress-Induced Proteins gp96, hsp90, and hsp70," J. Immunol., 152(11):5398-5403
C260	tumors from which they are isolated", J. Cell. Biochem. Suppl. 17D:113 (Abstract NZ225)
C261	ULLRICH et al., 1986, "A mouse tumor-specific transplantation antigen is a heat shock-related protein," Proc. Natl. Acad. Sci. USA 83(10):3121-3125
C262	URBANIAK AND ROBINSON, 1990, "ABC of transfusion. Therapeutic apheresis," BMJ 300(6725):662-5 Review
C263	
C264	<u> </u>
C265	VIJAYASARADHI et al., 1990 "The Melanoma Antigen gp75 Is The Human Homologue Of The Mouse b (Brown) Locus Gene Product." J. Exp. Med. 171:1375-1380
C266	<u> </u>
C267	WANG et al., 2001, "Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-497
C268	WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054.
C269	WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33
C270	WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884
C271	WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem. 257:14949-14959
C272	WELCH et al., 1985, "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237
C273	in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211
	WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64
C275	
C276	in vivo and in vitro." The Biochemical Journal. England 313:71-76 WONG et al., 1991, "Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus
6270	on chromosome 11," Clin. Exp. Immunol. 83(1):69-73
C277	XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment
<u></u>	of human thyroglobulin." Arch Biochem Biophys. 20;320(1):96-105

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformations considered. Include copy of this form with next communication to applicant.	nance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 9 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-178-999	09/873,403
	APPLICANT	
	Srivastava et al.	
	FILING DATE	ART UNIT
	June 4, 2001	1643

	NON PATENT LITERATURE DOCUMENTS
C278	YAMAUCHI et al., 2000, "Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study." Mycoses.43(5):197-202.
C279	YANG et al., 1999, "Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8+ and CD4+ T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity," Int. J. Cancer 83:532-540
C280	YEDAVELLI et al., 1999, "Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model" Int. J. Mol. Med. 3:243
C281	YU et al., 1991, "Sequence Analysis of Peptides Bound to MHC Class II Molecules", Nature 353:622-627
C282	
C283	ZIMECKI et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." Arch Immunol Ther Exp (Warsz). 47(2):13-8.

EXAMINER DATE CONSIDERED

box 3 of 3

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 1 of 9 of List of References

ATTY. DOCKET NO.

8449-178-999

APPLICANT

Srivastava et al.

Filing date

June 4, 2001

APPLICATION NO.

09/873,403

ART UNIT

1643

LISTOF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

· ·		\neg
	NON PATENT LITERATURE DOCUMENTS	١
C98	HINDS et al., 1990, "Mutant p53 DNA Clones from Human Colon Carcinomas Cooperate with ras in Transforming Primary Rat Cells: A Comparison of the "Hot Spot" Mutant Phenotypes" Cell Growth and Differentiation Vol. 1 571-580	
C99	HOLLINSHEAD, 1988, "Immunotherapy," in: Cancer: The Outlaw Cell, LaFond, ed., American Chemical Society, Washington, DC pp. 237-250 (Chapter 14)	
C100	HORN et al., 1995, "Analysis of the binding of Pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library", J. of Biol. Chem. 270 (20): 11770-11775.	
C101	HORWITZ et al., 1995, Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 92(5):1530-4	
C102	HOUGHTEN et al., 1991, "Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery," Science 354:84-86	
C103	HUBBARD et al., 1992, "Immunization of mice with mycobacterial culture filtrate proteins," Clin. Exp. Immunol. 87(1):94-8	
C104	HUGHES et al., 1970, "A Study In Clinical Cancer Immunotherapy", Cancer, 26:269-278	
C105	1 1 1 1 1	
C106	HUMPHREY et al., 1984, "Adjuvant immunotherapy for melanoma," J. Surg. Concol. 25:303-305	
C107	HUNTER, N. et al., 1991, "Suppression of experimental allergic encephalomyelitis by alpha(2)-macroglobulin," Immunology 73:58-63	
C108	ISAACS et al., 1988, "Use of anti-idiotypic antibodies to establish that monoclonal antibody 7H11D6 binds to the alpha2-macroglobulin receptor recognition site", J. Biol. Chem. 263(14): 6709-6714.	
C109	ISHII et al., 1999, "Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96", J Immunol. 162(3):1303-9	
C110		
C111	JAIN et al., 1994, "Barriers to drug delivery in solid tumors." Sc Am 171(1):58-65	
C112	JAKOB et al., 1993, "Small Heat Shock Proteins Are Molecular Chaperones", J. Biol. Chem. 268:1517-1520	
C113	Biol. Sci. p.43-47	
C114	JANETZKI et al., 2000, "Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study" <i>Int. J. of Cancer</i> 88:232-238	
C115	JANEWAY, Travers, Walport, and Shlomchick, 2001, Immunobiology, 5th ed., Garland Publishing, New York (Part V. Sections 13-1 to 13-15)	
C116	JARDETZKY et al., 1991, "Identification of Self Peptides Bound to Purified HLA-B27", Nature 353:326-329	
C117	JINDAL et al., 1989, "Primary structure of a human mitochondrial protein homologous to the bacterial and plant chaperonins and to the 65-kilodalton mycobacterial antigen. Mol Cell Biol. 9(5):2279-83	
C118		

EXAMINER

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 2 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	art unit 1643

	NON PATENT LITERATURE DOCUMENTS
C119	KATSANIS et al., 2000, "Augmentation of Tumor Lysate Immunogencity by enrichment of Chaperone Proteins Using Free Solution Isoelectric Focusing (FS-IEF)" Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer, abstract 431
C120	KATSUTANI et al., 1992, "Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice." Fundam Appl Toxicol.19(4):555-62.
C121	KIM et al., 1998, "A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognized apolipoprotein E", J. Biochem. 124: 1072-1076.
C122	KIMBER et al., 2002, "Lactoferrin: influences on langerhans cells, epidermal cytokines, and cutaneous inflammation." Biochem Cell Biol. 2002;80(1):103-7.
C123	KOJIMA et al., 2002, "Combination therapy of tumor-derived gp96 and GM-CSF or IL-12-gene transduced tumor cells in the control of LLC tumor," AACR 93 rd Annual Meeting, Vol. 43, Abstract #5516
C124	is an essential receptor for HSP60 activation of monomuclear cells", J Immunol. 164(1):13-17
	KOO, 1982, "Characterization of growth-inhibitory activities associated with an alpha-macroglobulin of mice," Cancer Res. 42(5):1788-97
C126	KORNFELD et al., 1980, "Plasmapheresis in Myasthenia Gravis," Plasma Therapy, 2(3): 127-133
C127	53:1333-1336
C128	protein (LRP) is the alpha 2-macroglobulin receptor", FEBS Lett. 276(1-2):151-5
C129	KUHLMANN et al., 1997, "Drug Research: from the idea to the product," International Journal of Pharmacology and Therapeutics 35:541-552
C130	Proc. Natl. Acad. Sci. USA 84:1659-1663
C131	LANZAVECCHIA, 1993, "Identifying Strategies for Immune Intervention", Science 260:937-944
	LÉVY, 1991, "ATP is Required for In Vitro Assembly of MHC Class I Antigens but Not for Transfer of Peptides across the ER Membrane", Cell 67:265-274
C133	LI and SRIVASTAVA, 1993, "Tumor rejection antigen gp96/grp94 is an ATPase: Implications for protein folding and antigen presentation", EMBO J. 12(8):3143-3151
C134	LIVINGSTON et al. 1985, "Serological Response of Melanoma Patients to Vaccines Prepared from VSV Lysates of Autologous and Allogeneic Cultured Melanoma Cells." Cancer, 55:713-720
	LODISH et al., <i>Molecular Cell Biology</i> , ch. 17.3 "Overview of the Secretory Pathway". pp 691-696, W.H. Freeman and Company 2000
C136	LUESCHER et al., 1991, "Specific Binding of Antigenic Peptides to Cell-associated MHC Class I Molecules", Nature 351:72-77
C137	induce protection against tumors", J. Exp. Med. 178:343-348
C138	LUSSOW et al., 1991, "Mycobacterial heat-shock proteins as carrier molecules", Eur J Immunol. 21(10):2297-302
C139	MADDEN et al., 1991, "The Structure of HLA-B27 Reveals Nonamer Self-peptides Bound in an Extended Conformation", <i>Nature</i> 353:321-325

EXAMINER	DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 3 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	filing date June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C140	MAKI (1991) "The Human Homologue of the Mouse Tumor Rejection Antigen GP96", Ph.D. thesis, Cornell University
C141	MARTIN et al., 1986, "Role of Murine Tumor Models in Cancer Treatment Research", Cancer Research 46:2189-2192
C142	
C143	MELCHER et al., 1998, "Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression", Nat. Med. 5:581-7
C144	
C145	MELNICK, 1985, "Virus Vaccines: An Overview", Proceedings of the First Annual Southwest Foundation for Biomedical Research International Symposium, Houston, Texas, 8-10 November 1984, American Society for Microbiology pp. 1-13
C146	idea whose time has come" Semin. in Oncology 25:654
C147	MENORET et al., 1995, "Co-segregation of tumor immunogenicity with expression of inducible but not constitutive hsp70 in rat colon carcinomas," J. Immunol. 155:740-7
C148	Clin. Apheresis 1: 25-32
C149	
C150	
C151	MOESTRUP et al., 1991, "Analysis of Ligand Recognition by the purified alpha-2M- macroglobulin receptor (low density lipoprotein receptor-related protein). J. Biol. Chem. 266(21):14011-14017.
C152	
C153	MSNBC News Services, 2000, "Mixed Results on new cancer drug."
C154	MULÉ et al., 1984, "Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2", Science 225:1487-1489
C155	MUNRO et al., 1986, "An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein", Cell 46(2):291-300
C156	
C157	NAIR et al., 1977 "Antigen-Presenting Cells Pulsed With Unfractionated Tumor-Derived Peptides Are Potent Tumor Vaccines." Eur. J. Immunol. 27:589-597
C158	NAIR et al., 1999, "Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides" J. Immunol. 162:6426
C159	

EXAMINER	DATE CONSIDERED
TEVANDED Is it is if of any an analyzed whather or not citation is in conform	nance with MRED 600. Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 4 of 9 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT		
	Srivastava et al.		
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

	NON PATENT LITERATURE DOCUMENTS	
C160	NIELAND et al., 1996, "Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94", Proc. Natl. Acad. Sci. USA 93:6135-6139	
C161		
C162		
C163	OFFICE ACTION mailed on 02/26/02 for U.S. Application No. 09/625,137 filed 07/25/00	
	OFFICE ACTION mailed on 05/18/05 for U.S. Application No. 09/625,137 filed 07/25/00	$\overline{}$
	OFFICE ACTION mailed on 10/05/04 for U.S. Application No. 09/625,137 filed 07/25/00	
C166	OFFICE ACTION mailed on 11/02/05 for U.S. Application No. 09/625,137 filed 07/25/00	Γ
C167		Γ
C168	OFFICE ACTION mailed on 02/08/06 for U.S. Application No. 09/668,724 filed 09/22/00	匚
C169	OFFICE ACTION mailed on 02/25/03 for U.S. Application No. 09/668,724 filed 09/22/00	
C170	OFFICE ACTION mailed on 05/07/02 for U.S. Application No. 09/668,724 filed 09/22/00	
C171		
C172	OFFICE ACTION mailed on 07/07/04 for U.S. Application No. 09/668,724 filed 09/22/00	_
C173	OFFICE ACTION mailed on 09/21/06 for U.S. Application No. 09/668,724 filed 09/22/00	
C174	OFFICE ACTION mailed on 03/13/06 for U.S. Application No. 09/750,972 filed 12/28/00	
C175		
C176	OFFICE ACTION mailed on 08/28/03 for U.S. Application No. 09/750,972 filed 12/28/00	L
C177	OFFICE ACTION mailed on 01/11/06 for U.S. Application No. 10/225,367 filed 08/20/02	
C178	OFFICE ACTION mailed on 03/30/05 for U.S. Application No. 10/225,367 filed 08/20/02	
C179		
C180	OFFICE ACTION mailed on 09/25/06 for U.S. Application No. 10/225,367 filed 08/20/02	Γ
C181	OFFICE ACTION mailed on 10/19/07 for U.S. Application No. 10/225,367 filed 08/20/02	Г
C182	OFFICE ACTION mailed on 01/03/06 for U.S. Application No. 10/427,857 filed 05/01/03	Γ
C183		
C184		
C185	OFFICE ACTION mailed on 08/07/06 for U.S. Application No. 10/784,012 filed 02/20/04	
C186	OFFICE ACTION mailed on 11/02/07 for U.S. Application No. 10/784,012 filed 02/20/04	Γ
C187	OHASHI et al., 2000, Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J. Immunol. 164:558-561	
C188	OLD et al., 1962 "Part II. Antigens Of Tumor Cells. Antigenic Properties Of Chemically-Induced Tumors." Ann. N.Y. Acad. Sci. 101:80-106	
C189	OPEKUN et al., 1999, "Novel therapies for Helicobacter pylori infection." Aliment Pharmacol Ther. 13(1):35-42.	
C190	PAL P.G., et al., 1992, "Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis." Infect Immun. 60(11):4781-92	

EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and reconsidered. Include copy of this form with next communication to applicant.		

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 5 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	filing date June 4, 2001	ART UNIT 1643	

	NON PATENT LITERATURE DOCUMENTS
Cl	PALLADINO et al., 1987, "Expression of shared tumor-specific antigen by two chemically induced BALB/c sarcomas", Cancer Research 47:5074-5079
Cl	
	PATTILLO, 1974 "Combination Chemotherapy-Immunotherapy Indirect Chemotherapy Sensitivity Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and Application: Proceedings of a Chicago Sumposium, Crispen, Ed. ITR, Chicago, IL, pp. 189-204
	PAUL, Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189- 220 Cited On pp.1173-1174
CI	PAUL. Fundamental Immunology. 1993 Third Edition, Raven PRess, NY
CI	PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390
	PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098
	PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041
Cı	PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573
	PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110
C2	PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110
C2	PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13
C2	PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667
C2	PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4
C2	PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184
C2	PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787
C2	PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778
C2	PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82
C2	PAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54
	REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80.
C2	REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific- Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882
C2	
C2	

EXAMINER		DATE CONSIDERED
*EVAMINED: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not		

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 6 of 9 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.
	8449-178-999	09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	
	Srivastava et al.	
	FILING DATE	ART UNIT
	June 4, 2001	1643

	NON PATENT LITERATURE DOCUMENTS
C214	ROTHMAN, 1989, "Polypeptide Chain Binding Proteins: Catalysts of Protein Folding and Related Processes in Cells", Cell 59:591-601
C215	RÖTZSCHKE et al., 1990, "Isolation and Analysis of Naturally Processed Viral Peptides as Recognized by Cytotoxic T cells", Nature 348:248-251
C216	ROTZSCHKE, 1990, "Characterization of Naturally Occurring Minor Histocompatibility Peptides including H-4 and H-Y" Science 249: 283-287
C217	SALK et al., 1993, "A Strategy for Prophylactic Vaccination Against HIV", Science 260:1270-1272
C218	maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha," J. Exp. Med. 179(4):1109-1118
C219	SANO et al., 1987, "The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity," Cancer Immunol. Immunother. 25(3):180-184
C220	SAUTER et al., 2000, "Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells", J. Exp. Med. 191:423-434
C221	923-955
C222	SCHUMACHER et al., 1991, "Peptide Selection by MHC Class I Molecules", Nature 350:703-706
C223	SENGUPTA et al., 2004, "Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA Class I and Class II," J. Immunol. 173:1987-1993
C224	cell vaccinates mice against tuberculosis", Immunology 82(2):244-8
C225	43:79-94
C226	Carcinoma Patients." Scand J. Immunol 33:699-706
C227	hsp90", J. Mol. Biol. 194(2):341-4
C228	Acta, Neurol, Scand, 98(5):314-7
C229	SPARKS et al., 1976, "Immunology and adjuvant chemoimmunotherapy of breast cancer," Arch. Surg. 111:1057-1062
C230	Surgical Procedures," 19-22
C231	SRIVASTAVA and HEIKE, 1986, "Tumor-specific immunogenicity of stress-induced proteins: Convergence of two evolutionary pathways of antigen presentation?", Seminars in Immunology 3:57-64
C232	Tumor Antigens and Specific Tumor Therapy, pages 63-71
C233	Curr, Opin, Immunol. 6:728
C234	SRIVASTAVA et al. (1990) "Immunization with Soluble Gp96 Antigens Elicits Tumor-Specific Cellular Immunity:, Cellular Immunity and the Immunotherapy of Cancer, pages 307-314

Initiality, Central minumer and the initiality of cancer, pages 307 31.		
EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformation considered. Include copy of this form with next communication to applicant.	nance with MPEP 609; Draw line through citation if not in conformance and not	

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 7 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C	SRIVASTAVA et al., 1984, "The Serologically Unique Cell Surface Antigen of Zajdela Ascitic Hepatoma is also its Tumor-Associated Transplantation Antigen", Int. J. Cancer 33:417-422
C	36 SRIVASTAVA et al., 1987, "5'-structural analysis of genes encoding polymorphic antigens of chemically induced tumors." Proc. Natl. Acad. Sci USA 84(11):3807-3811
С	SRIVASTAVA et al., 1988, "Individually distinct transplantation antigens of chemically induced mouse tumors," Immunol. Today 9:78-83
C	SRIVASTAVA et al., 1989, "Identification of a Human Homologue of the Murine Tumor Rejection Antigen GP96," Cancer Res. 49:1341-1343
С	SRIVASTAVA et al., 1991, "Protein Tumor Antigens", Curr. Opin. Immunol. 3:654-658
С	SRIVASTAVA et al., 1993, "Evidence for peptide-chaperoning by the endoplasmic reticular heat shock protein GP96: Implications for vaccination against cancer and infectious diseases", <i>J Cell Biochem Suppl</i> 17D:94 (Abstract NZ014)
С	SRIVASTAVA et al., 1998, "Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world", Immunity 8(6):657-65
С	SRIVASTAVA PK, 1994, "Heat shock proteins in immune response to cancer: the Fourth Paradigm", Experientia. (11-12):1054-60
C	SRIVASTAVA, 1993, "Peptide-Binding Heat Shock Proteins in the Endoplasmic Reticulum: Role in Immune Response to Cancer and in Antigen Presentation," Adv. Cancer Res. 62:153-177
C	SRIVASTAVA, 2002, "Roles of heat-shock proteins in innate and adaptive immunity," Nature Rev. Immunol, 2(3): 185-194
C	STACK et al., 1982, "Autologous x-irradiated tumour cells and percutaneous BCG in operable lung cancer," Thorax 37(8):588-593
C	STEINMAN, L., 2001, "Myelin-specific CD8+ T cells in the pathogenesis of experimental allergic encephalitis and multiple sclerosis," J. Exp. Med. 194:F27-F30
C	STENMAN et al., 1991, "A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer," Cancer Res. 51(1):222-6
C	STEVENSON, 1999, "DNA vaccines against cancer: from genes to therapy," Ann. Oncol. 10:1413-8 Review
C	SUBBARAO et al., 1992, "A General Overview of Viral Vaccine Development," Genetically Engineered Vaccines 327:51-57
C	SUZUE et al., 1997, "Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway," Proc. Natl. Acad. Sci. USA 94(24):13146-51
C	SUZUE K., Young R.A., 1996, "Heat shock proteins as immunological carriers and vaccines. in: Stress-Inducible Cellular Responses" (U. Feige, R. I. Morimoto, I. Yahara, B. S. Polla, eds.), Birkhauser/Springer, 77: 451-465
C	SUZUE K., Young R.A., 1996, "Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1" p24. J Immunol. 156(2):873-9
	TAILOR et al., 1990, "Nucleotide Sequence Of Human Prostatic Acid Phosphatase Determined From A Full-Length cDNA Clone." Nucl. Acids Res. 18:4928 (1990)
	TAIT, BD, 1990, "Genetic susceptibility to type I diabetes: a review," J. Autoimmun. 3 Suppl. 1:3-11
C	THE MERCK MANUAL of Diagnosis and Therapy, 1999, Beers and Berkow eds., Merck Research Laboratories, Whitehouse Station N.J., pp. 1871 and 1872

	Laboratories, Whitehouse Station N.J., pp. 1871 and 1872			
EXAMINER	R		DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 8 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C256	THOMAS et al., 1982, "Molecular and Cellular Effects of Heat Shock and Related Treatments of
	Mammalian Tissue-Culture Cells", Cold Springs Harbor Symp Quant Biol 46:985-996
C257	
	and targets immature dendritic cell precursors to enhance antigen uptake," J. Immunol. 163:1398-1408
C258	TWINING et al., 1977, "Large scale separation of protease inhibitors from malignant human breast
	tissue," Mol. Cell. Biochem. 18(2-3):101-7
C259	
	hsp90, and hsp70," J. Immunol., 152(11):5398-5403
C260	
	tumors from which they are isolated", J. Cell. Biochem. Suppl. 17D:113 (Abstract NZ225)
C261	===:::
	Proc. Natl. Acad. Sci. USA 83(10):3121-3125
C262	URBANIAK AND ROBINSON, 1990, "ABC of transfusion. Therapeutic apheresis," BMJ
	300(6725):662-5 Review
C263	VAAGE, 1968 "Nonvirus-Associated Antigens In Virus-Induced Mouse Mammary Tumors." Cancer Res.
	<u>28</u> :2477-2483
C264	
	the hsp70 heat shock family", J. Exp. Med. 170:1799-1809
C265	
	b (Brown) Locus Gene Product." J. Exp. Med. 171:1375-1380
C266	
	complex class I molecules in cellular peptide processing". Eur. J. Immunol 22:655-659
C267	
	cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-
C268	WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of
C208	ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054.
C269	
C270	
C271	WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem.
	257:14949-14959
C272	
	Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237
C273	
	in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat
	fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211
C274	WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64
C275	
	in vivo and in vitro." The Biochemical Journal. England 313:71-76
C276	
	on chromosome 11," Clin. Exp. Immunol. 83(1):69-73
C277	
	of human thyroglobulin." Arch Biochem Biophys. 20;320(1):96-105

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conform	nance with MPEP 609; Draw line through citation if not in conformance and not
considered. Include copy of this form with next communication to applicant	•

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 9 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS		
C278	YAMAUCHI et al., 2000, "Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study." Mycoses.43(5):197-202.		
C279	YANG et al., 1999, "Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8+ and CD4+ T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity," Int. J. Cancer 83:532-540		
C280	YEDAVELLI et al., 1999, "Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model" Int. J. Mol. Med. 3:243		
C281	YU et al., 1991, "Sequence Analysis of Peptides Bound to MHC Class II Molecules", Nature 353:622-627		
C282	ZIMECKI et al., 1998, "Immunoregulatory effects of a nutritional preparation containing bovine lactoferrin taken orally by healthy individuals." Arch Immunol Ther Exp (Warsz). 46(4):231-40.		
C283	ZIMECKI et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." Arch Immunol Ther Exp (Warsz). 47(2):113-8.		

EXAMINER

DATE CONSIDERED





box 3 of 3

Sheet 1 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
(Use several sheets if necessary)	APPLICANT Srivastava et al.		
NOV- 0 8 2007	FILING DATE June 4, 2001	ART UNIT 1643	
TRADBANK GE			

MADGAN	NON PATENT LITERATURE DOCUMENTS	
C98	HINDS et al., 1990, "Mutant p53 DNA Clones from Human Colon Carcinomas Cooperate with ras in Transforming Primary Rat Cells: A Comparison of the "Hot Spot" Mutant Phenotypes" Cell Growth and Differentiation Vol. 1 571-580	
C99	HOLLINSHEAD, 1988, "Immunotherapy," in: Cancer: The Outlaw Cell, LaFond, ed., American Chemical Society, Washington, DC pp. 237-250 (Chapter 14)	
C100	HORN et al., 1995, "Analysis of the binding of Pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library", J. of Biol. Chem. 270 (20): 11770-11775.	_
C101	HORWITZ et al., 1995, Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 92(5):1530-4	
C102	HOUGHTEN et al., 1991, "Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery," Science 354:84-86	
C103	HUBBARD et al., 1992, "Immunization of mice with mycobacterial culture filtrate proteins," Clin. Exp. Immunol. 87(1):94-8	
C104	HUGHES et al., 1970, "A Study In Clinical Cancer Immunotherapy", Cancer, 26:269-278	
C105	HUGHES et al., 1981, "Characterization of plasma membrane proteins identified by monoclonal antibodies", J. of Biol./ Chem. 256(2): 664-671.	
C106	HUMPHREY et al., 1984, "Adjuvant immunotherapy for melanoma," J. Surg. Concol. 25:303-305	
C107	HUNTER, N. et al., 1991, "Suppression of experimental allergic encephalomyelitis by alpha(2)-macroglobulin," Immunology 73:58-63	
C108		
C109	with heat shock proteins hsp70, hsp90, and gp96", J Immunol. 162(3):1303-9	
C110	ISRAELI et al., 1993, "Molecular Cloning Of A Complementary DNA Encoding A Prostate-Specific Membrane Antigen." Cancer Res. 53:227-230	
CIII	JAIN et al., 1994, "Barriers to drug delivery in solid tumors." Sc Am 171(1):58-65	
C112	1520	
C113	JAMES, K., 1980, "Alpha (2) macroglobulin and its possible importance in immune systems," Trends in Biol. Sci. p.43-47	
C114	protein gp96 preparations: a pilot study" Int. J. of Cancer 88:232-238	
C115	JANEWAY, Travers, Walport, and Shlomchick, 2001, Immunobiology, 5th ed., Garland Publishing, New York (Part V. Sections 13-1 to 13-15)	
C116	JARDETZKY et al., 1991, "Identification of Self Peptides Bound to Purified HLA-B27", Nature 353:326-329	
C117	plant chaperonins and to the 65-kilodalton mycobacterial antigen. Mol Cell Biol. 9(5):2279-83	
C118		

EXAMINER

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 2 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
	KATSANIS et al., 2000, "Augmentation of Tumor Lysate Immunogencity by enrichment of Chaperone Proteins Using Free Solution Isoelectric Focusing (FS-IEF)" Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer, abstract 431
C120	KATSUTANI et al., 1992, "Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice." Fundam Appl Toxicol.19(4):555-62.
C121	KIM et al., 1998, "A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognized apolipoprotein E", J. Biochem. 124: 1072-1076.
C122	KIMBER et al., 2002, "Lactoferrin: influences on langerhans cells, epidermal cytokines, and cutaneous inflammation." Biochem Cell Biol. 2002;80(1):103-7.
C123	KOJIMA et al., 2002, "Combination therapy of tumor-derived gp96 and GM-CSF or IL-12-gene transduced tumor cells in the control of LLC tumor," AACR 93 rd Annual Meeting, Vol. 43, Abstract #5516
C124	is an essential receptor for HSP60 activation of monomuclear cells", J Immunol. 164(1):13-17
C125	mice," Cancer Res. 42(5):1788-97
	KORNFELD et al., 1980, "Plasmapheresis in Myasthenia Gravis," Plasma Therapy, 2(3): 127-133
	KRIPKE, 1974 "Antigenicity Of Murine Skin Tumors Induced By Ultraviolet Light." J. Natl. Cancer Inst. 53:1333-1336
	KRISTENSEN et al., 1990, "Evidence that the newly cloned low-density-lipoprotein receptor related protein (LRP) is the alpha 2-macroglobulin receptor", FEBS Lett. 276(1-2):151-5
	KUHLMANN et al., 1997, "Drug Research: from the idea to the product," International Journal of Pharmacology and Therapeutics 35:541-552
	LAKEY et al., 1987, "Identification of a peptide binding protein that plays a role in antigen presentation", <i>Proc. Natl. Acad. Sci. USA</i> 84:1659-1663
C131	LANZAVECCHIA, 1993, "Identifying Strategies for Immune Intervention", Science 260:937-944
	LÉVY, 1991, "ATP is Required for In Vitro Assembly of MHC Class I Antigens but Not for Transfer of Peptides across the ER Membrane", Cell 67:265-274
	LI and SRIVASTAVA, 1993, "Tumor rejection antigen gp96/grp94 is an ATPase: Implications for protein folding and antigen presentation", EMBO J. 12(8):3143-3151
	LIVINGSTON et al. 1985, "Serological Response of Melanoma Patients to Vaccines Prepared from VSV Lysates of Autologous and Allogeneic Cultured Melanoma Cells." Cancer, 55:713-720
	LODISH et al., <i>Molecular Cell Biology</i> , ch. 17.3 "Overview of the Secretory Pathway". pp 691-696, W.H. Freeman and Company 2000
C136	LUESCHER et al., 1991, "Specific Binding of Antigenic Peptides to Cell-associated MHC Class I Molecules", Nature 351:72-77
C137	induce protection against tumors", J. Exp. Med. 178:343-348
C138	LUSSOW et al., 1991, "Mycobacterial heat-shock proteins as carrier molecules", Eur J Immunol. 21(10):2297-302
C139	MADDEN et al., 1991, "The Structure of HLA-B27 Reveals Nonamer Self-peptides Bound in an Extended Conformation", <i>Nature</i> 353:321-325

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conform	nance with MPEP 609. Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 3 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

	NON PATENT LITERATURE DOCUMENTS
C140	MAKI (1991) "The Human Homologue of the Mouse Tumor Rejection Antigen GP96", Ph.D. thesis,
	Cornell University
C141	MARTIN et al., 1986, "Role of Murine Tumor Models in Cancer Treatment Research", Cancer Research
	46:2189-2192
C142	
	harbors a unique mutation in a ribosomal protein," PNAS 98(7):3992-3997
C143	MELCHER et al., 1998, "Tumor immunogenicity is determined by the mechanism of cell death via
	induction of heat shock protein expression", Nat. Med. 5:581-7
C144	MELIEF et al., 1992, "Lessons from T Cell Responses to Virus Induced Tumours for Cancer Eradication
	in General", Career Surveys 13:81-99
C145	
	for Biomedical Research International Symposium, Houston, Texas, 8-10 November 1984, American
	Society for Microbiology pp. 1-13
C146	MÉNORET and CHANDAWARKAR, 1998, "Heat-shock protein-based anticancer immunotherapy: an
	idea whose time has come" Semin. in Oncology 25:654
C147	MENORET et al., 1995, "Co-segregation of tumor immunogenicity with expression of inducible but not
	constitutive hsp70 in rat colon carcinomas," J. Immunol. 155:740-7
C148	MILLWARD AND HOELTGE, 1982, "The Historical Development of Automated Hemapheresis", J. of
	Clin. Apheresis 1: 25-32
C149	MIZZEN et al., 1998, "Immune responses to stress proteins: applications to infectious disease and cancer,"
	Biotherapy 10:173-185
C150	MOESTRUP et al., 1990, "Immunocytochemical identification of the human aplpha 2-macroglobulin
	receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte
	differentiation antigen", Exper. Cell Res. 190: 195-203.
C151	MOESTRUP et al., 1991, "Analysis of Ligand Recognition by the purified alpha-2M- macroglobulin
0.31	receptor (low density lipoprotein receptor-related protein). J. Biol. Chem. 266(21):14011-14017.
C152	
	Complexed to Heat Shock PRotein 70." Proc. Natl. Acad. Sci. 97(7):3485-3490
	MSNBC News Services, 2000, "Mixed Results on new cancer drug."
C154	1
	Recombinant Interleukin-2", Science 225:1487-1489
C155	
	and immunoglobulin heavy chain binding protein", Cell 46(2):291-300
C156	1
	Studies." Cancer 40:680-686
C157	1
	Potent Tumor Vaccines." Eur. J. Immunol. 27:589-597
C158	
	against bound peptides" J. Immunol. 162:6426
C159	
	Melanomas By The Monoclonal Antibody 140.240 And Its Possible Prognostic Significance." Cancer,
	59:55-63

EXAMINER	DATE CONSIDERED
*EVANGINED. Living if reference considered whether or not citation is in conform	pance with MPEP 600. Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 4 of 9 of List of References

	ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403		
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	filing date June 4, 2001	ART UNIT 1643	

10160	Experience of the control of the con	7
C160	NIELAND et al., 1996, "Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94", Proc. Natl. Acad. Sci. USA 93:6135-6139	-
C161	NORRBY, 1985, "Summary," in: Vaccines 85, Lerner et al., eds., Cold Spring Harbor Laboratory, Cold	+
Citi	Spring Harbor, NY pp. 387-394	
C162		+
102	Therapy Of Cancer", Devitta et al., Eds., Lippincott, Philadelphia, PA, pp.87-119 (Chapter 6)	-
C163	OFFICE ACTION mailed on 02/26/02 for U.S. Application No. 09/625,137 filed 07/25/00	7
	OFFICE ACTION mailed on 05/18/05 for U.S. Application No. 09/625,137 filed 07/25/00	┪
	OFFICE ACTION mailed on 10/05/04 for U.S. Application No. 09/625,137 filed 07/25/00	٦
C166		
C167		
C168	OFFICE ACTION mailed on 02/08/06 for U.S. Application No. 09/668,724 filed 09/22/00	٦
C169		7
C170		┥
		4
	OFFICE ACTION mailed on 06/20/07 for U.S. Application No. 09/668,724 filed 09/22/00	4
	OFFICE ACTION mailed on 07/07/04 for U.S. Application No. 09/668,724 filed 09/22/00	4
C173		╝
C174	OFFICE ACTION mailed on 03/13/06 for U.S. Application No. 09/750,972 filed 12/28/00	į
C175	OFFICE ACTION mailed on 06/05/02 for U.S. Application No. 09/750,972 filed 12/28/00	
C176	OFFICE ACTION mailed on 08/28/03 for U.S. Application No. 09/750,972 filed 12/28/00	
C177	OFFICE ACTION mailed on 01/11/06 for U.S. Application No. 10/225,367 filed 08/20/02	-
C178	OFFICE ACTION mailed on 03/30/05 for U.S. Application No. 10/225,367 filed 08/20/02	
C179	OFFICE ACTION mailed on 04/18/07 for U.S. Application No. 10/225,367 filed 08/20/02	
C180	OFFICE ACTION mailed on 09/25/06 for U.S. Application No. 10/225,367 filed 08/20/02	
C181	OFFICE ACTION mailed on 10/19/07 for U.S. Application No. 10/225,367 filed 08/20/02	
C182	OFFICE ACTION mailed on 01/03/06 for U.S. Application No. 10/427,857 filed 05/01/03	-
C183	OFFICE ACTION mailed on 10/15/07 for U.S. Application No. 10/546,106 filed 10/11/05	
C184	OFFICE ACTION mailed on 02/22/07 for U.S. Application No. 10/784,012 filed 02/20/04	
C185	OFFICE ACTION mailed on 08/07/06 for U.S. Application No. 10/784,012 filed 02/20/04	
C186	OFFICE ACTION mailed on 11/02/07 for U.S. Application No. 10/784,012 filed 02/20/04	_
C187		_
	receptor-4 complex. J. Immunol. 164:558-561	
C188	OLD et al., 1962 "Part II. Antigens Of Tumor Cells. Antigenic Properties Of Chemically-Induced	
	Tumors." Ann. N.Y. Acad. Sci. 101:80-106	_
C189	1	
}	Aliment Pharmacol Ther. 13(1):35-42.	
C190	PAL P.G., et al., 1992, "Immunization with extracellular proteins of Mycobacterium tuberculosis induces	7
	cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary	ļ
	tuberculosis." Infect Immun. 60(11):4781-92	-

EXAMINER	DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 5 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C191	PALLADINO et al., 1987, "Expression of shared tumor-specific antigen by two chemically induced
	BALB/c sarcomas", Cancer Research 47:5074-5079
C192	PARDOLL, 2000, "Therapeutic vaccination for cancer", Clin. Immunol. 95(1 Pt 2): S44-62
C193	PATTILLO, 1974 "Combination Chemotherapy-Immunotherapy Indirect Chemotherapy Sensitivity
i	Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and
	Application: Proceedings of a Chicago Sumposium, Crispen, Ed. ITR, Chicago, IL, pp. 189-204
C194	PAUL, Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189-
	220 Cited On pp.1173-1174
C195	PAUL. Fundamental Immunology. 1993 Third Edition, Raven PRess, NY
C196	PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No.
	PCT/US03/14390
C197	PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No.
	PCT/US01/23098
C198	PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No.
	PCT/US01/18041
C199	PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No.
	PCT/US02/26573
C200	
	PCT/US2004/005110
C201	PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110
C202	
'	ADP-affinity chromatography" J. Immunol. Meth. 204:13
C203	
5232	Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667
C204	
COOS	
C205	
0006	heat shock protiens", Nature Vol 320 (13) 182-184
C206	
G007	oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787
C207	
6200	18:769-778.
C208	PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82
C209	RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol.
	3(2):139-54
C210	REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator
	in treated patients." Thromb Haemost. 64(2):276-80.
C211	REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-
	Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882
C212	
(212	and Related Techniques, December 1984
C213	ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated
(213	
	transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-
	induced sarcomas, Meth A and CI-4," Int. J. Cancer 27:789-796

EXAMINER	DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 6 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY, DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
	APPLICANT Srivastava et al.	
	filing date June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C214	ROTHMAN, 1989, "Polypeptide Chain Binding Proteins: Catalysts of Protein Folding and Related
	Processes in Cells". Cell 59:591-601
C215	RÖTZSCHKE et al., 1990, "Isolation and Analysis of Naturally Processed Viral Peptides as Recognized
	by Cytotoxic T cells", Nature 348:248-251
C216	ROTZSCHKE, 1990, "Characterization of Naturally Occurring Minor Histocompatibility Peptides
ļ	including H-4 and H-Y" Science 249: 283-287
C217	SALK et al., 1993, "A Strategy for Prophylactic Vaccination Against HIV", Science 260:1270-1272
C218	SALLUSTO et al., 1994, "Efficient presentation of soluble antigen by cultured human dendritic cells is
52.13	maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by
	tumor necrosis factor alpha," J. Exp. Med. 179(4):1109-1118
C219	SANO et al., 1987, "The augmentation of tumor-specific immunity using haptenic muramyl dipeptide
(21)	(MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-
	reactive helper T cell activity," Cancer Immunol. Immunother. 25(3):180-184
C220	
C220	tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells", J. Exp. Med.
	191:423-434
C221	
C221	923-955
Caaa	SCHUMACHER et al., 1991, "Peptide Selection by MHC Class I Molecules", <i>Nature</i> 350:703-706
C222	SENGUPTA et al., 2004, "Heat shock protein-mediated cross-presentation of exogenous HIV antigen on
C223	SENGUPTA et al., 2004, Heat snock protein-inediated cross-presentation of exogenous fit v antigen on
	HLA Class I and Class II," J. Immunol. 173:1987-1993 SILVA et al., 1994, "A single mycobacterial protein (hsp 65) expressed by a transgenic antigen-presenting
C224	cell vaccinates mice against tuberculosis", Immunology 82(2):244-8
C225	
C225	
600/	43:79-94 SMORODIN et al., 1991, "The complex of α-2 Macroglobulin with CD2 in the Plasma of Gastric
C226	SMORODIN et al., 1991, "The complex of a-2 iviacroglobulin with CD2 in the Flashia of Gastre
	Carcinoma Patients." Scand J. Immunol 33:699-706
C227	
	hsp90", J. Mol. Biol. 194(2):341-4
C228	
	Acta. Neurol. Scand. 98(5):314-7
C229	1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -
	111:1057-1062
C230	
	Surgical Procedures," 19-22
C231	
	Convergence of two evolutionary pathways of antigen presentation?", Seminars in Immunology 3:57-64
C232	
	Tumor Antigens and Specific Tumor Therapy, pages 63-71
C233	SRIVASTAVA and UDONO, 1994, "Heat shock protein-peptide complexes in cancer immunotherapy"
	Curr. Opin. Immunol. 6:728
C234	SRIVASTAVA et al. (1990) "Immunization with Soluble Gp96 Antigens Elicits Tumor-Specific Cellular
1	Immunity:, Cellular Immunity and the Immunotherapy of Cancer, pages 307-314

EXAMINER	DATE CONSIDERED
The state of the s	and with MDED 600. Draw line through distation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 7 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C23	SRIVASTAVA et al., 1984, "The Serologically Unique Cell Surface Antigen of Zajdela Ascitic Hepatoma
	is also its Tumor-Associated Transplantation Antigen", Int. J. Cancer 33:417-422
C236	
	induced tumors." Proc. Natl. Acad. Sci USA 84(11):3807-3811
C23	1
	tumors," Immunol. Today 9:78-83
C23	SRIVASTAVA et al., 1989, "Identification of a Human Homologue of the Murine Tumor Rejection
	Antigen GP96," Cancer Res. 49:1341-1343
C23	SRIVASTAVA et al., 1991, "Protein Tumor Antigens", Curr. Opin. Immunol. 3:654-658
C240	SRIVASTAVA et al., 1993, "Evidence for peptide-chaperoning by the endoplasmic reticular heat shock
	protein GP96: Implications for vaccination against cancer and infectious diseases", J Cell Biochem Suppl
	17D:94 (Abstract NZ014)
C24	SRIVASTAVA et al., 1998, "Heat shock proteins come of age: primitive functions acquire new roles in an
	adaptive world", Immunity 8(6):657-65
C24	•
	Experientia. (11-12):1054-60
C24:	SRIVASTAVA, 1993, "Peptide-Binding Heat Shock Proteins in the Endoplasmic Reticulum: Role in
	Immune Response to Cancer and in Antigen Presentation," Adv. Cancer Res. 62:153-177
C24	1
	Immunol. 2(3): 185-194
C24	STACK et al., 1982, "Autologous x-irradiated tumour cells and percutaneous BCG in operable lung
	cancer," Thorax 37(8):588-593
C24	STEINMAN, L., 2001, "Myelin-specific CD8+ T cells in the pathogenesis of experimental allergic
	encephalitis and multiple sclerosis," J. Exp. Med. 194:F27-F30
C24	STENMAN et al., 1991, "A complex between prostate-specific antigen and alpha 1-antichymotrypsin is
	the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex
	improves clinical sensitivity for cancer," Cancer Res. 51(1):222-6
C24	STEVENSON, 1999, "DNA vaccines against cancer: from genes to therapy," Ann. Oncol. 10:1413-8
1	Review
C24	SUBBARAO et al., 1992, "A General Overview of Viral Vaccine Development," Genetically Engineered
	Vaccines 327:51-57
C25	SUZUE et al., 1997, "Heat shock fusion proteins as vehicles for antigen delivery into the major
	histocompatibility complex class I presentation pathway," Proc. Natl. Acad. Sci. USA 94(24):13146-51
C25	
	Stress-Inducible Cellular Responses" (U. Feige, R. I. Morimoto, I. Yahara, B. S. Polla, eds.),
	Birkhauser/Springer, 77: 451-465
C25	SUZUE K., Young R.A., 1996, "Adjuvant-free hsp70 fusion protein system elicits humoral and cellular
1	immune responses to HIV-1" p24. J Immunol. 156(2):873-9
C25	TAILOR et al., 1990, "Nucleotide Sequence Of Human Prostatic Acid Phosphatase Determined From A
	Full-Length cDNA Clone." Nucl. Acids Res. 18:4928 (1990)
C25	
C25	
1	1 1111 MENTON MENTON OF PINGHOOD WING THEMPY, 1999, Deep wing Deline is add, Martin Research

EXAMINER	DATE CONSIDERED
*FXAMINER: Initial if reference considered, whether or not citation is in conform	nance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 8 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

C256 THOMAS et al., 1982, "Molecular and Cellular Effects of Heat Shock and Related Treatments of Mammalian Tissue-Culture Cells", Cold Springs Harbor Symp Quant Biol 46:985-996 C257 TODRY Ket al., 1999, "Heat shock protein 70 induced during tumor cell killing induces Th Lytokines and targets immature dendritic cell precursors to enhance antigen uptake," J. Immunol. 163:1398-1408 C258 TWINING et al., 1977, "Large scale separation of protease inhibitors from malignant human breast tissue," Mol. Cell. Biochem. 18(2-3):101-7 C259 UDONO et al., 1994, "Comparison of Tumor-Specific Immunogenicities of Stress-Induced Proteins gp96, hsp90, and hsp70," J. Immunol., 152(11):5398-5403 C260 UDONO, 1993, "Heat shock proteins HSP70, HSP90 and GP96 elicit tumor specific immunity to the tumors from which they are isolated," J. Cell. Biochem. Suppl. 17D:113 (Abstract NZ225) C261 ULLRICH et al., 1986, "A mouse tumor-specific transplantation antigen is a heat shock-related protein," Proc. Natl. Acad. Sci. USA 83(10):3121-3125 C262 URBANIAK AND ROBINSON, 1990, "ABC of transfusion. Therapeutic apheresis," BMJ 300(6725):662-5 Review C263 VAAGE, 1968 "Nonvirus-Associated Antigens In Virus-Induced Mouse Mammary Tumors." Cancer Res. 28:2477-2483 C264 VANBUSKIRK et al., 1989, "Peptide binding protein having a role in antigen presentation is a member of the hsp70 heat shock family". J. Exp. Med. 170:1799-1809 C265 VIJAYASARADHI et al., 1990 "The Melanoma Antigen gp75 is The Human Homologue Of The Mouse b (Brown) Locus Gene Product." J. Exp. Med. 171:1375-1380 C266 WALLNY et al., 1992, "Gene transfer experiments imply instructive role of major histocompatibility complex class I molecules in cellular peptide processing". Eur. J. Immunol. 22:655-659 C267 WANG et al., 2001, "Characterization of heat shock protein 110 and glucoses-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermian on vaccine activity," Inmunol. 166(1):490-497 C268 WANG et al., 1980, "Bramapheresis in multiple sclerosis: preliminary study," Ne		NON PATENT LITERATURE DOCUMENTS	
C257 TODRYK et al., 1999, "Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake," J. Immunol. 163:1388-1408 C258 TWNING et al., 1977, "Large scale separation of protease inhibitors from malignant human breast tissue," Mol. Cell. Biochem. 18(2-3):101-7 C290 UDONO et al., 1994, "Comparison of Tumor-Specific Immunogenicities of Stress-Induced Proteins gp96, hsp90, and hsp70," J. Immunol., 152(11):5398-5403 C200 UDONO, 1993, "Heat shock proteins HSP70. HSP90 and GP96 elicit tumor specific immunity to the tumors from which they are isolated", J. Cell. Biochem. Suppl. 17D:113 (Abstract NZ225) C261 ULLRICH et al., 1986, "A mouse tumor-specific transplantation antigen is a heat shock-related protein," Proc. Natl. Acad. Sci. USA 83(10):3121-3125 C262 URBANIAK AND ROBINSON, 1990, "ABC of transfusion. Therapeutic apheresis," BMJ 300(6725):662 - Seeview C263 VAAGE, 1968 "Nonvirus-Associated Antigens In Virus-Induced Mouse Mammary Tumors." Cancer Res. 28:2477-2483 C264 VANBUSKIRK et al., 1989, "Peptide binding protein having a role in antigen presentation is a member of the hsp70 heat shock family". J. Exp. Med. 170:1799-1809 C265 VIJAYASARADH et al., 1990 "The Melanoma Antigen gp75 Is The Human Homologue Of The Mouse b (Brown) Locus Gene Product." J. Exp. Med. 171:1375-1380 C266 WALINY et al., 1999. "Gene transfer experiments imply instructive role of major histocompatibility complex class I molecules in cellular peptide processing". Eur. J. Immunol 22:655-659 WANG et al., 2001, "Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity." J. Immunol. 166(1):490-497 C268 WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 257:14949-14959 C270 WEINER et al., 1980, "Plasmapheresis in multip	C256		
tissue," Mol. Cell. Biochem. 18(2-3):101-7 C259 UDONO et al., 1994, "Comparison of Tumor-Specific Immunogenicities of Stress-Induced Proteins gp96, hsp90, and hsp70," J. Immunol., 152(11):5398-5403 C260 UDONO, 1993, "Heat shock proteins HSP70. HSP90 and GP96 elicit tumor specific immunity to the tumors from which they are isolated", J. Cell. Biochem. Suppl. 17D:113 (Abstract NZ225) C261 UILRICH et al., 1986, "A mouse tumor-specific transplantation antigen is a heat shock-related protein," Proc. Natl. Acad. Sci. USA 83(10):3121-3125 C262 URBANIAK AND ROBINSON, 1990, "ABC of transfusion. Therapeutic apheresis," BMJ 300(6725):662-5 Review C263 VAAGE, 1968 "Nonvirus-Associated Antigens In Virus-Induced Mouse Mammary Tumors." Cancer Res. 28:2477-2483 C264 VANBUSKIRK et al., 1989, "Peptide binding protein having a role in antigen presentation is a member of the hsp70 heat shock family". J. Exp. Med. 170:1799-1809 C265 VUAYASARADHI et al., 1990 "The Melanoma Antigen gp75 Is The Human Homologue Of The Mouse b (Brown) Locus Gene Product." J. Exp. Med. 171:1375-1380 C266 WALLNY et al., 1992, "Gene transfer experiments imply instructive role of major histocompatibility complex class 1 molecules in cellular peptide processing". Eur. J. Immunol 22:655-659 C267 WANG et al., 2001, "Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-497 C268 WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054. C269 WEINER et al., 1980, "Plasmapheresis in multiple sclerosis preliminary study," Neurology 30: 1029-33 C270 WEINER et al., 1985, "Rapid Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem. 257:149491-44959 C272 WELCH et al., 1998, "Purification of the Major Mammalian stress response: characterization of changes in cytoplasm	C257	and targets immature dendritic cell precursors to enhance antigen uptake," J. Immunol. 163:1398-1408	
hsp90, and hsp70," J. Immunol., 152(11):5398-5403 C260 UDONO, 1993, "Heat shock proteins HSP70. HSP90 and GP96 elicit tumor specific immunity to the tumors from which they are isolated", J. Cell. Biochem. Suppl. 17D:113 (Abstract NZ225) C261 ULLRICH et al., 1986, "A mouse tumor-specific transplantation antigen is a heat shock-related protein," Proc. Natl. Acad. Sci. USA 83(10):3121-3125 C262 URBANIAK AND ROBINSON, 1990, "ABC of transfusion. Therapeutic apheresis," BMJ 300(6725):662-5 Review C263 VAAGE, 1968 "Nonvirus-Associated Antigens In Virus-Induced Mouse Mammary Tumors." Cancer Res. 28:2477-2483 C264 VANBUSKIRK et al., 1989, "Peptide binding protein having a role in antigen presentation is a member of the hsp70 heat shock family", J. Exp. Med. 170:1799-1809 C265 VIJAYASARADH et al., 1990 "The Melanoma Antigen gp75 Is The Human Homologue Of The Mouse b (Brown) Locus Gene Product." J. Exp. Med. 171:1375-1380 C266 WALLNY et al., 1992, "Gene transfer experiments imply instructive role of major histocompatibility complex class I molecules in cellular peptide processing". Eur. J. Immunol 22:655-659 C267 WANG et al., 2001, "Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-497 C268 WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054. C269 WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33 C270 WEINER et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem. 257:14949-14959 C272 WELCH et al., 1985, "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the Proteins for Nucleotides", Mol. Cell. Biol. 5:11229-1237 C273 WELCH et al., 1986, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in v	C258	tissue," Mol. Cell. Biochem. 18(2-3):101-7	
tumors from which they are isolated", <i>J. Cell. Biochem.</i> Suppl. 17D:113 (Abstract NZ225) C261 ULLRICH <i>et al.</i> , 1986, "A mouse tumor-specific transplantation antigen is a heat shock-related protein," Proc. Natl. Acad. Sci. USA 83(10):3121-3125 C262 URBANIAK AND ROBINSON, 1990, "ABC of transfusion. Therapeutic apheresis," BMJ 300(6725):662-5 Review C263 VAAGE, 1968 "Nonvirus-Associated Antigens In Virus-Induced Mouse Mammary Tumors." <i>Cancer Res.</i> 28:2477-2483 C264 VANBUSKIRK et al., 1989, "Peptide binding protein having a role in antigen presentation is a member of the hsp70 heat shock family", <i>J. Exp. Med.</i> 170:1799-1809 C265 VIJAYASARADHI <i>et al.</i> , 1990 "The Melanoma Antigen gp75 Is The Human Homologue Of The Mouse <i>b</i> (Brown) Locus Gene Product." <i>J. Exp. Med.</i> 171:1375-1380 C266 WALLNY et al., 1992, "Gene transfer experiments imply instructive role of major histocompatibility complex class I molecules in cellular peptide processing". Eur. <i>J. Immunol</i> 22:655-659 C267 WANG et al., 2001, "Characterization of heat shock protein 110 audicose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," <i>J. Immunol</i> 166(1):490-497 C268 WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein," <i>J. Biol. Chem.</i> 268(29):22046-22054. C269 WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33 C270 WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884 C271 WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", <i>J. Biol. Chem.</i> 257:14949-14959 C272 WELCH et al., 1985, "Rapid Purification of Mammalian stress response: characterization of changes in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibrobasts after heat-shock treatment," <i>J. Cell. Biol.</i> 101:1198-121 C274 WELCH et al.	C259	hsp90, and hsp70," J. Immunol., 152(11):5398-5403	
Proc. Natl. Acad. Sci. USA 83(10):3121-3125 C262 URBANIAK AND ROBINSON, 1990, "ABC of transfusion. Therapeutic apheresis," BMJ 300(6725):662-5 Review C263 VAAGE, 1968 "Nonvirus-Associated Antigens In Virus-Induced Mouse Mammary Tumors." Cancer Res. 28:2477-2483 C264 VANBUSKIRK et al., 1989, "Peptide binding protein having a role in antigen presentation is a member of the hsp70 heat shock family". J. Exp. Med. 170:1799-1809 C265 VIJAYASARADHI et al., 1990 "The Melanoma Antigen gp75 Is The Human Homologue Of The Mouse b (Brown) Locus Gene Product." J. Exp. Med. 171:1375-1380 C266 WALLNY et al., 1992, "Gene transfer experiments imply instructive role of major histocompatibility complex class I molecules in cellular peptide processing". Eur. J. Immunol 22:655-659 C267 WANG et al., 2001, "Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-497 C268 WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054. C269 WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33 C270 WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884 C271 WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem. 257:14949-14959 C272 WELCH et al., 1985, "Papid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237 C273 WELCH et al., 1995, "Morphological study of the mammalian stress response: characterization of changes in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-117-76 C274 WELCH et al., 1995, "The Biochemical Journal. England 313:7	C260	tumors from which they are isolated", J. Cell. Biochem. Suppl. 17D:113 (Abstract NZ225)	
C263 VAAGE, 1968 "Nonvirus-Associated Antigens In Virus-Induced Mouse Mammary Tumors." Cancer Res. 28:2477-2483 C264 VANBUSKIRK et al., 1989, "Peptide binding protein having a role in antigen presentation is a member of the hsp70 heat shock family". J. Exp. Med. 170:1799-1809 C265 VIAYASARADH et al., 1990 "The Melanoma Antigen gp75 Is The Human Homologue Of The Mouse b (Brown) Locus Gene Product." J. Exp. Med. 171:1375-1380 C266 WALLNY et al., 1992, "Gene transfer experiments imply instructive role of major histocompatibility complex class I molecules in cellular peptide processing". Eur. J. Immunol 22:655-659 C267 WANG et al., 2001, "Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-497 C268 WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054. C269 WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33 C270 WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884 C271 WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem. 257:14949-14959 C272 WELCH et al., 1985, "Rapid Purification of Mammalian Heat Shock Proteins" Affinity of the Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237 C273 WELCH et al., 1995, "Morphological study of the mammalian stress response: characterization of changes in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211 C274 WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64 C275 WILCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64 C276 WONG et al., 1995, "Characterization of hormonogenic sites	C261	Proc. Natl. Acad. Sci. USA 83(10):3121-3125	
28:2477-2483 C264 VANBUSKIRK et al., 1989, "Peptide binding protein having a role in antigen presentation is a member of the hsp70 heat shock family". <i>J. Exp. Med.</i> 170:1799-1809 C265 VIJAYASARADHI et al., 1990 "The Melanoma Antigen gp75 Is The Human Homologue Of The Mouse <i>b</i> (Brown) Locus Gene Product." <i>J. Exp. Med.</i> 171:1375-1380 C266 WALLNY et al., 1992, "Gene transfer experiments imply instructive role of major histocompatibility complex class I molecules in cellular peptide processing". Eur. J. Immunol 22:655-659 C267 WANG et al., 2001, "Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-497 C268 WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054. C269 WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33 C270 WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884 C271 WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem. 257:14949-14959 C272 WELCH et al., 1985, "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237 C273 WELCH et al., 1995, "Morphological study of the mammalian stress response: characterization of changes in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211 C274 WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64 C275 WILNOW et al., 1996, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro." The Biochemical Journal. England 313:71-76 C276 WONG et al., 1991, "Susceptibility to type I dia	C262	300(6725):662-5 Review	
the hsp70 heat shock family", J. Exp. Med. 170:1799-1809 C265 VIJAYASARADHI et al., 1990 "The Melanoma Antigen gp75 Is The Human Homologue Of The Mouse b (Brown) Locus Gene Product." J. Exp. Med. 171:1375-1380 C266 WALLNY et al., 1992, "Gene transfer experiments imply instructive role of major histocompatibility complex class I molecules in cellular peptide processing". Eur. J. Immunol 22:655-659 C267 WANG et al., 2001, "Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-497 C268 WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054. C269 WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33 C270 WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884 C271 WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem. 257:14949-14959 C272 WELCH et al., 1985, "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237 C273 WELCH et al., 1985, "Mapid Deligical study of the mammalian stress response: characterization of changes in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211 C274 WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64 C275 WILLNOW et al., 1996, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro." The Biochemical Journal. England 313:71-76 C276 WONG et al., 1991, "Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus on chromosome 11," Clin. Exp. Immunol. 83(1):69-73 C277 XIAO et al.,	C263	<u>28</u> :2477-2483	
C266 WALLNY et al., 1992, "Gene transfer experiments imply instructive role of major histocompatibility complex class I molecules in cellular peptide processing". Eur. J. Immunol 22:655-659 C267 WANG et al., 2001, "Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-497 C268 WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054. C269 WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33 C270 WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884 C271 WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem. 257:14949-14959 C272 WELCH et al., 1985, "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237 C273 WELCH et al., 1995, "Morphological study of the mammalian stress response: characterization of changes in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211 C274 WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64 C275 WELLNOW et al., 1996, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro." The Biochemical Journal. England 313:71-76 C276 WONG et al., 1991, "Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus on chromosome 11," Clin. Exp. Immunol. 83(1):69-73 C277 XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment	C264	the hsp70 heat shock family", J. Exp. Med. 170:1799-1809	
complex class I molecules in cellular peptide processing". Eur. J. Immunol 22:655-659 C267 WANG et al., 2001, "Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-497 C268 WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054. C269 WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33 C270 WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884 C271 WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem. 257:14949-14959 C272 WELCH et al., 1985, "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237 C273 WELCH et al., 1995, "Morphological study of the mammalian stress response: characterization of changes in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211 C274 WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64 C275 WILLNOW et al., 1996, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro." The Biochemical Journal. England 313:71-76 C276 WONG et al., 1991, "Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus on chromosome 11," Clin. Exp. Immunol. 83(1):69-73 C277 XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment		b (Brown) Locus Gene Product." J. Exp. Med. 171:1375-1380	
cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-497 C268 WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054. C269 WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33 C270 WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884 C271 WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem. 257:14949-14959 C272 WELCH et al., 1985, "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237 C273 WELCH et al., 1995, "Morphological study of the mammalian stress response: characterization of changes in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211 C274 WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64 C275 WILLNOW et al., 1996, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro." The Biochemical Journal. England 313:71-76 C276 WONG et al., 1991, "Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus on chromosome 11," Clin. Exp. Immunol. 83(1):69-73 C277 XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment	C266	complex class I molecules in cellular peptide processing". Eur. J. Immunol 22:655-659	
ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054. C269 WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33 C270 WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884 C271 WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem. 257:14949-14959 C272 WELCH et al., 1985, "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237 C273 WELCH et al., 1995, "Morphological study of the mammalian stress response: characterization of changes in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211 C274 WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64 C275 WILLNOW et al., 1996, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro." The Biochemical Journal. England 313:71-76 C276 WONG et al., 1991, "Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus on chromosome 11," Clin. Exp. Immunol. 83(1):69-73 C277 XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment	C267	cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-	
C270 WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884 C271 WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", <i>J. Biol. Chem.</i> 257:14949-14959 C272 WELCH et al., 1985, "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the Proteins for Nucleotides", <i>Mol. Cell. Biol.</i> 5:1229-1237 C273 WELCH et al., 1995, "Morphological study of the mammalian stress response: characterization of changes in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211 C274 WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64 C275 WILLNOW et al., 1996, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro." The Biochemical Journal. England 313:71-76 C276 WONG et al., 1991, "Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus on chromosome 11," Clin. Exp. Immunol. 83(1):69-73 C277 XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment	C268		
C271 WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", <i>J. Biol. Chem.</i> 257:14949-14959 C272 WELCH et al., 1985, "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the Proteins for Nucleotides", <i>Mol. Cell. Biol.</i> 5:1229-1237 C273 WELCH et al., 1995, "Morphological study of the mammalian stress response: characterization of changes in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211 C274 WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64 C275 WILLNOW et al., 1996, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro." The Biochemical Journal. England 313:71-76 C276 WONG et al., 1991, "Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus on chromosome 11," Clin. Exp. Immunol. 83(1):69-73 C277 XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment	C269	WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33	
257:14949-14959 C272 WELCH et al., 1985, "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237 C273 WELCH et al., 1995, "Morphological study of the mammalian stress response: characterization of changes in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211 C274 WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64 C275 WILLNOW et al., 1996, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro." The Biochemical Journal. England 313:71-76 C276 WONG et al., 1991, "Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus on chromosome 11," Clin. Exp. Immunol. 83(1):69-73 C277 XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment	C270	WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884	
Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237 C273 WELCH et al., 1995, "Morphological study of the mammalian stress response: characterization of changes in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211 C274 WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64 C275 WILLNOW et al., 1996, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro." The Biochemical Journal. England 313:71-76 C276 WONG et al., 1991, "Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus on chromosome 11," Clin. Exp. Immunol. 83(1):69-73 C277 XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment	C271	257:14949-14959	
in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211 C274 WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64 C275 WILLNOW et al., 1996, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro." The Biochemical Journal. England 313:71-76 C276 WONG et al., 1991, "Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus on chromosome 11," Clin. Exp. Immunol. 83(1):69-73 C277 XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment		Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237	
C275 WILLNOW et al., 1996, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro." The Biochemical Journal. England 313:71-76 C276 WONG et al., 1991, "Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus on chromosome 11," Clin. Exp. Immunol. 83(1):69-73 C277 XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment		in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211	
in vivo and in vitro." The Biochemical Journal. England 313:71-76 C276 WONG et al., 1991, "Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus on chromosome 11," Clin. Exp. Immunol. 83(1):69-73 C277 XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment			
on chromosome 11," Clin. Exp. Immunol. 83(1):69-73 C277 XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment		in vivo and in vitro." The Biochemical Journal. England 313:71-76	
		on chromosome 11," Clin. Exp. Immunol. 83(1):69-73	
of human thyroglobulin." Arch Biochem Biophys. 20;320(1):96-105	C277	XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment of human thyroglobulin." Arch Biochem Biophys. 20;320(1):96-105	

EXAMINER		DATE CONSIDERED
*EVALUNED.	Initial if reference considered subother or not sitution is in conform	annea with MPEP 600: Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 9 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	filing date June 4, 2001	ART UNIT 1643

NON PATENT LITERATURE DOCUMENTS		
C278	YAMAUCHI et al., 2000, "Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study." Mycoses.43(5):197-202.	
C279	YANG et al., 1999, "Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8+ and CD4+ T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity," Int. J. Cancer 83:532-540	
C280	YEDAVELLI et al., 1999, "Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model" <i>Int. J. Mol. Med.</i> 3:243	
C281	YU et al., 1991, "Sequence Analysis of Peptides Bound to MHC Class II Molecules", Nature 353:622-627	
C282		
C283	ZIMECKI et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." Arch Immunol Ther Exp (Warsz). 47(2):113-8.	

EXAMINER /Christopher Yaen/ DATE CONSIDERED 02/18/2008